Quarterlytics / Basic Materials / Chemicals - Specialty / DuPont

DuPont

dd · NYSE Basic Materials
Claim this profile
Ticker dd
Exchange NYSE
Sector Basic Materials
Industry Chemicals - Specialty
Employees 10,000+
← All annual reports
FY2016 Annual Report · DuPont
Sign in to download
Loading PDF…
2016  
DUPONT  
ANNUAL  
REPORT

A world leader in science and innovation, DuPont continues to work toward sustainable, renewable and market-driven 
solutions for some of our biggest global challenges. We are helping to provide healthy food for people everywhere, 
decreasing dependence on fossil fuels, and protecting life and the environment. 

For more than two centuries, our ability to meet the changing needs of our customers and society through world-class 
science and innovation has been the key to our success. DuPont’s current transformation will position each of our 
businesses with a clear focus and allow us to deliver superior solutions and choices for our customers. For additional 
information about DuPont and its commitment to inclusive innovation, please visit dupont.com.

2016 SEGMENT NET SALES

[U.S. DOLLARS IN MILLIONS]

$147

$2,954

$5,249

$9,516

$3,268

$1,960

$1,500

2016 TOTAL SEGMENT 
OPERATING EARNINGS AND TOTAL SEGMENT
 OPERATING MARGINS [1]

$6,000

$5,000

$4,000

$3,000

$2,000

$1,000

$0

S
N
O
I
L
L
I
M
N

I

$

2015

2016

I

N
G
R
A
M

19.5%

19.0%

18.5%

18.0%

17.5%

17.0%

16.5%

16.0%

15.5%

AGRICULTURE

NUTRITION & HEALTH

ELECTRONICS & COMMUNICATIONS

PERFORMANCE MATERIALS

INDUSTRIAL BIOSCIENCES

PROTECTION SOLUTIONS

OTHER

2016 OPERATING MARGINS BY SEGMENT 

30%

25%

20%

15%

10%

5%

0%

S   &  
TI O
A

N I C
N I C

O

U

R
M

C

T

M

L T

U

R I C

G

A

E

R

U

          E L E
          C

O

S

N

S

U

D

              I N
                 B I O

R I A L           
C IE

C

N

T

S

S

E

R ITI O

T

U

N

E

N   &   H

H

O

R

M

A L T
                    M
          P

R F

E

E  
R I A L S

C
T

E

A

N

A

S

N

N  
TI O

TI O
U
L

T

O

C

O

E
S

R

P

2015

2016

 
 
Dear DuPont Shareowners,

2016 was a year of transformation and 
accomplishment for DuPont. We made meaningful 
progress improving the fundamentals of the business 
and significantly strengthened our competitive 
position, so that we started 2017 operating at a 
new standard of excellence. Our actions delivered 
strong results, while laying the foundation to drive 
sustainable value for shareholders over the long 
term. As we look ahead, we expect our continued 
strategic focus and discipline will advance our 
standing among global industry leaders. We 
accomplished all this while also making progress 
to prepare for the next major step in the company’s 
214-year history – the proposed merger of equals 
with The Dow Chemical Company and the intended 
creation of three industry-leading companies. 

Driving Performance 
In 2016, we focused our efforts on increasing 
efficiency and productivity to improve our 
performance against metrics we identified as key 
to shareholder value creation. Even as we faced 
continued macroeconomic headwinds, we drove 
progress in each of our businesses. The 2016 results 
speak for themselves:

36%  

GAAP[2] EPS

21%  

OPERATING EPS[1]

60 BPS[3] 

GROSS MARGINS

~200 BPS 

SEGMENT OPERATING 
MARGINS

5%  

GAAP OPERATING 
COSTS[4]

11%  

OPERATING COSTS[1, 5]

27%  

CAPITAL SPENDING [6]

$1.6 BN 

FREE CASH FLOW [1, 7]

Edward D. Breen
Chair of the Board & Chief Executive Officer

We are also continuing DuPont’s historic 
commitment to invest in the future. When you look 
beyond our 2016 numbers, you see customer wins, 
strong execution and a robust pipeline – all results 
of our unparalleled innovation engine. All of our 
businesses are building on competitive positions 
in their markets by drawing on world-class science, 
technology and engineering expertise to deliver  
the value-added solutions our customers want  
and need. 

In 2016, we introduced nearly 1,600 new products 
into the marketplace, including our Pioneer® brand 
Optimum® Leptra® hybrids, a powerful pyramid  
of traits that protects plant health, yield and grain 
quality against a wide range of pests. The Optimum® 
Leptra® product lineup was one of the fastest 
technology ramp-ups in DuPont Pioneer history and 
counted for nearly 70 percent of our sales in the 
Brazil summer season. We also had success with our 
DuPont™ Zorvec™ fungicide launch, which exceeded 
expectations and will continue to drive sales in 2017.  
In Industrial Biosciences, our new lineup of bioactive 
products is serving industries ranging from food 
and grain processing to household products. And 
in Electronics & Communications, new product 
introductions in DuPont™ Solamet® paste resulted  
in market share gains over the prior year.  

[1]See inside back cover for additional information regarding these non-GAAP financial measures. [2]Generally Accepted Accounting Principles 
(GAAP). [3]Excludes a 70-basis-point benefit from a non-operating pension/OPEB curtailment gain. [4]GAAP operating costs defined as other 
operating charges, selling, general & administrative, and research & development costs. [5]Excludes significant items and non-operating 
pension/OPEB costs. [6]Excludes Chemours. [7]Free cash flow is defined as cash used for operating activities less purchases of property, 
plant and equipment. 

1

 
Our ongoing investment in R&D and product 
development continues to drive strong near-
term results and strengthens our position in the 
marketplace, while ensuring sustainable top-line 
growth for our businesses over the long term.  
As always, innovation remains a defining feature 
of DuPont’s past, present and future.  

More Focused, Effective and Efficient
We recognize that sustainable success requires 
we are not only innovative, but also productive 
and efficient. To this end, going into 2016, we 
identified three critical priorities to help us achieve 
best-in-class operating efficiency: cost savings, 
disciplined and productive capital spending, 
and improved working capital performance. We 
successfully executed – and in many cases exceeded 
expectations – against all three. 

Our continued efforts to streamline the organization 
delivered $750 million in year-over-year cost savings, 
surpassing our goal for 2016. At the same time, 
our capital expenditures for the year declined, 
putting our capital spending back in line with 
depreciation and amortization. These investments 
focused on our most compelling growth projects 
and offer solid returns. We also worked to improve 
our working capital in 2016 – and set a goal for a 
$1 billion improvement over the medium term – 
while increasing our free cash flow. 

Each of these is a critical metric, enabling the 
necessary investments in the business and in 
capital projects that will drive our long-term 
growth. For example, there is growing interest and 
understanding of the benefits of probiotics today 
and this market is rapidly expanding. As a leading 
company in this space, we are uniquely positioned 
to seize this opportunity, and we approved  
an investment in probiotic production facility  
expansion in New York and Wisconsin of  
more than $100 million. 

We will continue to keep rigorous focus in the 
coming year as we build on this success and pursue 
new paths for growth going forward.

Progress Toward Closing the Merger 
We continue to work through the regulatory review 
process for our intended merger with Dow. Merging 
our highly complementary portfolios gives us the 
ability to create three strong global businesses in 
Agriculture, Specialty Products and Material  
Science on the foundation of our combined assets, 
capabilities and scale. Following the merger and 
subject to the approval of the DowDuPont Board,  
we intend to separate into three independent 
companies that will be industry leaders. With greater 
focus, each company will be able to unlock its full 
growth potential by allocating capital more effectively, 
applying its powerful innovation more productively 
and expanding products and solutions to more 
customers worldwide. With lower cost structures and 
increased agility, they will be better positioned to 
grow and thrive over the long term – reinvesting in 
science and innovation, delivering significant value  
for shareholders and helping customers address 
global challenges.

We are extremely excited about the opportunities 
in 2017 and beyond. We finished 2016 in a much 
stronger position than we started, with our 
businesses delivering on our strategic priorities  
and generating positive momentum across the 
board. We are driving growth that is rooted in the 
fundamental business model that has assured 
DuPont’s success for more than 200 years – 
adapting to change, connecting science to the 
marketplace, forging ahead in new markets and 
creating new opportunities.    

Together, we are laying the foundation for a bright 
future ahead.  

Thank you for your investment in DuPont.

Edward D. Breen
Chair of the Board & Chief Executive Officer

2

2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2016

OR

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

____________________________________________________________________________

Commission file number 1-815

E. I. DU PONT DE NEMOURS AND COMPANY
(Exact name of registrant as specified in its charter)

DELAWARE
(State or Other Jurisdiction of Incorporation or Organization)

51-0014090
(I.R.S. Employer Identification No.)

974 Centre Road
Wilmington, Delaware 19805
(Address of principal executive offices)
Registrant's telephone number, including area code: 302-774-1000
Securities registered pursuant to Section 12(b) of the Act
(Each class is registered on the New York Stock Exchange, Inc.):
Title of Each Class
__________________________________________________
Common Stock ($.30 par value)
Preferred Stock
(without par value-cumulative)
$4.50 Series
$3.50 Series
No securities are registered pursuant to Section 12(g) of the Act.
_____________________________________________________

Indicate by check mark whether the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act).               

Yes

       No 

Indicate  by  check  mark  whether  the  registrant  is  not  required  to  file  reports  pursuant  to  Section 13  or  Section 15(d)  of  the 

Act.    Yes 

       No 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities 
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), 
and (2) has been subject to such filing requirements for the past 90 days.    Yes

       No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every 
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes 

        No 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will
not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III
of this Form 10-K or any amendment to this Form 10-K.  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition 

of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer 

Accelerated filer 

Non-accelerated filer 

Smaller reporting  company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes
The aggregate market value of voting stock held by nonaffiliates of the registrant (excludes outstanding shares beneficially owned

No

by directors and officers and treasury shares) as of June 30, 2016, was approximately $56.6 billion.

As of January 31, 2017, 864,574,000 shares (excludes 87,041,000 shares of treasury stock) of the company's common stock, $0.30

par value, were outstanding.

Documents Incorporated by Reference
(Specific pages incorporated are indicated under the applicable Item herein):

The company's 2017 Annual Meeting Proxy Statement to be filed within 120 days of the company's fiscal year ended December
31, 2016.

Incorporated
By Reference
In Part No.

III

 
E. I. du Pont de Nemours and Company

Form 10-K

Table of Contents

The  terms  "DuPont"  or  the  "company"  as  used  herein  refer  to  E. I.  du Pont  de  Nemours  and  Company  and  its  consolidated 
subsidiaries, or to E. I. du Pont de Nemours and Company, as the context may indicate.

PART I

Item 1.

Item 1A.

Item 1B.
Item 2.

Item 3.

PART II

Item 5.

Item 6.

Item 7.
Item 7A.

Item 8.

Item 9.

Item 9A.

Item 9B.

PART III

Item 10.

Item 11.

Item 12.

Item 13.

Item 14.

PART IV

Item 15.
SIGNATURES 

Business

Risk Factors

Unresolved Staff Comments
Properties

Legal Proceedings

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of 
Equity Securities

Selected Financial Data

Management's Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk

Financial Statements and Supplementary Data

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

Controls and Procedures

Other Information

Directors, Executive Officers and Corporate Governance

Executive Compensation

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder 
Matters

Certain Relationships and Related Transactions, and Director Independence

Principal Accountant Fees and Services

Exhibits and Financial Statement Schedules

Page

2

9

17

17

18

19

21

22

51
52

52

52

52

53

54

55

56

56

57

60

Note on Incorporation by Reference

Information pertaining to certain Items in Part III of this report is incorporated by reference to portions of the company's definitive 
2016 Annual Meeting Proxy Statement to be filed within 120 days after the end of the year covered by this Annual Report on 
Form 10-K, pursuant to Regulation 14A (the Proxy).

1

                                                               
 
 
ITEM 1.  BUSINESS
SS

S

Part I

DuPont was founded in 1802 and was incorporated in Delaware in 1915. Today, DuPont is helping customers find solutions to 
capitalize on areas of growing global demand — enabling more, safer, nutritious food; creating high-performance, cost-effective
and energy efficient materials for a wide range of industries; and increasingly delivering renewably sourced bio-based materials 
and fuels. Total worldwide employment at December 31, 2016 was about 46,000 people. The company has operations in about 
90 countries worldwide and 61 percent of consolidated net sales are made to customers outside the United States of America 
(U.S.).  See Note 20 to the Consolidated Financial Statements for additional details on the location of the company's sales and
property.

Subsidiaries and affiliates of DuPont conduct manufacturing, seed production or selling activities and some are distributors of
products manufactured by the company.  As a science and technology based company, DuPont competes on a variety of factors 
such as product quality and performance or specifications, continuity of supply, price, customer service and breadth of product
line, depending on the characteristics of the particular market involved and the product or service provided.  Most products are 
marketed  primarily  through  the  company's  sales  force,  although  in  some  regions,  more  emphasis  is  placed  on  sales  through 
distributors.  The company utilizes numerous suppliers as well as internal sources to supply a wide range of raw materials, energy, 
supplies, services and equipment.  To ensure availability, the company maintains multiple sources for fuels and many raw materials, 
including hydrocarbon feedstocks.  Large volume purchases are generally procured under competitively priced supply contracts.

DuPont Dow Merger of Equals 
On December 11, 2015, DuPont and The Dow Chemical Company (Dow) announced entry into an Agreement and Plan of Merger 
(the Merger Agreement), under which the companies will combine in an all-stock merger of equals (the Merger Transaction)
subject to satisfaction of customary closing conditions, including receipt of regulatory approval. Subject to the terms and conditions 
of the Merger Agreement, (i) Dow Merger Sub, a Delaware corporation that was formed on December 9, 2015, as a wholly owned 
subsidiary of DowDuPont Inc., a company jointly owned by Dow and DuPont, (DowDuPont) will be merged with and into Dow,
with Dow surviving as a subsidiary of DowDuPont, (the Dow Merger), and (ii) DuPont Merger Sub, a Delaware corporation that 
was formed on December 9, 2015 as a wholly owned subsidiary of DowDuPont, will be merged with and into DuPont, with DuPont 
surviving the merger as a subsidiary of DowDuPont, (the DuPont Merger and, together with the Dow Merger, the Mergers). As a
result of the Mergers, among other things, (a) DowDuPont will become the ultimate parent of Dow, DuPont and their respective 
subsidiaries and (b) existing Dow stockholders and DuPont stockholders will receive DowDuPont common stock, in accordance 
with the terms of the Merger Agreement.  On July 20, 2016, stockholders of both DuPont and Dow voted to approve all stockholder 
proposals necessary to complete the Merger Transaction at their respective special meetings. Following the consummation of the 
Merger Transaction, DuPont and Dow intend to pursue, subject to the receipt of approval by the Board of Directors of DowDuPont,
the separation of the combined company’s agriculture business, specialty products business and material science business through
a series of tax-efficient transactions (collectively, the Intended Business Separations).

Subject to the terms and conditions of the Merger Agreement, each share of common stock, par value $0.30 per share, of DuPont 
(DuPont Common Stock) issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement),
excluding any shares of DuPont Common Stock that are held in treasury, will be converted into the right to receive 1.2820 shares 
of common stock, par value $0.01 per share, of DowDuPont (DowDuPont Common Stock), for each share of DuPont Common 
Stock with cash in lieu of any fractional share of DowDuPont. Each share of DuPont Preferred Stock-$4.50 Series and DuPont 
Preferred Stock-$3.50 Series, in each case issued and outstanding immediately prior to the Effective Time, shall remain issued 
and outstanding and be unaffected by the merger.

Subject to the terms and conditions set forth in the Merger Agreement, at the Effective Time, each share of common stock, par 
value $2.50 per share, of Dow (the Dow Common Stock) issued and outstanding immediately prior to the Effective Time, excluding
any shares of Dow Common Stock that are held in treasury, will be converted into the right to receive one share of DowDuPont 
Common Stock. Pursuant to the terms of the Merger Agreement, each share of Cumulative Convertible Perpetual Preferred Stock,
Series A, par value $1.00 per share, of Dow (the Dow Preferred) issued and outstanding immediately prior to the Effective Time 
would be automatically canceled and each holder of shares of Dow Preferred would be deemed to hold the same number of shares
of preferred stock of DowDuPont on equivalent terms. However, on December 30, 2016, (the Dow Preferred Conversion Date)
each share of Dow Preferred was converted into 24.2010 shares of Dow Common Stock. In connection therewith, on the Dow
Preferred Conversion date, Dow issued 96,804,000 shares of Dow Common Stock. As a result, it is expected that no shares of 
preferred stock of DowDuPont will be issued pursuant to the terms of the Merger Agreement at the Effective Time. 

2

ITEM 1.  BUSINESS, continued

Part I

DuPont and Dow continue to work constructively with regulators in key jurisdictions to obtain approval and to prepare for closing
as soon as possible after closing conditions have been met. Consummation of the Merger Transaction is contingent on satisfaction
of customary closing conditions, including the receipt of regulatory approval from the U.S., European Union, China, Brazil and 
Canada. Subject to satisfaction of customary closing conditions, including the receipt of regulatory approvals, closing would be 
expected to occur in first half of 2017.

See the discussion entitled Merger Risks Part I, Item 1A, Risk Factors, and Part II, Item 7 Management’s Discussion and Analysis 
of Financial Condition and Results of Operations, and Note 2 to the Consolidated Financial Statements for further details and a
discussion of some of the risks related to the transaction.  Additional information about the Merger Transaction and the Merger
Agreement is set forth in the definitive registration statement on Form S-4 (File No. 333-209869) (as amended, the Registration
Statement) that includes a joint proxy statement of Dow and DuPont and that also constitutes a prospectus of DowDuPont and the 
company's Current Report on Form 8-K filed with the SEC on December 11, 2015.

Spin-off of Performance Chemicals
On July 1, 2015, DuPont completed the separation of its Performance Chemicals segment through the spin-off of all of the issued
and outstanding stock of The Chemours Company (Chemours).  In connection with the separation, the company and Chemours 
entered into a Separation Agreement and a Tax matters Agreement as well as certain ancillary agreements.  In accordance with
generally accepted accounting principles in the U.S. (GAAP), the financial position and results of operations of the Performance 
Chemicals segment are presented as discontinued operations and, as such, have been excluded from continuing operations and 
segment results for all periods presented.  Additional details regarding the separation and other related agreements can be found u
in Note 3 to the Consolidated Financial Statements.

Productivity and Cost Savings Initiatives
On December 11, 2015, DuPont announced a 2016 global cost savings and restructuring plan designed to reduce $730 million in 
costs in 2016 compared with 2015, which represents a reduction of operating costs on a run-rate basis of about $1.0 billion by end 
of 2016. As part of the plan, the company committed to take structural actions across all businesses and staff functions globally
to operate more efficiently by further consolidating businesses and aligning staff functions more closely with them.  In connection
with the restructuring actions, the company recorded a pre-tax charge to earnings of $798 million in the fourth quarter 2015, 
comprised of $656 million of severance and related benefit costs, $109 million of asset related charges, and $33 million of contract 
termination costs.  The restructuring actions associated with the charge are substantially complete and the plan delivered the target 
cost reductions in 2016 versus prior year.  Additional details related to this plan can be found in Item 7, Management's Discussion 
and Analysis of Financial Condition and Results of Operations, on page 24 of this report and Note 4 to the Consolidated Financial 
Statements.

In June 2014, DuPont announced its global, multi-year initiative to redesign its global organization and operating model to reduce 
costs and improve productivity and agility across all businesses and functions.  DuPont commenced a restructuring plan to realign
and rebalance staff function support, enhance operational efficiency, and to reduce residual costs associated with the separation
of its Performance Chemicals segment.  Cost reductions from the 2014 operational redesign were essentially completed during 
2015  and  for  full  year  2015,  the  company  delivered  incremental  cost  savings  of  approximately  $440  million  year  over  year.
Additional details related to this plan can be found in Item 7, Management's Discussion and Analysis of Financial Condition and
Results of Operations, on page 24 of this report and Note 4 to the Consolidated Financial Statements.

dd

Business Segments
The company consists of 7 businesses which are aggregated into 6 reportable segments based on similar economic characteristics,
the nature of the products and production processes, end-use markets, channels of distribution and regulatory environment.  The
company's  reportable  segments  are Agriculture,  Electronics &  Communications,  Industrial  Biosciences,  Nutrition  &  Health, 
Performance Materials and Protection Solutions. The company includes certain businesses not included in the reportable segments, 
such as pre-commercial programs, nonaligned businesses and pharmaceuticals in Other.  Additional information with respect to 
business segment results is included in Item 7, Management's Discussion and Analysis of Financial Condition and Results of 
Operations, on page 31 of this report and Note 21 to the Consolidated Financial Statements.

Effective January 1, 2016, the DuPont Packaging & Industrial Polymers business consolidated with the DuPont Performance 
Polymers business within the Performance Materials segment, and the DuPont Protection Technologies business consolidated 
with the DuPont Building Innovations business within the former Safety & Protection segment (now Protection Solutions).  The 
consolidations were undertaken to create greater efficiency and enhanced capabilities in the two segments where these businesses 
operate.  These changes did not result in a change in reportable segments.  

3

ITEM 1.  BUSINESS, continued

Part I

DuPont Sustainable Solutions, previously within the company's former Safety & Protection segment (now Protection Solutions), 
was comprised of two business units: clean technologies and consulting solutions.  Effective January 1, 2016, the clean technologies
business  unit  became  part  of  the  Industrial  Biosciences  segment  with  the  focus  on  working  with  customers  to  improve  the
performance, productivity and sustainability of their products and processes.  The company is exploring a range of options to 
maximize the growth of the consulting solutions business unit which effective January 1, 2016 is reported within Other.

Agriculture 
Agriculture  businesses,  DuPont  Pioneer  (Pioneer)  and  DuPont  Crop  Protection  (Crop  Protection),  leverage  the  company's
technology, customer relationships and industry knowledge to improve the quantity, quality and safety of the global food supply
and the global production agriculture industry.  Land available for worldwide agricultural production is increasingly limited so
production growth will need to be achieved principally through improving crop yields and productivity rather than through increases 
in planted area.  The segment's businesses deliver a broad portfolio of products and services that are specifically targeted to achieve
gains in crop yields and productivity, including Pioneer® brand seed products and well-established brands of insecticides, fungicides 
and herbicides. Research and development focuses on leveraging technology to increase grower productivity and to enhance the 
value of grains and oilseeds through improved seed traits, superior seed germplasm and effective use of insecticides, herbicides 
and fungicides.  Agriculture accounted for 57 percent of the company's total research and development expense in 2016.

Sales of the company's products in this segment are affected by the seasonality of global agriculture markets and weather patterns. 
Sales and earnings performance in the Agriculture segment are significantly stronger in the first versus second half of the year 
reflecting the northern hemisphere planting season. As a result of the seasonal nature of its business, Agriculture's inventory is at 
its highest level at the end of the calendar year and is sold down in the first and second quarters. Trade receivables in the Agriculture 
segment are at a low point at year-end and increase through the northern hemisphere selling season to peak at the end of the second 
quarter.

y

Pioneer is a world leader in developing, producing and marketing hybrid corn seed and soybean seed varieties which improve the 
productivity and profitability of its customers.  Additionally, Pioneer develops, produces and markets canola, sunflower, sorghum, 
wheat and rice seed, as well as silage inoculants.  As the world's population grows and the middle class expands, the need for 
crops for animal feed, food, biofuels and industrial uses continues to increase. The business competes with other seed and plant 
biotechnology companies.  Pioneer seed sales amounted to 27 percent of the company's total consolidated net sales for the years
ended December 31, 2016, 2015 and 2014.

hh

Pioneer's research and development focuses on integrating high yielding germplasm with value added proprietary and/or licensed 
native and biotechnology traits with local environment and service expertise.  Pioneer uniquely develops integrated products for 
specific regional application based on local product advancement and testing of the product concepts.  Research and development
in this arena requires long-term commitment of resources, extensive regulatory efforts and collaborations, partnerships and business
arrangements to successfully bring products to market. To protect its investment, the business employs the use of patents covering
germplasm and native and biotechnology traits in accordance with country laws. Pioneer holds multiple long-term biotechnology
trait licenses from third parties as a normal course of business.  The biotechnology traits licensed by Pioneer from third parties 
are contained in a variety of Pioneer crops, including corn hybrids and soybean varieties.  The majority of Pioneer’s corn hybrids 
and soybean varieties sold to customers contain biotechnology traits licensed from third parties under these long term licenses.          

Pioneer is actively pursuing the development of innovations for corn hybrids, soybean varieties, and canola, sunflower, wheat and 
rice seed based on market assessments of the most valuable opportunities.  In corn seeds, programs include innovations for insect 
protection, drought, yield and yield stability.  In soybean seeds, programs include products with enhanced end-use value and insect 
protection. 

a

Pioneer has seed production facilities located throughout the world. Seed production is performed directly by the business or 
contracted  with  independent  growers  and  conditioners.  Pioneer's  ability  to  produce  seeds  primarily  depends  upon  growing 
conditions and availability of reliable contract growers.

Pioneer markets and sells seed product primarily under the Pioneer® brand but also sells and distributes products utilizing additional 
brand names.  Pioneer promotes its products through multiple marketing channels around the world. In the corn and soybean 
markets  of  the  U.S.  Corn  Belt,  Pioneer®  brand  products  are  sold  primarily  through  a  specialized  force  of  independent  sales 
representatives. Outside of North America, Pioneer's products are marketed through a network of subsidiaries, joint ventures and 
independent producer-distributors.

4

            
ITEM 1.  BUSINESS, continued

Part I

Crop Protection serves the global production agriculture industry with crop protection products for field crops such as wheat, corn, 
soybean and rice and specialty crops such as fruit, nut, vine and vegetables. Principle crop protection products are weed control, 
disease control and insect control offerings for foliar application or as a seed treatment. Crop Protection products are marketed 
and sold to growers and other end users through a network of wholesale distributors and crop input retailers. Sales for the business'
insect control portfolio is led by DuPontTM Rynaxypyr® insecticide, a product that is used across a broad range of core agricultural 
crops. 

The major commodities, raw materials and supplies for the Agriculture segment include: benzene derivatives, other aromatics and
carbamic acid related intermediates, corn and soybean seeds, insect control products, natural gas and seed treatments.

Agriculture net sales outside the U.S. accounted for 51 percent of the segment's total sales in 2016.

Electronics & Communications 
Electronics & Communications (E&C) is a leading supplier of differentiated materials and systems for consumer electronics, 
photovoltaics  (PV),  displays  and  advanced  printing  that  enable  superior  performance  and  lower  total  cost  of  ownership  for 
customers.  The segment leverages the company's strong materials and technology base to target attractive growth opportunities 
in circuit and semiconductor fabrication and packaging materials, PV materials, display materials, packaging graphics, and digital 
printing.  

In the consumer electronics market, E&C materials add value across multiple devices, with growth driven largely by smart phones. 
The segment has a portfolio of materials for semiconductor fabrication and packaging, as well as innovative materials for circuit 
applications, to address critical needs of electronic component and device manufacturers.  In the growing PV market, E&C is an 
industry-leading innovator and supplier of metallization pastes and backsheet materials that improve the efficiency and lifetime 
of solar cells and solar modules. Solar modules, which are made up of solar cells and other materials, are installed to generate 
power.  DuPont is a leading global supplier of materials to the PV industry.  In packaging graphics, E&C is a leading supplier of 
flexographic printing systems, including Cyrel® photopolymer plates and platemaking systems, and is investing in new products 
to strengthen its market leadership position.   The segment supplies pigmented inks used in digital printing applications for textile, 
commercial and home-office use.  In the displays market, E&C has developed solution-process technology, which it licenses for 
active matrix organic light emitting diode (AMOLED) television displays.

The major commodities, raw materials and supplies for E&C include: acrylic monomers, acetoxystyrene monomer, black and 
color  pigments,  styrenic  block  copolymers,  color  dyes,  copper  foil,  difluoroethane,  diglycolamine,  DMAC,  hydroxylamine, 
monomers and polymer resins, oxydianiline, polyester film, polymer films, precious metals and pyromellitic dianhydride. 

E&C net sales outside the U.S. accounted for 79 percent of the segment's total sales in 2016.

Industrial Biosciences
Industrial Biosciences is a leader in developing and manufacturing a broad portfolio of bio-based products.  The segment's enzymes 
add value and functionality to processes and products across a broad range of markets such as animal nutrition, detergents, food 
manufacturing, ethanol production and industrial applications.  The result is cost and process benefits, better product performance 
and improved environmental outcomes.  Industrial Biosciences also makes DuPontTM Sorona® PTT renewably sourced polymer 
for use in carpet and apparel fibers. In addition, the clean technologies business unit provides offerings that help reduce sulfur and 
other emissions, formulate cleaner fuels, and dispose of liquid waste. 

The  segment  includes  a  joint  venture  with Tate &  Lyle PLC,  DuPont Tate  &  Lyle  Bio  Products  Company, LLC,  to  produce 
BioPDOTM 1,3 propanediol using a proprietary fermentation and purification process.  BioPDOTM is the key building block for 
DuPontTM Sorona® PTT polymer. 

The major commodities, raw materials and supplies for the Industrial Biosciences segment include: terephthalic acid, processed 
grains (including dextrose and glucose), and glycols.

Industrial Biosciences net sales outside the U.S. accounted for 59 percent of the segment's total sales in 2016.

5

ITEM 1.  BUSINESS, continued

Part I

Nutrition & Health 
Nutrition & Health offers a wide range of sustainable, bio-based ingredients, providing innovative solutions for specialty food
ingredients, food nutrition, health and safety.  The segment's product solutions include the wide-range of DuPont™ Danisco® food 
ingredients  such  as  cultures  and  probiotics,  notably  Howaru®,  emulsifiers,  texturants,  natural  sweeteners  such  as  Xivia®  and 
Supro®soy-based  food  ingredients.  These  ingredients  hold  leading  market  positions  based  on  industry  leading  innovation,
knowledge and experience, relevant product portfolios and close-partnering with the world's food manufacturers. Nutrition & 
Health serves various end markets within the food industry including dairy, bakery, meat and beverage segments. Nutrition & 
Health has research, production and distribution operations around the world.    

Nutrition & Health products are marketed and sold under a variety of brand names and are distributed primarily through its direct 
route to market. The direct route to market focuses on strong customer collaborations and insights with multinational customers
and regional customers alike.    

The major commodities, raw materials and supplies for the Nutrition & Health segment include: cellulose, gelatin, glycerol, guar, a
organic oils, peels, saccharides, seaweed, soybeans, sugars and yeasts.

In November 2016, DuPont announced an investment to expand probiotics production capacity in the United States. The investment 
is the second phase of a broader probiotics expansion project due to the rapidly growing global demand for probiotics. Phase one,
supporting current growth, is ongoing in Madison, Wis., and Rochester, N.Y., and is partially complete as of the end of 2016. The 
second phase is scheduled to span two-years, represents an investment of approximately $100 million, and increases the company’s 
probiotics production capacity by an additional 70 percent. Production will be optimized with the installation of new, high-volume 
fermenters and other processing equipment.

In December 2016, DuPont and Hygenia LLC announced an agreement to sell DuPont's global food safety diagnostic business to 
Hygenia LLC. The transaction is expected to close in the first half of 2017, pending satisfaction of customary closing conditions,
including receipt of regulatory approval.

Nutrition & Health net sales outside the U.S. accounted for 66 percent of the segment's total sales in 2016. 

Performance Materials
DuPont Performance Materials (Performance Materials) provides its customers with innovative polymer science solutions and 
expert application development assistance to enhance the performance, reduce the total system cost and optimize the sustainability
of their products. Solutions include productive, higher performance polymers, elastomers, films, parts, and systems and solutions 
which improve the uniqueness, functionality and profitability of its customers' offerings. Key market segments include automotive 
and transportation, packaging for food and beverages, electrical/electronic components, material handling, healthcare, construction, 
semiconductor and aerospace. The segment has several large customers, primarily in the motor vehicle OEM industry supply 
chain. The company has long-standing relationships with these customers and they are considered to be important to the segment's 
operating results.  

Performance Materials product portfolio includes elastomers and thermoplastic and thermoset engineering polymers which are 
used by customers to fabricate components for mechanical, chemical and electrical systems. The main products include: DuPontTM
Zytel® long chain nylon polymers, Zytel® HTN nylon resins, Zytel® nylon resins, Crastin® PBT polymer resins, Rynite® PET
polymer resins, Delrin® acetal resins, Hytrel® polyester thermoplastic elastomer resins, Vespel® parts and shapes, Vamac® ethylene 
acrylic elastomer and Kalrez® perfluoroelastomer.

Performance Materials also specializes in resins and films used in packaging and industrial polymer applications, sealants and 
adhesives and sporting goods. Key brands include: DuPontTM Surlyn® ionomer resins, Bynel® coextrudable adhesive resins, Elvax®
EVA resins, Nucrel® Elvaloy®polymer modifiers and Elvaloy® copolymer resins. Performance Materials product portfolio also
includes the DuPont Teijin Films joint venture, whose primary products are Mylar® and Melinex® polyester films.

In November 2013, DuPont entered into a definitive agreement to sell Glass Laminating Solutions/Vinyls (GLS/Vinyls) to Kuraray
Co. Ltd. In June 2014, the sale was completed which resulted in a pre-tax gain of $391 million ($273 million net of tax). The gain 
was recorded in other income, net in the company's Consolidated Income Statement for the year ended December 31, 2014.  GLS/
Vinyls specializes in interlayers for laminated safety glass and its key brands include SentryGlas®and Butacite® laminate interlayers. 

6

ITEM 1.  BUSINESS, continued

Part I

The major commodities, raw materials and supplies for the Performance Materials segment include: acetic acid, acrylic monomers,
adipic  acid,  butanediol,  dimethyl  terephthalate,  dodecanedioic  acid,  ethane,  fiberglass,  hexamethylene  diamine,  methanol, 
methacrylic acid, methylacrylate, natural gas, paraxylene, perfluoromethylvinyl ether, polytetramethylene glycol, polyethylene,
polyolefin resin,purified terephthalic acid, and vinyl acetate monomer.

Performance Materials net sales outside the U.S. accounted for 71 percent of the segment's total sales in 2016.

Protection Solutions
Protection Solutions satisfies the growing global needs of businesses, governments, and consumers for solutions that make life
safer, healthier, and more secure. By uniting market-driven science with the strength of highly regarded brands, the segment 
delivers  products  to  a  broad  array  of  markets,  including,  industrial,  construction,  consumer,  military  and  law  enforcement,
automotive, aircraft, and energy. Protection Solutions is also investing in future growth initiatives such as protection of perishable
and temperature-sensitive food and pharmaceutical products and roofing underlayment.  

With highly recognized brands like DuPont™ Kevlar® high-strength material, Nomex® thermal-resistant material, and Tyvek®
protective  material,  the  business  has  a  broad  portfolio  of  industry  leading  solutions  for  applications  such  as:  aerospace,  life
protection, personal protection, medical packaging, graphics, and protection and energy efficiency of buildings. DuPont™ Corian®, 
Montelli®, and Zodiaq® solid surfaces offer durable, functional, and aesthetically appealing materials for residential and commercial 
interior and exterior applications.

The major commodities, raw materials, and supplies for the Protection Solutions segment include: alumina trihydrate, aniline, 
benzene, calcium chloride, carbon monoxide, chlorine, high-density polyethylene, isophthalic acid, metaphenylenediamine, methyl
methacrylate, polyester resin, polypropylene, quartz, sulfuric acid, and terephthalic acid.  

Protection Solutions net sales outside the U.S. accounted for 56 percent of the segment's total sales in 2016.

Backlog
In general, the company does not manufacture its products against a backlog of orders and does not consider backlog to be a 
significant indicator of the level of future sales activity.  Production and inventory levels are based on the level of incoming orders 
as well as projections of future demand.  Therefore, the company believes that backlog information is not material to understanding
its overall business and should not be considered a reliable indicator of the company's ability to achieve any particular level of 
revenue or financial performance.

Intellectual Property 
As a science and technology based company, DuPont believes that securing intellectual property is an important part of protecting
its research. Some DuPont businesses operate in environments in which the availability and protection of intellectual property 
rights affect competition.  Information on the importance of intellectual property rights to Pioneer is included in Item 1 Agriculture 
business discussion beginning on page 4 of this report.

Trade secrets are an important element of the company's intellectual property.  Many of the processes used to make DuPont products
are kept as trade secrets which, from time to time, may be licensed to third parties.  DuPont vigilantly protects all of its intellectual 
property including its trade secrets.  When the company discovers that its trade secrets have been unlawfully taken, it reports the 
matter to governmental authorities for investigation and potential criminal action, as appropriate.  In addition, the company takes
measures to mitigate any potential impact, which may include civil actions seeking redress, restitution and/or damages based on
loss to the company and/or unjust enrichment.

Patents & Trademarks:  DuPont continually applies for and obtains U.S. and foreign patents and has access to a large patent 
portfolio, both owned and licensed.  DuPont’s rights under these patents and licenses, as well as the products made and sold under 
them, are important to the company in the aggregate. The protection afforded by these patents varies based on country, scope of
individual patent coverage, as well as the availability of legal remedies in each country.  This significant patent estate may be 
leveraged to align with the company’s strategic priorities within and across segments.  At December 31, 2016, the company owned
about 6,500 active U.S. patents and about 10,000 active patents outside of the U.S., of which about 55 and 30 percent, respectively, 
relate to the Agriculture segment.

7

ITEM 1.  BUSINESS, continued

Remaining life of granted patents owned as of December 31, 2016:

Part I

Within 5 years

6 to 10 years

11 to 16 years

16 to 20 years

Total

U.S.
1,400

1,600

2,400

1,100

6,500

Other Countries
1,900

4,100

3,700

300

10,000

In addition to its owned patents, the company owns over 8,300 patent applications.

The company owns or licenses many trademarks that have significant recognition at the consumer retail level and/or business to 
business level.  Ownership rights in trademarks do not expire if the trademarks are continued in use and properly protected.

Research and Development
DuPont’s investment in research and development (R&D) was $1.6 billion in 2016, $1.9 billion in 2015 and $2.0 billion in 2014. 
DuPont conducts R&D activities to renew our portfolio, create new product lines, and transform markets to deliver results in the 
short, mid and long term. Each business in the company directs R&D activities that support its business objectives, and the company 
supports cross-business and cross-functional investment to incubate new science-intensive growth opportunities additive to the 
existing business portfolios. The R&D portfolio is managed by senior business and R&D leaders to ensure consistency with the
corporate and business strategies and to capitalize on the application of emerging science. DuPont’s R&D leverages the company's 
unique world-class science, technology and engineering capabilities, deep understanding of markets and value chains, and research 
collaborations, to drive revenue and profit growth.

mm

The company protects its R&D investment through its intellectual property strategy.  See discussion under “Intellectual Property” 
beginning on page 7.

tt

Additional information with respect to R&D related to Agriculture is included on page 4.

Environmental Matters
Information related to environmental matters is included in several areas of this report: (1) Environmental Proceedings beginning
on page 18, (2) Management's Discussion and Analysis of Financial Condition and Results of Operations beginning on pages 43,
48-50 and (3) Notes 1 and 15 to the Consolidated Financial Statements.

Available Information
The company is subject to the reporting requirements under the Securities Exchange Act of 1934. Consequently, the company is 
required to file reports and information with the Securities and Exchange Commission (SEC), including reports on the following
forms: annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports
filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

The public may read and copy any materials the company files with the SEC at the SEC's Public Reference Room at 100 F Street,
NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the 
SEC at 1-800-SEC-0330. The SEC also maintains an Internet site at http://www.sec.gov that contains reports, proxy and information
statements, and other information regarding issuers that file electronically with the SEC.

The company's annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to 
those reports are also accessible on the company's website at http://www.dupont.com by clicking on the section labeled "Investors",
then on "Filings & Reports" and then on "SEC Filings." These reports are made available, without charge, as soon as is reasonably
practicable after the company files or furnishes them electronically with the SEC.

Executive Officers of the Registrant
Information  related  to  the  company's  Executive  Officers  is  included  in  Item 10,  Directors,  Executive  Officers  and  Corporate 
Governance, beginning on page 53 of this report.

8

ITEM 1A.  RISK FACTORS

Part I

Risks relating to the Mergers 
The risk factors below should be read in conjunction with the risk factors and other information related to the Mergers set forthrr
in the Registration Statement and the risk factors related to the company’s operations set forth below as well as the other information 
contained in this report.

ff

Regulatory approvals may not be received, may take longer than expected or may impose conditions that are not presently 
anticipated or that cannot be met.
Before the Mergers may be completed, various approvals, authorizations and declarations of non-objection must be obtained from
certain regulatory and governmental authorities. Subject to the terms and conditions of the Merger Agreement, Dow and DuPont 
have each agreed to use their reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and 
to assist and cooperate with each other in doing, all things necessary, proper or advisable to consummate and make effective, as 
soon as possible following the date of the Merger Agreement, the Mergers and the other transactions contemplated by the Merger 
Agreement. For purposes of the foregoing, "reasonable best efforts" includes (i) the sale, divestiture or disposition of such assets 
or businesses of either party or its subsidiaries or affiliates and (ii) restrictions or actions that after the Effective Time would limit 
DowDuPont's or its subsidiaries' or affiliates' freedom of action or operations with respect to retaining, or its ability to retain, one 
or more of its or its subsidiaries' businesses, product lines or assets. These regulatory and governmental entities may impose 
conditions on the granting of such approvals and if such regulatory and governmental entities seek to impose such conditions, 
lengthy negotiations may ensue among such regulatory or governmental entities, DuPont and Dow. Such conditions and the process 
of obtaining regulatory approvals could have the effect of delaying completion of the Mergers and such conditions may not be 
satisfied for an extended period of time. Such conditions may also impose additional costs or limitations on the combined companyaa
following the completion of the Mergers, including the requirement that the respective Dow and DuPont businesses divest certain
assets if necessary in order to obtain certain regulatory approvals, and may limit the ability of the combined company to integrate 
parts of the DuPont and Dow businesses and negatively impact the ultimate composition of the entities we expect to constitute in
connection with the Intended Business Separations. These conditions may therefore reduce the anticipated benefits of the Mergers,
which could also have a material adverse effect on the combined company’s business and cash flows and results of operations, 
and DuPont cannot predict what, if any, changes may be required by regulatory or governmental authorities whose approvals are
required. The regulatory approvals may not be received at all, may not be received in a timely fashion, and may contain conditions 
on the completion of the Mergers.

DuPont or Dow may waive one or more of the closing conditions without re-soliciting stockholder approval.
DuPont or Dow may determine to waive, in whole or in part, one or more of the conditions to its obligations to consummate the 
Mergers. DuPont or Dow currently expect to evaluate the materiality of any waiver and its effect on DuPont stockholders or Dow 
stockholders,  as  applicable,  in  light  of  the  facts  and  circumstances  at  the  time  to  determine  whether  any  amendment  of  the 
Registration Statement or any re-solicitation of proxies or voting cards is required in light of such waiver. Any determination
whether to waive any condition to the Mergers or as to re-soliciting stockholder approval or amending the Registration Statement 
as  a  result  of  the  waiver  will  be  made  by  DuPont  or  Dow,  as  applicable,  at  the  time  of  such  waiver  based  on  the  facts  and 
circumstances as they exist at that time.

The Merger Agreement may be terminated in accordance with its terms and the Mergers may not be completed.
The completion of the Mergers is subject to the satisfaction or waiver of a number of conditions. Those conditions include: (i) the 
receipt of certain domestic and foreign regulatory approvals under competition laws, including the termination or expiration of
the waiting period under the HSR Act; (ii) the absence of certain governmental restraints or prohibitions preventing completion
of the DuPont Merger or the Dow Merger; (iii) the approval of the shares of DowDuPont Common Stock to be issued to DuPont 
stockholders and Dow stockholders for listing on the NYSE; (iv) the reasonable determination by DuPont and Dow that neither 
the DuPont Merger nor the Dow Merger will constitute an acquisition of a 50 percent or greater interest in Dow or DuPont, under
Section 355(e) of the Code; (v) the truth and correctness of the representations and warranties made by both parties (generally
subject to certain “materiality” and “material adverse effect” qualifiers); (vi) the performance by DuPont and Dow of their respective 
obligations under the Merger Agreement in all material respects; and (vii) the receipt by both parties of legal opinions from their 
respective tax counsels with respect to the tax-free nature of each of the Mergers.

t

9

ITEM 1A.  RISK FACTORS, continued

Part I

These conditions to the closing may not be fulfilled and, accordingly, the Mergers may not be completed. In addition, if the Mergers 
are not completed by March 15, 2017 (subject to extension to June 15, 2017, by either party if certain antitrust-related conditions 
to the closing have not been satisfied), either DuPont or Dow may choose not to proceed with the Mergers, and the parties can 
mutually decide to terminate the Merger Agreement at any time prior to the consummation of the Mergers. In addition, DuPont 
or Dow may elect to terminate the Merger Agreement in certain other circumstances. If the Merger Agreement is terminated, Dow
and  DuPont  may  incur  substantial  fees  in  connection  with  termination  of  the  Merger Agreement  and  will  not  recognize  the 
anticipated benefits of the Mergers.

Termination of the Merger Agreement could negatively impact DuPont. 
If the Merger Agreement is terminated in accordance with its terms and the Mergers are not consummated, the ongoing businesses 
of DuPont may be adversely affected by a variety of factors. DuPont's respective businesses may be adversely impacted by the 
failure to pursue other beneficial opportunities during the pendency of the Mergers, by the failure to obtain the anticipated benefits 
of completing the Mergers, by payment of certain costs relating to the Mergers, and by the focus of DuPont's management on the 
Mergers for an extended period of time rather than on management opportunities or other issues. The market price of DuPont 
common stock might decline as a result of any such failures to the extent that the current market prices reflect a market assumptionmm
that the Mergers will be completed.

In addition, if the Merger Agreement is terminated under certain circumstances, DuPont or Dow may be required to pay a termination
fee of $1.9 billion to the other party, depending on the circumstances surrounding the termination. DuPont may also be negatively
impacted  if  the  Merger Agreement  is  terminated  and  it  seeks  but  is  unable  to  find  another  business  combination  or  strategic 
transaction offering equivalent or more attractive consideration than the consideration to be provided in the Mergers, or if DuPont 
becomes subject to litigation related to entering into or failing to consummate the Mergers, including direct actions by DuPont
stockholders against the directors and/or officers of DuPont for breaches of fiduciary duty, and stockholder derivative actions. 

There can be no assurance that the expected benefits of the Mergers, including the Intended Business Separations, will 
occur or be fully or timely realized.
The success of the Mergers will depend, in part, on the combined company’s ability to successfully combine the businesses of 
DuPont and Dow. If the combined company is not able to successfully combine the businesses of DuPont and Dow in an efficient 
and effective manner, including if the Intended Business Separations are delayed or ultimately not consummated, the anticipated
benefits, synergies, operational efficiencies and cost savings may not be realized fully or at all, or may take longer to realize than 
expected, and the value of common stock, the revenues, levels of expenses and results of operations of the combined company 
may be adversely affected.

The combination of two independent businesses is a complex, costly and time consuming process, and the management of the
combined company may face significant challenges in implementing such integration, including, without limitation:

• 

• 

• 
• 
• 

• 

latent impacts resulting from the diversion of management’s attention from ongoing business concerns as a result of the 
devotion of management’s attention to the Mergers and resulting performance shortfalls;
ongoing diversion of the attention of management from the operation of the combined company’s business as a result of 
the Intended Business Separations;
difficulties in achieving anticipated cost savings, synergies, business opportunities and growth prospects;
difficulties in managing a larger combined company addressing differences in business culture and retaining key personnel;
the possibility of faulty assumptions underlying expectations regarding the integration process, including with respect to 
the Intended Business Separations;
unanticipated  issues  in  integrating  information  technology,  communications  programs,  financial  procedures  and 
operations, and other systems, procedures and policies;
unanticipated changes in applicable laws and regulations;

• 
•  managing tax costs or inefficiencies associated with integrating the operations of the combined company and the Intended 

Business Separations;
coordinating geographically separate organizations; and unforeseen expenses or delays associated with the Mergers.

• 

10

ITEM 1A.  RISK FACTORS, continued

Part I

Some of these factors will be outside of the control of management and any one of them could result in increased costs and diversion
of management’s time and energy, as well as decreases in the amount of expected revenues which could materially impact the 
company’s business, financial conditions and results of operations. The integration process and other disruptions resulting from
the Mergers may also adversely affect the combined company’s relationships with employees, suppliers, customers, distributors, 
licensors and others with whom DuPont and Dow have business or other dealings, and difficulties in integrating the businesses
or regulatory functions of DuPont and Dow could harm the reputation of the combined company.

If the combined company is not able to successfully combine the businesses of DuPont and Dow in an efficient, cost-effective 
and timely manner, the anticipated benefits and cost savings of the Mergers (including the Intended Business Separations) may 
not be realized fully, or at all, or may take longer to realize than expected, and the value of DowDuPont common stock, the 
revenues, levels of expenses and results of operations may be affected adversely. If the combined company is not able to adequately 
address integration challenges, the combined company may be unable to integrate successfully DuPont’s and Dow’s operations,
effect the Intended Business Separations or to realize the anticipated benefits of the transactions.

DuPont will be subject to business uncertainties and contractual restrictions until the Mergers are consummated.
Uncertainty about the completion or effect of the Mergers on employees, suppliers, customers, distributors, licensors and licensees 
as well as regulatory permits, licenses, contracts and other agreements, particularly for which the Mergers could be deemed a 
“change-in-control” under the applicable  terms and conditions may have an adverse effect on DuPont, Dow and consequently on 
the combined company.  Changes to existing business relationships, including termination or modification, could negatively affect 
each of DuPont’s and/or Dow's revenues, earnings and cash flow, as well as the market price of its common stock.  These uncertainties 
may impair each party’s ability to attract, retain and motivate key personnel until the consummation of the Mergers, and could 
cause  suppliers,  customers  and  others  that  deal  with  the  parties  to  seek  to  change  existing  business  relationships  with  them. 
Retention of employees could be challenging during the pendency of the Mergers due to uncertainty about their future roles. If 
key employees depart because of issues related to the uncertainty and difficulty of integration or a desire not to remain with the 
businesses, the combined company’s business following the consummation of the Mergers could be negatively impacted. Further,
no assurance can be given that the combined company will be able to attract or retain key management personnel and other key 
employees of DuPont and Dow to the same extent that DuPont and Dow have previously been able to attract or retain their 
employees.

In addition, the Merger Agreement restricts each of DuPont and Dow, without the consent of the other party, from making certain
acquisitions and divestitures, entering into certain contracts, incurring certain indebtedness and expenditures, paying dividends 
in excess of certain thresholds, repurchasing or issuing securities outside of existing share repurchase and equity award programs,
and taking other specified actions until the earlier of the completion of the Mergers or the termination of the Merger Agreement. 
These  restrictions  may  prevent  or  delay  pursuit  of  strategic  corporate  or  business  opportunities  that  may  arise  prior  to  the 
consummation of the Mergers. Adverse effects arising during the pendency of the Mergers could be exacerbated by any delays in 
consummation of the Mergers or termination of the Merger Agreement.

Inability to access the debt capital markets could impair DuPont's liquidity, business or financial condition.
DuPont has relied and continues to rely on access to the debt capital markets to finance its day-to-day and long-term operations.
In connection with the Mergers, Dow and DuPont do not intend for DowDuPont to incur debt obligations or guarantee the debt 
obligations of Dow or DuPont.

Any limitation on DuPont’s ability to raise money in the debt markets could have a substantial negative effect on its liquidity. 
Access to the debt capital markets in amounts adequate to finance DuPont's activities could be impaired as a result of the existence 
of material nonpublic information about the Intended Business Separations and other potential factors, including factors that are a
not specific to DuPont, such as a severe disruption of the financial markets and interest rate fluctuations.

DuPont expects to incur substantial transaction-related costs in the connection with the Mergers. 
DuPont expects to incur significant costs, expenses and fees for professional services and other transaction costs in connection
with the transaction. During the years ended December 31, 2016 and 2015, the company incurred transaction-related costs of $386
million and $10 million, respectively.  The substantial majority of these costs are and will continue to be expenses relating to the 
Mergers and the Intended Business Separations, including costs relating to integration and separation planning.  These costs could 
adversely affect the financial condition and results of operation of DuPont prior to the Mergers and of the combined company
following the Mergers.

11

ITEM 1A.  RISK FACTORS, continued

Part I

The determination to proceed with the Intended Business Separations will not be made at the time of the consummation 
of the Mergers, and the expected benefits of such transactions, if they occur, will be uncertain.
In connection with the Mergers, Dow and DuPont have announced their intention that the combined company will pursue the 
separation of the combined company’s agriculture business, material science business and specialty products business through
one or more tax-efficient transactions, resulting in three independent, publicly traded companies. However, consummation of the
Mergers is not conditioned on the Intended Business Separations, and the determination as to whether to pursue such transactions 
will be made by the DowDuPont Board following the consummation of the Mergers. Following the consummation of the Mergers, 
the  DowDuPont  Board  may  ultimately  determine  to  abandon  one  or  more  of  the  Intended  Business  Separations,  and  such
determination could have an adverse impact on the value of the combined company. Additionally, there are many determinations
with respect to the Intended Business Separations that, by their nature, cannot be determined until the completion of the Mergers, 
including definitive determinations with regard to the capital structure of the various businesses and allocation of liabilities among 
them. As such, there are many factors that could, through the closing and prior to the determination by the DowDuPont Board to 
proceed with the Intended Business Separations, impact the structure or timing of, the anticipated benefits from, or determination
to ultimately proceed with, the Intended Business Separations, including, among others, global economic conditions, instability
in credit markets, declining consumer and business confidence, fluctuating commodity prices and interest rates, volatile exchange 
rates, tax considerations, and other challenges that could affect the global economy, specific market conditions in one or more of 
the industries of the businesses proposed to be separated, and changes in the regulatory or legal environment. Such changes could 
adversely  impact  the  value  of  one  or  more  of  the  Intended  Business  Separations  to  the  combined  company’s  stockholders. 
Additionally, to the extent the DowDuPont Board determines to proceed with the Intended Business Separations, the consummation 
of such transactions is a complex, costly and time consuming process, and there can be no assurance that the intended benefits of 
such transactions will be achieved. An inability to realize the full extent of the anticipated benefits of the Intended Business 
Separations, as well as any delays encountered in the process, could have an adverse effect upon the revenues, level of expenses 
and operating results of the agriculture business, the specialty products business, the material science business and/or the combined 
company.

Risks Related to the Company’s Operations 

The company's operations could be affected by various risks, many of which are beyond its control. Based on current information, 
the company believes that the following identifies the most significant risk factors that could affect its businesses. Past financial 
performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or 
trends in future periods.

The company’s operations outside the United States are subject to risks and restrictions, which could negatively affect our 
results of operations, financial condition, and cash flows.
The company’s operations outside the United States are subject to risks and restrictions, including fluctuations in currency values 
and foreign-currency exchange rates; exchange control regulations; changes in local political or economic conditions; import and 
trade restrictions; import or export licensing requirements and trade policy and other potentially detrimental domestic and foreign 
governmental practices or policies affecting U.S. companies doing business abroad.  Although DuPont has operations throughout 
the world, sales outside the U.S. in 2016 were principally to customers in Eurozone countries, China, Brazil, and Japan. Further, 
the company’s largest currency exposures are the European euro, the Chinese yuan, the Brazilian real, and the Japanese yen. 
Market uncertainty or an economic downturn in these geographic areas could reduce demand for the company’s products and 
result in decreased sales volume, which could have a negative impact on DuPont’s results of operations.  In addition, changes in
exchange rates may affect the company’s results from operations, financial condition and cash flows in future periods.  The company 
actively manages currency exposures that are associated with net monetary asset positions, committed currency purchases and 
sales, foreign currency-denominated revenues and other assets and liabilities created in the normal course of business.  

mm

Volatility in energy and raw materials costs could have a significant impact on the company's sales and earnings.
The company's manufacturing processes consume significant amounts of energy and raw materials, the costs of which are subject 
to worldwide supply and demand as well as other factors beyond the control of the company. Significant variations in the cost of 
energy, which primarily reflect market prices for oil, natural gas, and raw materials affect the company's operating results from
period to period. Legislation to address climate change by reducing greenhouse gas emissions and establishing a price on carbon
could create increases in energy costs and price volatility. 

12

ITEM 1A.  RISK FACTORS, continued

Part I

When possible, the company purchases raw materials through negotiated long-term contracts to minimize the impact of price 
fluctuations. Additionally, the company enters into over-the-counter and exchange traded derivative commodity instruments to 
hedge its exposure to price fluctuations on certain raw material purchases. The company takes actions to offset the effects of higher 
energy and raw material costs through selling price increases, productivity improvements and cost reduction programs. Success 
in offsetting higher raw material costs with price increases is largely influenced by competitive and economic conditions and could 
vary significantly depending on the market served. If the company is not able to fully offset the effects of higher energy and raw 
material costs, it could have a significant impact on the company's financial results.

The  company's  results  of  operations  and  financial  condition  could  be  seriously  impacted  by  business  disruptions  and
security breaches, including cybersecurity incidents.
Business  and/or  supply  chain  disruptions,  plant  and/or  power  outages  and  information  technology  system  and/or  network 
disruptions, regardless of cause including acts of sabotage, employee error or other actions, geo-political activity, weather events
and natural disasters could seriously harm the company's operations as well as the operations of its customers and suppliers. Failure
to effectively prevent, detect and recover from security breaches, including attacks on information technology and infrastructure 
by hackers; viruses; breaches due to employee error or actions; or other disruptions could result in misuse of the company's assets, 
business disruptions, loss of property including trade secrets and confidential business information, legal claims or proceedings,
reporting errors, processing inefficiencies, negative media attention, loss of sales and interference with regulatory compliance. 
Like most major corporations, the company is the target of industrial espionage, including cyber-attacks, from time to time. The 
company has determined that these attacks have resulted, and could result in the future, in unauthorized parties gaining access to
at least certain confidential business information. However, to date, the company has not experienced any material financial impact,
changes in the competitive environment or business operations that it attributes to these attacks. Although management does not
believe that the company has experienced any material losses to date related to security breaches, including cybersecurity incidents, 
there can be no assurance that it will not suffer such losses in the future. The company actively manages the risks within its control 
that could lead to business disruptions and security breaches. As these threats continue to evolve, particularly around cybersecurity,
the company may be required to expend significant resources to enhance its control environment, processes, practices and other 
protective measures. Despite these efforts, such events could have a material adverse effect on the company's business, financial 
condition or results of operations.

mm

Unpredictable seasonal and weather factors could impact sales and earnings from the company’s Agriculture segment.
The agriculture industry is subject to seasonal and weather factors, which can vary unpredictably from period to period. Weather 
factors can affect the presence of disease and pests on a regional basis and, accordingly, can positively or adversely affect the 
demand for crop protection products, including the mix of products used. The weather also can affect the quality, volume and cost 
of seeds produced for sale as well as demand and product mix. Seed yields can be higher or lower than planned, which could lead
to higher inventory and related-write-offs and affect the ability to supply.

t

Inability to discover, develop and protect new technologies and enforce the company's intellectual property rights could
adversely affect the company's financial results.
The company competes with major global companies that have strong intellectual property estates, including intellectual propertytt
rights  supporting  the  use  of  biotechnology  to  enhance  products,  particularly  agricultural  and  bio-based  products.  Speed  in 
discovering, developing and protecting new technologies and bringing related products to market is a significant competitive 
advantage. Failure to predict and respond effectively to this competition could cause the company's existing or candidate products 
to become less competitive, adversely affecting sales. Competitors are increasingly challenging intellectual property positions and 
the outcomes can be highly uncertain. If challenges are resolved adversely, it could negatively impact the company's ability to
obtain licenses on competitive terms, commercialize new products and generate sales from existing products.

Intellectual  property  rights,  including  patents,  plant  variety  protection,  trade  secrets,  confidential  information,  trademarks,
tradenames and other forms of trade dress, are important to the company's business. The company endeavors to protect its intellectual 
property rights in jurisdictions in which its products are produced or used and in jurisdictions into which its products are imported. 
However, the company may be unable to obtain protection for its intellectual property in key jurisdictions. Further, changes in
government policies and regulations, including changes made in reaction to pressure from non-governmental organizations, could 
impact the extent of intellectual property protection afforded by such jurisdictions.

mm

13

ITEM 1A.  RISK FACTORS, continued

Part I

The company has designed and implemented internal controls to restrict access to and distribution of its intellectual property.
Despite these precautions, the company's intellectual property is vulnerable to unauthorized access through employee error or 
actions, theft and cybersecurity incidents, and other security breaches. When unauthorized access and use or counterfeit products 
are discovered, the company reports such situations to governmental authorities for investigation, as appropriate, and takes measures
to mitigate any potential impact. Protecting intellectual property related to biotechnology is particularly challenging because theft 
is difficult to detect and biotechnology can be self-replicating. Accordingly, the impact of such theft can be significant. See Part I, 
Item 1 for additional details on the company's intellectual property.

Market acceptance, government policies, rules, regulations and competition could affect the company's ability in certain
markets to generate and sustain sales or affect profitability from products based on biotechnology.
The company is using biotechnology to create and improve products, particularly in its Agriculture and Industrial Biosciences 
segments. The company is also using biotechnology in the development of certain products and pre-commercial programs in Other. 
These  products  enable  cost  and  process  benefits,  better  product  performance  and  functionality,  and  improve  environmental 
outcomes in a broad range of products, technologies and processes such as seeds, enzymes, animal nutrition, detergents, food 
ingredients, ethanol production and industrial applications. The company's ability to generate and sustain sales from such products 
could be impacted by market acceptance, including perception of benefits and costs relative to products based on conventional 
technologies,  as  well  as  governmental  policies,  laws  and  regulations  that  affect  the  development,  manufacture  and 
commercialization of products, particularly the testing and planting of seeds containing biotechnology traits and the import of
grains, food and food ingredients and other products derived from those seeds.

dd

In order to maintain its right to produce or sell existing products or to commercialize new products containing biotechnology traits, 
particularly seed products, the company must be able to demonstrate its ability to satisfy the requirements of regulatory agencies. 
Sales into and use of seeds with biotechnology traits in jurisdictions where cultivation has been approved could be affected if key 
import markets have not approved the import of grains, food and food ingredients and other products derived from those seeds.
If import of grains, food and food ingredients and other products derived from those seeds containing such biotechnology traits
occurs in these markets, it could lead to disruption in trade and potential liability for the company.

f

tt

In addition, the company’s regulatory compliance could be affected by the detection of low level presence of biotechnology traits 
in conventional seed or products produced from such seed. Furthermore, the detection of biotechnology traits not approved in the 
country of cultivation may affect the company’s ability to supply product and could affect exports of products produced from such 
seeds and even result in crop destruction or product recalls.

DuPont’s ability to obtain and maintain regulatory approval for some of its products in the Agriculture segment could 
limit sales or affect profitability in certain markets.
In most jurisdictions, the company must test the safety, efficacy and environmental impact of its Agricultural products to satisfy 
regulatory requirements and obtain the necessary approvals. In certain jurisdictions the company must periodically renew its 
approvals which may require it to demonstrate compliance with then-current standards. The regulatory environment is lengthy,
complex and in some markets unpredictable,  with requirements that can vary by product, technology, industry and country. The 
regulatory environment may be impacted by the activities of non-governmental organizations and special interest groups and 
stakeholder reaction to actual or perceived impacts of new technology, products or processes on safety, health and the environment. 
Obtaining and maintaining regulatory approvals requires submitting a significant amount of information and data, which may
require participation from technology providers. Regulatory standards and trial procedures are continuously changing. The pace 
of change together with the lack of regulatory harmony could result in unintended noncompliance. 

Responding to these changes and meeting existing and new requirements may involve significant costs or capital expenditures or 
require changes in business practice that could result in reduced profitability.  The failure to receive necessary permits or approvals 
could have near- and long-term effects on the company’s ability to produce and sell some current and future products.

aa

14

ITEM 1A.  RISK FACTORS, continued

Part I

Failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions could adversely impact our 
future results.
From time to time, the company evaluates acquisition candidates that may strategically fit its business and/or growth objectives.
If the company is unable to successfully integrate and develop acquired businesses, the company could fail to achieve anticipated 
synergies and cost savings, including any expected increases in revenues and operating results, which could have a material adverse 
effect on the company’s financial results. The company continually reviews its portfolio of assets for contributions to the company’s 
objectives and alignment with its growth strategy. However, the company may not be successful in separating underperforming 
or non-strategic assets and gains or losses on the divestiture of, or lost operating income from, such assets may affect the company’s 
earnings.  Moreover,  the  company  might  incur  asset  impairment  charges  related  to  acquisitions  or  divestitures  that  reduce  its 
earnings.

mm

The company's business, including its results of operations and reputation, could be adversely affected by process safety 
and product stewardship issues. 
Failure to appropriately manage safety, human health, product liability and environmental risks associated with the company's 
products,  product  life  cycles  and  production  processes  could  adversely  impact  employees,  communities,  stakeholders,  the
environment, the company's reputation and its results of operations. Public perception of the risks associated with the company's 
products and production processes could impact product acceptance and influence the regulatory environment in which the company
operates. While the company has procedures and controls to manage process safety risks, issues could be created by events outside 
of its control including natural disasters, severe weather events, acts of sabotage and substandard performance by third parties 
with which the company collaborates.

As a result of the company's current and past operations, including operations related to divested businesses, the company 
could incur significant environmental liabilities.
The company is subject to various laws and regulations around the world governing the environment, including the discharge of 
pollutants and the management and disposal of hazardous substances. As a result of its operations, including its past operations 
and operations of divested businesses, the company could incur substantial costs, including remediation and restoration costs. The
costs of complying with complex environmental laws and regulations, as well as internal voluntary programs, are significant and
will continue to be so for the foreseeable future. The ultimate costs under environmental laws and the timing of these costs are 
difficult to predict. The company's accruals for such costs and liabilities may not be adequate because the estimates on which the 
accruals are based depend on a number of factors including the nature of the matter, the complexity of the site, site geology, the 
nature and extent of contamination, the type of remedy, the outcome of discussions with regulatory agencies and other Potentially
Responsible Parties (PRPs) at multi-party sites and the number and financial viability of other PRPs. 

At December 31, 2016, the company had recognized a liability of $457 million related to the matters. Since considerable uncertainty
exists, under adverse changes in circumstances, the potential liability may range up to $900 million above the amount accrued at aa
December  31,  2016. As  described  in  Note  3  to  the  Consolidated  Financial  Statements,  DuPont  and  Chemours  entered  into  a
Separation Agreement in connection with the spin-off of Chemours on July 1, 2015.  Pursuant to the Separation Agreement, the 
company is indemnified by Chemours for certain environmental matters, included in the liability of $457 million, that have an 
estimated liability of $250 million as of December 31, 2016 and a potential exposure that ranges up to approximately $500 million
above the amount accrued.  As such, the company has recorded an indemnification asset of $250 million corresponding to the 
company’s accrual balance related to these matters at December 31, 2016. If the company could no longer continue to recognize
the related indemnification asset due to potential disputes related to recovery or solvency of Chemours, it could adversely impact 
DuPont’s financial position and results of operations. 

Additional details on the company’s risks associated with environmental laws, regulations and environmental liabilities can be 
found in Part I, Item 1, Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, 
on page 48 of this report and Note 15 to the Consolidated Financial Statements.

15

ITEM 1A.  RISK FACTORS, continued

Part I

The company's results of operations could be adversely affected by litigation and other commitments and contingencies.
The company faces risks arising from various unasserted and asserted litigation matters, including, but not limited to, product
liability, patent infringement, antitrust claims, and claims for third party property damage or personal injury stemming from alleged 
environmental torts. The company has noted a nationwide trend in purported class actions against chemical manufacturers generally
seeking relief such as medical monitoring, property damages, off-site remediation and punitive damages arising from alleged 
environmental torts without claiming present personal injuries. The company also has noted a trend in public and private nuisance 
suits being filed on behalf of states, counties, cities and utilities alleging harm to the general public. Various factors or developments
can lead to changes in current estimates of liabilities such as a final adverse judgment, significant settlement or changes in applicable 
law. A future adverse ruling or unfavorable development could result in future charges that could have a material adverse effect 
on the company. An adverse outcome in any one or more of these matters could be material to the company's financial results.

In  the  ordinary  course  of  business,  the  company  may  make  certain  commitments,  including  representations,  warranties  and 
indemnities relating to current and past operations, including those related to divested businesses and issue guarantees of third 
party obligations. If the company were required to make payments as a result, they could exceed the amounts accrued, thereby 
adversely affecting the company's results of operations.

Pursuant  to  the  Separation  Agreement,  Chemours  indemnifies  DuPont  against  certain  litigation,  environmental,  workers' 
compensation and other liabilities that arose prior to the distribution. The term of this indemnification is indefinite and includes 
defense costs and expenses, as well as monetary and non-monetary settlements and judgments. If the company could no longer 
continue to recognize the related indemnification asset due to potential disputes related to recovery or solvency of Chemours, it 
could adversely impact DuPont’s financial position and results of operations. 

16

ITEM 1B.  UNRESOLVED STAFF COMMENTS

None.

ITEM 2.  PROPERTIES
S

O

Part I

h
d

h d

The company's corporate headquarters are located in Wilmington, Delaware. The company's manufacturing, processing, marketing
and research and development facilities, as well as regional purchasing offices and distribution centers are located throughout hthe 
world. Additional information with respect to the company's property, plant and equipment and leases is contained in Notes 10, 
15 and 20 to the Consolidated Financial Statements.

i
d h
i d i

h
ddi i

ili i
i h

l
h i

k i
t

ld
d

ffi
l

ll
h

ib i

l i f

d i

d di

il
i

d d

lid

d l

i l

d i

d

h

h

h

f

f

l

i

l

l

i

l

i

i

i

The company has investments in property, plant and equipment related to global manufacturing operations. Collectively there are
approximately 290 principal sites in total. The number of sites used by their applicable segment(s) by major geographic area around 
the world is as follows:

Asia Pacific

EMEA2

Latin America

U.S. & Canada

Number of Sites

Agriculture

Electronics &
Communications

Industrial
Biosciences

Nutrition &
Health

Performance
Materials

Protection
Solutions

Other

Total 1

23

26

22

60

131

10

3

—

16

29

2

8

1

11

22

12

28

10

17

67

16

6

1

13

36

6

3

1

6

16

2

—

2

1

5

71

74

37

124

306

1.  
2.  

Sites that are used by multiple segments are included more than once in the figures above.
Sites that are used by multiple segments are included more than once in the figures above.
Europe, Middle East, and Africa (EMEA).

i

l

i

i

h

The company's principal sites include facilities which, in the opinion of management, are suitable and adequate for their use a dnd 
i i
ili i
have sufficient capacity for the company's current needs and expected near-term growth.  Properties are primarily owned by the
have sufficient capacity for the company's current needs and expected near-term growth
company; however, certain properties are leased.  No title examination of the properties has been made for the purpose of this 
report and certain properties are shared with other tenants under long-term leases.

hi h i

l d f

i bl

d d

h i

h

aa

f

f

i

17

  
  
ITEM 3.  LEGAL PROCEEDINGS

Part I

The company is subject to various litigation matters, including, but not limited to, product liability, patent infringement, antitrust 
claims, and claims for third party property damage or personal injury stemming from alleged environmental torts. Information
regarding certain of these matters is set forth below and in Note 15 to the Consolidated Financial Statements.

Litigation 
PFOA: Environmental and Litigation Proceedings
For purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt
and does not distinguish between the two forms.  Information related to this matter is included in Note 15 to the Consolidated 
Financial Statements under the heading PFOA.

La Porte Plant, La Porte, Texas - Crop Protection - release Incident Investigations
On November 15, 2014, there was a release of methyl mercaptan at the company’s La Porte facility. The release occurred at the 
site’s Crop Protection unit resulting in four employee fatalities inside the unit. DuPont continues to cooperate with governmental 
agencies,  including  the  U.S.  Environmental  Protection Agency  (EPA)  and  the  Department  of  Justice  (DOJ),  still  conducting 
investigations. These investigations could result in sanctions and penalties against the company.

Environmental Proceedings
The company believes it is remote that the following matters will have a material impact on its financial position, liquidity or 
results of operations.  The descriptions are included per Regulation S-K, Item 103(5)(c) of the Securities Exchange Act of 1934.  

La Porte Plant, La Porte, Texas - EPA Multimedia Inspection
The EPA conducted a multimedia inspection at the La Porte facility in January 2008. DuPont, EPA and DOJ began discussions in
the  fall  2011  relating  to  the  management  of  certain  materials  in  the  facility's  waste  water  treatment  system,  hazardous  waste
management, flare and air emissions. These negotiations continue.

Sabine Plant, Orange, Texas - EPA Multimedia Inspection
In June 2012, DuPont began discussions with EPA and DOJ related to a multimedia inspection that EPA conducted at the Sabine 
facility in March 2009 and December 2015.  The discussions involve the management of materials in the facility's waste water 
treatment system, hazardous waste management, flare and air emissions, including leak detection and repair.  These negotiations
continue.

La Porte Plant, La Porte, Texas - OSHA Release Incident Citations
In May 2015, the Occupational Safety & Health Administration (OSHA) cited the company in connection with the November 
2014 release for 14 violations (twelve serious, one repeat and one other-than-serious) with an aggregate associated penalty of 
$99,000. The  company  has  contested  the  citations  and  the  matter  is  before  the  U.S.  Occupational  Safety  and  Health  Review
Commission (the OSHRC). A hearing before an administrative law judge appointed by OSHRC is scheduled for the first quarter 
2017.

La Porte Plant, La Porte, Texas - OSHA Process Safety Management (PSM) Audit
In 2015, OSHA conducted a PSM audit of the Crop Protection and Fluoroproducts units at the La Porte Plant.  In July 2015, OSHA 
cited the company for three willful, one repeat and five serious PSM violations and placed the company in its Severe Violator 
Enforcement Program. OSHA has proposed a penalty of $273,000. The company has contested the citations and the matter is
before the OSHRC. A hearing before an administrative law judge appointed by OSHRC is scheduled for the first quarter 2017.

18

Part II

ITEM  5.  MARKET  FOR  REGISTRANT'S  COMMON  EQUITY,  RELATED  STOCKHOLDER  MATTERS  AND

ISSUER PURCHASES OF EQUITY SECURITIES

Market for Registrant's Common Equity and Related Stockholder Matters
The company's common stock is listed on the New York Stock Exchange, Inc. (symbol DD).  The number of record holders of 
common stock was approximately 59,000 at January 31, 2017.

Holders of the company's common stock are entitled to receive dividends when they are declared by the Board of Directors.  While 
it is not a guarantee of future conduct, the company has continuously paid a quarterly dividend since the fourth quarter 1904.
Dividends on common stock and preferred stock are usually declared in January, April, July and October. When dividends on 
common stock are declared, they are usually paid mid-March, June, September and December. Preferred dividends are paid on
or  about  the  25th of  January,  April,  July  and October.    The  Stock  Transfer  Agent  and  Registrar  is  Computershare  Trust 
Company, N.A.

The company's quarterly high and low trading stock prices and dividends per common share for 2016 and 2015 are shown below.

2016
Fourth Quarter
Third Quarter
Second Quarter
First Quarter

2015
Fourth Quarter
Third Quarter
Second Quarter
First Quarter

Market Prices1

High

Low

Per Share
Dividend
Declared

$

$

75.86 $
71.09
69.40
65.70

75.72 $
61.93
75.80
80.65

66.19 $
61.12
61.62
50.71

47.43 $
47.11
63.55
70.19

0.38
0.38
0.38
0.38

0.38 2
0.38 2
0.49
0.47

1.

2.

Historical market prices do not reflect any adjustment for the impact of the spin-off of The Chemours Company (Chemours).
Per share dividend declared includes impact of the spin-off of Chemours.

Issuer Purchases of Equity Securities 
In connection with the completion of the spin-off of Chemours, the Board of Directors authorized the use of the distribution 
proceeds received from Chemours to buy back about $4 billion shares of the company's common stock as follows: $2 billion to
be purchased and retired by December 31, 2015 with the remainder to be purchased and retired by December 31, 2016. During 
2015, the company purchased and retired 35 million shares through a $2 billion accelerated share repurchase agreement. The 
company had limited opportunity to repurchase shares in 2016, primarily due to the planned merger with The Dow Chemical 
Company (Dow). However, during 2016, the company purchased and retired 13.2 million shares in the open market for a cost of 
$916 million. As of January 1, 2017, the share authorization under this buyback program has expired.

In January 2014, the company's Board of Directors authorized a $5 billion share buyback plan. The company purchased and retired
34.7 million shares for a total cost of $2.4 billion under this program. As a result, $2.6 billion buyback authority remains under 
this program. There is no required completion date for purchases under this plan.

See Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, on page 40 of this 
report and Note 16 to the Consolidated Financial Statements for additional information.

19

    
Part II

ITEM  5.  MARKET  FOR  REGISTRANT'S  COMMON  EQUITY,  RELATED  STOCKHOLDER  MATTERS  AND    

ISSUER PURCHASES OF EQUITY SECURITIES, continued

The following table summarizes information with respect to the company's purchase of its common stock during the three months 
ended December 31, 2016:

Month

November:

Total Number of Shares
Purchased

Average Price
Paid per Share

Total Number of 
Shares Purchased as
Part of Publicly 
Announced Program

Approximate Value
of Shares that May 
Yet Be Purchased 
Under the Program(1)
(Dollars in millions)

Open Market Purchases

5,752,436 $

December:

Open Market Purchases

Total

1.

1,386,149 $

7,138,585

Represents approximate value of shares that may yet be purchased under the 2014 plan.

69.48

72.35

5,752,436

1,386,149

7,138,585 $

2,647

Stock Performance Graph 
The following graph presents the cumulative five-year total shareholder return for the company's common stock compared with
the S&P 500 Stock Index and the Dow Jones Industrial Average. 

Stock Performance Graph

$250

$200

$150

$100

$50

$0

2011

2012

2013

2014

2015

2016

DuPont

S&P 500 Index

Dow Jones Industrial Average

12/31/2011

12/31/2012

12/31/2013

12/31/2014

12/31/2015

12/31/2016

DuPont
S&P 500 Index
Dow Jones Industrial Average

$

100 $
100
100

102 $
116
110

152 $
154
143

178 $
175
157

173 $
177
158

196
198
184

The graph assumes that the values of DuPont common stock, the S&P 500 Stock Index and the Dow Jones Industrial Average
were each $100 on December 31, 2011 and that all dividends were reinvested.

20

Part II

ITEM 6.  SELECTED FINANCIAL DATA

(Dollars in millions, except per share)
Summary of operations1
Net sales

Employee separation / asset related charges, net

2016

2015

2014

2013

2012

$ 24,594 $ 25,130 $ 28,406 $ 28,998 $ 27,610

$

552 $

810 $

476 $

112 $

457

Income from continuing operations before income taxes

$ 3,265 $ 2,591 $ 4,313 $ 2,566 $ 1,290

Provision for income taxes on continuing operations

$

744 $

696 $ 1,168 $

360 $

122

Net income attributable to DuPont

$ 2,513 $ 1,953 $ 3,625 $ 4,848 $ 2,755

Basic earnings per share of common stock from continuing operations
$
Diluted earnings per share of common stock from continuing operations $
Financial position at year-end
Working capital2,3
Total assets

2.86 $
2.85 $

2.10 $
2.09 $

3.42 $
3.39 $

2.36 $
2.34 $

1.21
1.20

$ 8,220 $ 7,071 $ 8,220 $ 10,055 $ 6,866
$ 39,964 $ 41,166 $ 50,490 $ 52,142 $ 50,339

Borrowings and capital lease obligations

Short-term
Long-term

Total equity
General

For the year

Purchases of property, plant & equipment and investments in 
    affiliates
Depreciation1
Research and development expense1
Weighted-average number of common shares outstanding (millions)

Basic

Diluted

Dividends per common share4

At year-end

Employees (thousands)5
Closing stock price

Common stockholders of record (thousands)

429 $ 1,165 $ 1,422 $ 1,721 $ 1,275
$
$ 8,107 $ 7,642 $ 9,233 $ 10,699 $ 10,429

$ 10,196 $ 10,200 $ 13,378 $ 16,286 $ 10,299

$ 1,038 $ 1,705 $ 2,062 $ 1,940 $ 1,890

939 $

978 $ 1,006 $ 1,027 $ 1,065
$
$ 1,641 $ 1,898 $ 1,958 $ 2,037 $ 2,001

873

877

894

900

915

922

926

933

933

942

$

1.52 $

1.72 $

1.84 $

1.78 $

1.70

46

52

54

55

61

$ 73.40 $ 66.60 $ 73.94 $ 64.97 $ 44.98

59

63

66

70

74

1.

Information has been restated to reflect the impact of discontinued operations, as applicable.  See Note 1 to the Consolidated Financial Statements for further 
information.

2. Working capital has been restated to exclude the assets and liabilities related to the Performance Chemicals segment.  The assets and liabilities related to the
Performance Chemicals business are presented as assets of discontinued operations and liabilities of discontinued operations, respectively, in the Consolidated 
Balance Sheets for all periods presented.  At December 31, 2012, working capital included approximately $2 billion of net assets related to the Performance 
Coatings business, of which approximately $1.3 billion was previously considered to be noncurrent and was classified as held for sale as of December 31, 
2012.  Working capital at December 31, 2013 includes cash received from the sale of the Performance Coatings business.  See Note 3 to the Consolidated 
Financial Statements for further information.

3. Working capital has been restated for all years presented to reflect the impact of the reclassification of deferred tax assets and liabilities from current to non-
current in connection with the company's adoption of Accounting Standards Update (ASU) No. 2015-17.  See Note 1 to the Consolidated Financial Statements
for further information. 
Per share dividend declared in 2015 includes impact of the spin-off of The Chemours Company (Chemours).
Number of employees excludes employees associated with the Performance Chemicals segment for all periods presented.

4.

5.

21

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS

CAUTIONARY STATEMENTS ABOUT FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,”
“anticipates,”  “believes,”  “intends,”  “projects,”  “estimates”  or  other  words  of  similar  meaning. All  statements  that  address 
expectations or projections about the future, including statements about the company's strategy for growth, product development, 
regulatory approval, market position, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring
actions, outcome of contingencies, such as litigation and environmental matters, expenditures, and financial results, and timing 
of, as well as expected benefits, including synergies, from the planned merger with The Dow Chemical Company (Dow) and the
the separation of the combined company’s agriculture business, specialty products business and material science business through 
a series of tax-efficient transactions (the Intended Business Separations), are forward-looking statements.

tt

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or 
realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control.  While 
the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative,
no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present 
significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results
as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, 
operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse
effect on Dow’s or DuPont’s consolidated financial condition, results of operations, credit rating or liquidity.  Some of the important 
factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements 
are:

dd

•  Risks related to the agreement entered on December 11, 2015 between DuPont and Dow to effect an all-stock merger of 
equals, including the completion of the proposed transaction on anticipated terms and timing, the ability to fully and 
timely realize the expected benefits of the proposed transaction and risks related to the Intended Business Separations 
contemplated to occur after the completion of the proposed transaction. Important risk factors relating to the proposed 
transaction and Intended Business Separations include, but are not limited to, (i) the completion of the proposed transaction
on anticipated terms and timing, including obtaining regulatory approvals, anticipated tax treatment, unforeseen liabilities, 
future  capital  expenditures,  revenues,  expenses,  earnings,  synergies,  economic  performance,  indebtedness,  financial
condition, losses, future prospects, business and management strategies for the management, expansion and growth of 
the new combined company’s operations and other conditions to the completion of the merger, (ii) the various approvals, 
authorizations  and  declarations  of  non-objections  from  certain  regulatory  and  governmental  authorities  may  not  be 
obtained, on a timely basis or otherwise, including that these regulatory or governmental authorities may impose conditions
on the granting of such approvals, including regarding the respective Dow and DuPont businesses to divest certain assets 
if necessary to obtain certain regulatory approval or otherwise limiting the ability of the combined company to integrate 
parts of the Dow and DuPont businesses, (iii) the ability of Dow and DuPont to integrate the businesses successfully and 
to achieve anticipated synergies, risks and costs and pursuit and/or implementation of the potential separations, including
anticipated timing, any changes to the configuration of businesses included in the potential separation if implemented,
(iv) the intended separation of the agriculture, material science and specialty products businesses of the combined company
post-mergers in one or more tax efficient transactions on anticipated terms and timing, including a number of conditions 
which could delay, prevent or otherwise adversely affect the proposed transactions, including possible issues or delays 
in obtaining required regulatory approvals or clearances, disruptions in the financial markets or other potential barriers, 
(v) continued availability of capital and financing and rating agency actions, (vi) potential business uncertainty, including 
changes  to  existing  business  relationships,  during  the  pendency  of  the  merger  that  could  affect  DuPont’s  financial
performance, (vii) certain restrictions during the pendency of the merger that may impact DuPont’s ability to pursue 
certain business opportunities or strategic transactions. These risks, as well as other risks associated with the proposed 
merger, are more fully discussed in the joint proxy statement/prospectus included in the Registration Statement. 

•  Volatility in energy and raw material prices;
• 
•  Outcome of significant litigation and environmental matters, including those related to divested businesses, including 

Failure to develop and market new products and optimally manage product life cycles; 

realization of associated indemnification assets, if any;
Failure to appropriately manage process safety and product stewardship issues;

• 
•  Ability to obtain and maintain regulatory approval for its products especially in the Agriculture segment;
• 
Failure to realize all of the expected benefits from cost and productivity initiatives to the extent and as anticipated;
•  Effect of changes in tax, environmental and other laws and regulations or political conditions in the United States of 

America (U.S.) and other countries in which the company operates;

22

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS

•  Conditions in the global economy and global capital markets, including economic factors such as inflation, deflation, 

• 

• 

fluctuation in currency rates, interest rates and commodity prices;
Failure to appropriately respond to market acceptance, government rules, regulations and policies affecting products 
based on biotechnology;
Impact of business disruptions, including supply disruptions, and security threats, regardless of cause, including acts of 
sabotage, cyber-attacks, terrorism or war, natural disasters and weather events and patterns which could affect demand 
as well as availability of product, particularly in the Agriculture segment;

•  Ability to discover, develop and protect new technologies and enforce the company's intellectual property rights; and
• 

Successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses.  

For some of the important factors that could cause the company's actual results to differ materially from those projected in any 
such forward-looking statements, see the Risk Factors discussion set forth under Part I, Item 1A beginning on page 9.

Overview

DuPont Dow Merger of Equals  On December 11, 2015, DuPont and Dow announced entry into an Agreement and Plan of 
Merger (the Merger Agreement), under which the companies will combine in an all-stock merger of equals (the Merger Transaction),
subject to satisfaction of customary closing conditions, including receipt of regulatory approval. The combined company will be
named DowDuPont Inc. (DowDuPont). DuPont's special meeting of stockholders was held on July 20, 2016, which resulted in a
vote for adoption of the Merger Agreement and approval of related matters.  Closing of the Merger Transaction is expected to 
occur in the first half of 2017, pending satisfaction of customary closing conditions, including receipt of regulatory approval.

Following the consummation of the merger, Dow and DuPont intend to pursue, subject to the receipt of approval by the board of 
directors of DowDuPont, the separation of the combined company’s agriculture business, specialty products business and material
science business through a series of tax-efficient transactions (the Intended Business Separations). Dow and DuPont currently
anticipate that the Intended Business Separations will occur about 18 months after the merger is consummated.

During the years ended December 31, 2016 and 2015, the company incurred $386 million and $10 million, respectively, of costs
in connection with the planned merger with Dow and the Intended Business Separations, including costs relating to integration
and separation planning. These costs were recorded in selling, general and administrative expenses in the company's Consolidated 
Income Statements and primarily include financial advisory, legal, accounting, consulting and other advisory fees and expenses.

See the discussion entitled DuPont Dow Merger of Equals under Part 1, Item 1 Business of this report, Part 1, Item 1A, Risk 
Factors, and Note 2 to the Consolidated Financial Statements for further details and a discussion of some of the risks related to
the transaction.

Purpose    DuPont’s businesses serve markets where the increasing demand for more and healthier food, renewably sourced 
materials  and  fuels,  and  advanced  industrial  materials  is  creating  substantial  growth  opportunities.  The  company’s  unique
combination of sciences, proven research and development (R&D) engine, broad global reach, and deep market penetration are 
distinctive competitive advantages that position the company to continue capitalizing on this enormous potential.

DuPont has dramatically refined its portfolio to focus investment in areas where it sees significant opportunity and secular growth; 
enhanced its innovation platform to deliver substantial revenues from new products; increased focus on efficiency, cost discipline,
and accountability; and expanded markets geographically. 

The  company  is  committed  to  maintaining  a  strong  balance  sheet  and  to  return  excess  cash  to  shareholders  unless  there  is  a 
compelling opportunity to invest for growth. 

Results    DuPont 2016 sales were $24.6 billion, 2 percent below last year, reflecting a 1 percent decline from the negative impact 
of weaker currencies and a 1 percent decline due to lower prices and product mix.  Volume growth in Performance Materials, 
Nutrition & Health, and Industrial Biosciences was offset by declines in the other segments.  Income from continuing operations
before taxes of $3.3 billion was up 26 percent versus $2.6 billion in prior year, on cost savings and lower pension and other post 
employment benefits (OPEB) costs.  Pension and OPEB costs were down 63 percent year over year, primarily due to curtailment 
gains recognized as a result of changes made to the U.S. Pension and OPEB benefits in 2016. 

23

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Part II

Analysis of Operations 
2016 Global Cost Savings and Restructuring Plan   On December 11, 2015, DuPont announced a 2016 global cost savings and 
restructuring plan (the 2016 global cost savings and restructuring plan) designed to reduce costs in 2016 by $730 million compared 
with 2015, which represents a reduction of operating costs on a run-rate basis of about $1.0 billion by the end of 2016.  As part 
of the plan, the company committed to take structural actions across all businesses and staff functions globally to operate more 
efficiently  by  further  consolidating  businesses  and  aligning  staff  functions  more  closely  with  them.     In  connection  with  the 
restructuring actions, the company recorded a pre-tax charge to earnings of $798 million in the fourth quarter 2015, comprised of 
$656 million of severance and related benefit costs, $109 million of asset related charges, and $33 million of contract termination
costs.  During the year ended December 31, 2016, in connection with the restructuring actions, the company recorded a net pre-
tax benefit to earnings of $85 million, comprised of a net reduction of $154 million in severance and related benefit costs, offset 
by $53 million of asset related charges, and $16 million of contract termination costs. This was primarily due to a reduction in
severance and related benefit costs partially offset by the identification of additional projects in certain segments.  The reduction 
in severance and related benefit costs was driven by elimination of positions at a lower cost than expected as a result of redeployments 
and attrition as well as lower than estimated individual severance costs. 

dd

a

ff

The 2016 global cost savings and restructuring plan delivered the target cost reductions versus prior year.  The restructuring actions
associated with this charge affected approximately 10 percent of DuPont’s workforce and are now substantially complete.

Redesign Initiative and 2014 Restructuring Plan      In June 2014, DuPont announced its global, multi-year initiative to redesign 
its global organization and operating model to reduce costs and improve productivity and agility across all businesses and functions.  
DuPont commenced a restructuring plan to realign and rebalance staff function support, enhance operational efficiency, and to
reduce residual costs associated with the separation of its Performance Chemicals segment.  As a result, during the year ended 
December 31, 2014, a pre-tax charge of $541 million was recorded. Cost reductions from the 2014 operational redesign were
essentially completed during 2015 and for full year 2015, the company delivered incremental cost savings of approximately $440
million year over year.  Additional details related to this plan can be found in Note 4 to the Consolidated Financial Statements.

Separation of Performance Chemicals     In October 2013, DuPont announced its intention to separate its Performance Chemicals
segment through a U.S. tax-free spin-off to shareholders, subject to customary closing conditions.  In July 2015, DuPont completed 
the separation of its Performance Chemicals segment through the spin-off of all of the issued and outstanding stock of The Chemours 
Company (Chemours).

24

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

(Dollars in millions)
NET SALES

2016

2015

2014

$

24,594 $

25,130 $

28,406

2016 versus 2015   The table below shows a regional breakdown of 2016 consolidated net sales based on location of customers
and percentage variances from prior year:

5

(Dollars in billions)

Worldwide

U.S. & Canada
EMEA1
Asia Pacific

Latin America

Percent Change Due to:

2016
Net Sales

Percent
Change vs.
2015

Local
Price and 
Product Mix

Currency

Volume

Portfolio and
Other

$

24.6

10.4

5.7

5.8

2.7

(2)

(3)

(5)

3

(3)

(1)
(2)
1
(1)
2

(1)
—
(3)
(1)
(2)

—

—
(2)
4
(2)

—
(1)
(1)
1
(1)

1. 

Europe, Middle East, and Africa (EMEA).

Net sales of $24.6 billion were 2 percent below prior year, reflecting a 1 percent reduction due to currency and a 1 percent decrease
due to lower local prices. Negative currency impact was primarily due to the weaker European euro, Mexican peso, and Chinese 
yuan, partly offset by the stronger Japanese yen and Brazilian real.  The 1 percent negative impact from lower local prices primarily 
reflects lower prices in Performance Materials, largely polymers, lower Electronics & Communications prices and flat prices for
Agriculture where higher prices in EMEA and Latin America were offset by declines in North America. Worldwide volume was 
flat as growth in Performance Materials, Nutrition & Health, and Industrial Biosciences was offset by lower volume in Electronics 
& Communications, Protection Solutions, and Agriculture, the latter due to lower sales of crop protection products. Net sales in
developing markets, were $8.4 billion, up 2 percent, with 4 percent higher volume, principally due to strong growth in Agriculture, 
Performance Materials, Electronics & Communications, and Nutrition & Health, in developing Asia Pacific.  Sales growth in 
developing markets was partly offset by a negative currency impact. Representing 34 percent of total company sales, developing 
markets include China, India, and countries in Southeast Asia, Latin America, Eastern and Central Europe, Middle East, and Africa.

tt

25

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

2015 versus 2014   The table below shows a regional breakdown of 2015 consolidated net sales based on location of customers
and percentage variances from prior year:

4

(Dollars in billions)

Worldwide

U.S. & Canada
EMEA1
Asia Pacific

Latin America

Percent Change Due to:

2015
Net Sales

Percent
Change vs.
2014

Local
Price and 
Product Mix

Currency

Volume

Portfolio and
Other

$

25.1

10.8

6.0

5.6

2.7

(12)

(6)

(17)

(9)

(23)

—
(2)
2
(2)
2

(7)
(1)
(15)
(3)
(15)

(3)
(2)
(2)
(2)
(9)

(2)
(1)
(2)
(2)
(1)

1. 

Europe, Middle East, and Africa (EMEA).

Net sales of $25.1 billion were down 12 percent versus prior year reflecting a 7 percent negative impact from weaker currencies, 
particularly the Brazilian real and the European euro, 3 percent lower volume and a 2 percent negative impact from the absence
of sales from divested businesses. Lower volume principally reflects a 6 percent decline in Agriculture that was primarily driven 
by lower seed volume and reduced demand for insect control products in Latin America, a 7 percent decline in volumes for 
Electronics & Communications, primarily driven by competitive pressures impacting sales of Solamet® paste, and a 2 percent 
decline in volumes for Industrial Biosciences due to lower demand for biomaterials and clean technologies offerings. These declines 
more than offset volume growth for Performance Materials, Nutrition & Health, and Protection Solutions. Portfolio and other 
reflects the impact of the prior year sales of Glass Laminating Solutions/Vinyls within the Performance Materials segment and 
Sontara® within the Protection Solutions segment. The impact from local prices and product mix was about even with prior year 
as  3  percent  higher Agriculture  prices  were  offset  primarily  by  lower  prices  in  Performance  Materials  and  Electronics  & 
Communications. Net sales in developing markets were $8.2 billion, 33 percent of total company net sales versus 34 percent in
2014, representing a slight decline principally due to lower Agriculture volume in Latin America. Developing markets include
China, India, countries located in Latin America, Eastern and Central Europe, Middle East, Africa and South East Asia.

(Dollars in millions)

COST OF GOODS SOLD
As a percent of net sales

2016
14,469

$

2015
15,112

$

2014
17,023

$

59%

60%

60%

5

2016 versus 2015    Cost of goods sold (COGS) decreased $0.6 billion, or 4 percent, principally due to lower raw material costs,
lower pension and OPEB costs, and the strengthening of the U.S. dollar versus global currencies. COGS as a percentage of sales
was 59 percent versus 60 percent last year, principally due to lower raw material costs and lower pension and OPEB costs. 

4

2015  versus  2014    COGS  decreased  $1.9  billion,  or  11  percent,  principally  reflecting  declines  from  currency  due  to  the 
strengthening of the U.S. dollar versus global currencies, productivity improvements, impacts of portfolio changes, lower volume 
and lower raw material costs.  COGS as a percent of sales was unchanged from prior year at 60 percent as the benefit of productivity 
improvements offset the negative impact of currency which decreased sales by 7 percent and COGS by 4 percent.

(Dollars in millions)

OTHER OPERATING CHARGES
As a percent of net sales

2016

2015

2014

$

686

$

3%

459

$

2%

645

2%

5

®
2016 versus 2015  Other operating charges increased $227 million, or 49 percent, reflecting a $152 million decrease in Imprelis
herbicide insurance recoveries, and a $23 million reduction in the estimated liability related to Imprelis® herbicide claims versus 
a $130 million accrual reduction in the prior year.

4

2015 versus 2014   Other operating charges decreased $186 million, or 29 percent, principally reflecting $130 million reduction
in the estimated liability related to Imprelis® herbicide claims, cost savings from the company's operational redesign initiative
partially offset by lower insurance recoveries year over year related to Imprelis® herbicide claims.

26

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

(Dollars in millions)

2016

2015

2014

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

$

4,319

$

4,615

$

4,891

As a percent of net sales

18%

18%

17%

5

2016  versus  2015    The  $296  million  decrease  was  primarily  due  to  lower  costs  related  to  the  2016  global  cost  savings  and 
restructuring plan, lower selling expense, and a decrease in pension and OPEB costs, partially offset by $386 million of transaction 
costs associated with the planned merger with Dow. 

4

2015 versus 2014    The $276 million decrease was primarily due to the strengthening of the U.S. dollar versus global currencies, 
cost savings from the company's 2014 operational redesign initiative, and lower selling and commission expense, mainly within 
the Agriculture segment, partially offset by an increase in pension and OPEB costs. Selling, general and administrative expenses 
as a percentage of net sales increased by 1 percent, primarily due to lower sales and higher pension and OPEB costs.

(Dollars in millions)

2016

2015

2014

RESEARCH AND DEVELOPMENT EXPENSE

$

1,641

$

1,898

$

1,958

As a percent of net sales

7%

8%

7%

5

2016  versus  2015    The  $257  million  decrease  was  primarily  due  to  lower  costs  related  to  the  2016  global  cost  savings  and 
restructuring plan, a decrease in pension and OPEB costs and the strengthening of the U.S. dollar versus global currencies. Research 
and development expense as a percent of sales decreased 1 percent, primarily due to cost savings from the company’s 2016 global
cost savings and restructuring plan and a decrease in pension and OPEB costs.

4

2015 versus 2014    The $60 million decrease was primarily due to the strengthening of the U.S. dollar versus global currencies, 
cost savings from the company's operational redesign initiative, partially offset by higher pension and OPEB costs. Research and 
development expense as a percent of sales increased due to lower sales.

(Dollars in millions)

OTHER INCOME, NET

2016

2015

2014

$

708 $

697 $

1,277

2016 versus 2015   The $11 million increase was primarily due to gains on sales of businesses and other assets, including a $369 
million gain on the sale of DuPont (Shenzhen) Manufacturing Limited, partially offset by an increase in pre-tax exchange losses
and the absence of a $145 million gain associated with the company's settlement of a legal claim in the prior year related to the 
Protection Solutions segment.  Pre-tax exchange losses increased $136 million compared to prior year.  See Notes 5 and 19 to the 
Consolidated Financial Statements for further discussion of the company's policy of hedging the foreign currency-denominated 
monetary assets and liabilities.

t

2015 versus 2014   The $580 million decrease was primarily due to the absence of prior year gains on sales of businesses and 
other assets, including a $391 million gain on the sale of GLS/Vinyls, within the Performance Materials segment, and a $240 
million gain on the sale of copper fungicides and land management businesses, both within the Agriculture segment, partially 
offset by gains on sales of businesses and assets in 2015, primarily in the Agriculture and Performance Materials segments. In 
addition, pre-tax exchange gains decreased $166 million compared to prior year driven by lower gains on foreign currency exchange 
contracts.  See Notes 5 and 19 to the Consolidated Financial Statements for further discussion of the company's policy of hedging
the foreign currency-denominated monetary assets and liabilities. These decreases were partially offset by $145 million gain
associated with the company's settlement of a legal claim related to the Protection Solutions segment and $85 million increase in
equity in earnings of affiliates, primarily due to the absence of $65 million for charges associated with the restructuring actions 
of a joint venture within the Performance Materials segment recorded in 2014.

Additional information related to the company's other income, net is included in Note 5 to the Consolidated Financial Statements.

27

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

(Dollars in millions)

INTEREST EXPENSE

2016

2015

2014

$

370 $

342 $

377

The $28 million increase in 2016 was primarily due to lower capitalized interest related to construction projects partially offset 
by lower interest on borrowings.

ff

The $35 million decrease in 2015 was primarily due to lower average borrowings partially offset by slightly higher average interest 
rates compared to prior year.

(Dollars in millions)

2016

2015

2014

EMPLOYEE SEPARATION/ASSET RELATED CHARGES, NET

$

552 $

810 $

476

The $552 million in charges recorded during 2016 in employee separation / asset related charges, net consist of $593 million of
asset impairment charges discussed below, and a $68 million charge related to the decision to not re-start the Agriculture segment’s 
insecticide manufacturing facility at the La Porte site located in La Porte, Texas.  These charges were partially offset by a net $88 
million benefit related to the 2016 restructuring plan, primarily due to a reduction in severance and related benefit costs driven 
by the elimination of positions at a lower cost than expected, and a  $21 million benefit related to the 2014 restructuring plan for 
adjustments to the previously recognized severance costs.

aa

The $810 million in charges recorded during 2015 in employee separation / asset related charges, net consist of a $793 million 
charge related to the 2016 restructuring plan discussed below, and a $38 million impairment charge discussed below, partly offset 
by a $21 million net benefit related to the 2014 restructuring plan.  The $21 million net benefit was recorded to adjust the estimated 
costs  associated  with  the  2014  restructuring  program  due  to  lower  than  estimated  individual  severance  costs  and  workforce 
reductions achieved through non-severance programs, offset by the identification of additional projects in certain segments.

On December 11, 2015, DuPont announced a 2016 global cost savings and restructuring plan designed to reduce $730 million in 
costs compared to 2015.  As part of the plan, the company committed to take structural actions across all businesses and staff 
functions globally to operate more efficiently by further consolidating businesses and aligning staff functions more closely with
them.  As a result, during the year ended December 31, 2015, a pre-tax charge of $798 million was recorded, consisting of $793
million of employee separation / asset related charges, net and $5 million in other income, net.  The charges consisted of $656
million in severance and related benefit costs, $109 million in asset related charges, and $33 million in contract termination charges. 
The $476 million in charges recorded during 2014 in employee separation / asset related charges, net related to the 2014 global, 
multi-year initiative to redesign its global organization and operating model to improve productivity and agility across all businesses
and  functions.   DuPont  commenced  a  restructuring  plan  to  realign  and  rebalance  staff  function  support,  enhance  operational
efficiency, and to reduce residual costs associated with the separation of its Performance Chemicals segment.  As a result, during
the  year  ended  December  31,  2014,  a  pre-tax  charge  of  $541  million  was  recorded,  consisting  of  $476  million  in  employee
separation / asset related charges, net and $65 million in other income, net.  The charges consisted of $301 million severance and 
related benefit costs, $17 million of other non-personnel costs, and $223 million of asset related costs, including $65 million of 
costs associated with the restructuring actions of a joint venture within the Performance Materials segment. 

n

Asset Impairments 
p
During 2016, the company recorded an asset impairment charge of $435 million related to its uncompleted enterprise resource
planning (ERP) system.  The company intends to complete the ERP system project, however, given the uncertainties related to 
timing as well as potential developments and changes to technologies in the market place at the time of restart, use of the ERP
system can no longer be considered probable. See Note 4 to the Consolidated Financial Statements for additional details related
to this charge. 

During 2016, the company recorded a $158 million impairment charge related to indefinite-lived intangible trade names within
the Industrial Biosciences segment as a result of the realignment of brand marketing strategies and a determination to phase out 
the use of certain acquired trade names.

During  2015,  the  company  recorded  an  impairment  charge  of  $38  million  in  the  Other  segment,  the  majority  relating  to  an
impairment of a cost basis investment.

28

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Additional details related to the restructuring programs and asset impairments discussed above can be found in Note 4 to the 
Consolidated Financial Statements.

Below is a summary of the net impact related to items recorded in employee separation / asset related charges, net:

 (Dollars in millions)

Agriculture

Electronics & Communications

Industrial Biosciences

Nutrition & Health

Performance Materials

Protection Solutions

Other

Corporate expenses

Total Charges

2016 (Charges)
and Credits

2015 (Charges)
and Credits

2014 (Charges)
and Credits

$

(85) $

4

(152)

9

3

14

(11)

(334)

$

(552) $

(164) $

(134)

(78)

(61)

(50)

(58)

(40)

(40)

(319)

(810) $

(84)

(20)

(15)

(34)

(45)

(10)

(134)

(476)

(Dollars in millions)
PROVISION FOR INCOME TAXES ON CONTINUING OPERATIONS $
Effective income tax rate

2016

2015

2014

744

$

22.8%

696

$

1,168

26.9%

27.1%

In 2016, the company recorded a tax provision on continuing operations of $744 million, reflecting a marginal increase from 2015. 
The  decrease  in  the  2016  effective  tax  rate  compared  to  2015  was  largely  due  to  the  impact  of  reduced  net  exchange  losses 
recognized on the re-measurement of net monetary asset positions which were not tax deductible in the relevant local jurisdictions.

In 2015, the company recorded a tax provision on continuing operations of $696 million, reflecting a $472 million decrease from
2014. The decrease was largely due to the impact associated with the company’s policy of hedging the foreign currency-denominated 
monetary assets and liabilities of its operations, the absence of 2014 gains on sales of businesses and other assets in the Performance 
Materials and Agriculture segments, as well as increased tax benefits on employee separation / asset related charges.
See Note 6 to the Consolidated Financial Statements for additional details related to the provision for income taxes on continuing
operations, as well as items that significantly impact the company's effective income tax rate.

(Dollars in millions)
INCOME FROM CONTINUING OPERATIONS AFTER INCOME
TAXES

2016

2015

2014

$

2,521 $

1,895 $

3,145

Income from continuing operations after income taxes for 2016 was $2.5 billion compared to $1.9 billion in 2015 and $3.1 billion
in 2014.  The changes between periods were due to the reasons noted above.

29

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Corporate Outlook 
Globally, GDP and industrial production are expected to grow 2.7 and 2.4 percent, respectively, in 2017.  The company expects 
this growth will be challenged by the current difficult global economic conditions in agriculture, economic uncertainty in the U.S., 
political and economic uncertainty in Europe and slowing conditions in China from the continued shift of industrial production 
to services and consumer sectors.  The company expects headwinds from currency due to the continued strengthening of the U.S. 
dollar against most currencies.  

In the agriculture sector, commodity prices are under pressure from record yields and crop productions.  As farmers look to relative 
economics between crop alternatives, the company expects them to favor soybeans over corn in North America which is generally 
less favorable to the company’s overall income from continuing operations.  In crop protection, the company expects the industryrr
decline to ease in 2017, but continues to be negatively impacted by high inventory levels, a stronger U.S. dollar, and the continued 
penetration of insect-resistant soybeans.  

In the auto sector, according to IHS, auto growth is expected to slow in 2017, with 1 percent growth year over year.  

As the company prepares for the close of the planned merger with Dow, the company expects income from continuing operations 
in 2017 to be impacted by transaction related costs associated with the merger and the Intended Business Separations, including
costs related to integration and separation planning.

Recent Accounting Pronouncements
See Note 1 to the Consolidated Financial Statements for a description of recent accounting pronouncements. 

30

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Segment Reviews
Segment operating earnings is defined as income (loss) from continuing operations before income taxes excluding significant pre-
tax benefits (charges), non-operating pension and OPEB costs, exchange gains (losses), corporate expenses and interest.  Non-
operating pension and OPEB costs includes all of the components of net periodic benefit cost from continuing operations with 
the exception of the service cost component. See Note 21 to the Consolidated Financial Statements for details related to significant 
pre-tax benefits (charges) excluded from segment operating earnings.  All references to prices are based on local price unless
otherwise specified.  

ff

A reconciliation of segment operating earnings to income from continuing operations before income taxes for 2016, 2015 and 
2014 is included in Note 21 to the Consolidated Financial Statements.  

DuPont Sustainable Solutions, previously within the company's former Safety & Protection segment (now Protection Solutions), 
was comprised of two business units: clean technologies and consulting solutions.  Effective January 1, 2016, the clean technologies
business  unit  became  part  of  the  Industrial  Biosciences  segment  with  the  focus  on  working  with  customers  to  improve  the
performance, productivity and sustainability of their products and processes.  The company is exploring a range of options to 
maximize  the  growth  of  the  consulting  solutions  business  unit  which  effective  January  1,  2016  is  reported  within  Other.  
Reclassifications of prior year data have been made to conform to current year classifications.

31

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

AGRICULTURE

(Dollars in millions)

Net sales

Operating earnings
Operating earnings margin

Change in net sales from prior period due to:

Local Price and Product Mix

Currency

Volume

Portfolio and Other

Total change

2016

2015

$

$

9,516

1,758

$

$

18%

9,798

1,646

$

$

17%

2014
11,296

2,352

21%

2016

2015

— %

(2)%

(1)%

— %

(3)%

3 %

(9)%

(6)%

(1)%

(13)%

2016 versus 2015    Full year 2016 segment net sales of $9.5 billion decreased 3 percent, primarily due to the negative impact of 
currency and lower crop protection volumes.  Lower crop protection volumes are primarily due to lower insecticide volumes from
low pest pressure and high inventories, and lower fungicide volumes.  Seed volumes were flat year over year as increased corn 
seed volumes in Latin America and North America due to higher acreage and new product launches, were offset by the shift in 
timing of seed sales primarily related to the southern U.S. route-to-market change and lower soybean volumes.  The shift in timing
moved approximately $200 million of sales from fourth quarter 2016 to first quarter 2017.

2016 operating earnings and operating earnings margin increased as cost savings and lower product costs were partially offset by
timing of seed deliveries, primarily related to the southern U.S. route-to-market change and the negative impact of currency.

i

i

d

d l

2015 versus 2014    Full year 2015 segment net sales of $9.8 billion decreased $1.5 billion, or 13 percent, primarily due to the 
    Full year 2015 segment net sales of $9.8 billion decreased $1.5 billion, or 13 percent, primarily due to the 
negative impact of currency and lower seed and crop protection volumes, primarily in Brazil and North America, which were 
d
f
partly offset by higher local corn seed prices. 
 In Brazil, lower corn seed volume reflects the impact of a reduction in summer 
partly offset by higher 
planted hectares of corn and fall armyworm resistance impacting performance of certain corn hybrids.  In North America, lower 
planted hectares of corn and fall armyworm resistance impacting performance of certain corn hybrids.
soybean volume reflects between 1 and 2 points of share loss and lower soybean planted area; lower corn planted area was partially
offset by higher local corn seed prices. Lower crop protection volume is primarily due to low expected insect pressure, the adoption
of insect protected soybean varieties, higher inventories, and a challenging macro environment. Insect control volumes were also 
impacted by the shutdown of the La Porte manufacturing facility in Texas. 

il
h i

h
f

hi h

i
fl

il l

i
l

il

d

d

d

i

i

i

i

l

2015 operating earnings and operating earnings margin decreased primarily due to the negative impact of currency of $538 million,  
lower sales, and an approximately $120 million negative impact of the shutdown of the La Porte manufacturing facility and the 
absence of prior year impacts from performance-based compensation adjustments, partially offset by cost reductions and continued 
productivity improvements.

32

    
ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

ELECTRONICS & COMMUNICATIONS

(Dollars in millions)

Net sales

Operating earnings
Operating earnings margin

Change in net sales from prior period due to:

Local Price and Product Mix

Currency

Volume

Portfolio and Other

Total change

2016

2015

2014

$

$

1,960

358

$

$

18%

2,070

359

$

$

17%

2,381

336

14%

2016

2015

(2)%

— %

(3)%

— %

(5)%

(4)%

(2)%

(7)%

— %

(13)%

2016 versus 2015    Full year 2016 segment net sales of $2.0 billion decreased 5 percent, due largely to lower demand for products 
for the consumer electronics market.  In photovoltaics materials, share gains in Solamet® paste and higher pricing from the pass-
through of higher average metal prices were offset by volume declines in Tedlar® film and price pressure in both Solamet® and 
Tedlar®.

2016 operating earnings were flat with prior year as cost savings were offset by lower sales and a $16 million litigation expense. 
Operating earnings margin increased primarily due to cost savings.

2015 versus 2014   Full year 2015 segment net sales of $2.1 billion decreased $0.3 billion, or 13 percent, primarily due to competitive 
Full year 2015 segment net sales of $2.1 billion decreased $0.3 billion, or 13 percent, primarily due to competitive 
pressures impacting Solamet®
f
h f l
pressures impacting Solamet
 paste and lower pricing from the pass-through of lower metals prices and the negative impact of 
f
i i
currency, partially offset by volume growth in Tedlar® fil
 film for photovoltaics and products for the consumer electronics market.
f
d
currency, partially offset by volume growth in Tedlar

d h

h
l

d l

h

k

h

h

d

f

i

i

l

i

l

i

i

2015 operating earnings and operating earnings margin increased as cost reductions and continued productivity improvements
more than offset lower sales.

33

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

INDUSTRIAL BIOSCIENCES

(Dollars in millions)

Net sales

Operating earnings

Operating earnings margin

Change in net sales from prior period due to:

Local Price and Product Mix

Currency

Volume

Portfolio and Other

Total change

2016

2015

2014

$

$

1,500

270

$

$

18%

1,478

243

$

$

16%

1,624

269

17%

2016

2015

— %

(2)%

2 %

1 %

1 %

(3)%

(4)%

(2)%

— %

(9)%

2016 versus 2015    Full year 2016 segment net sales of $1.5 billion increased 1 percent, as volume growth in biomaterials and 
bioactives and portfolio changes were partially offset by weak demand in clean technologies and a negative impact from currency.  
Volume growth in biomaterials and bioactives was primarily driven by increased demand in apparel markets and for enzymes, 
principally for food products and home and personal care, 

2016 operating earnings and operating earnings margin increased as cost savings and higher sales were partially offset by the
negative impact of currency.

2015 versus 2014    Full year 2015 segment net sales of $1.5 billion decreased 9 percent, primarily due to the negative impact of 
currency, lower prices and demand for biomaterials and clean technologies offerings, partially offset by volume growth in enzymes, 
principally for home and personal care, food markets and ethanol production.

2015 operating earnings and operating earnings margin decreased primarily due to lower sales, partially offset by cost reductions
and continued productivity improvements.

34

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

NUTRITION & HEALTH

(Dollars in millions)

Net sales

Operating earnings
Operating earnings margin

Change in net sales from prior period due to:

Local Price and Product Mix

Currency

Volume

Portfolio and Other

Total change

$

$

2016

3,268

504

$

$

15%

2015

3,256

373
11%

$

$

2014

3,529

369
10%

2016

2015

— %

(2)%

2 %

— %

— %

— %

(9)%

2 %

(1)%

(8)%

2016 versus 2015    Full year 2016 segment net sales of $3.3 billion were flat with prior year as broad-based volume growth led 
by probiotics, ingredient systems, and specialty proteins was offset by the negative impact of currency.

2016 operating earnings and operating earnings margin increased on cost savings, volume growth and a $27 million gain on the 
sale of an asset.

2015 versus 2014    Full year 2015 segment net sales of $3.3 billion decreased 8 percent, primarily due to the negative impact of 
currency. Volume growth in probiotics, ingredient systems, texturants and cultures was partially offset by lower volumes in specialty 
proteins due to competitive challenges.

2015 operating earnings and operating earnings margin increased as cost reductions and continued productivity improvements and 
volume gains were mostly offset by the negative impact from currency of $53 million and the absence of the prior year $18 million
gain from the termination of a distribution agreement.

35

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

PERFORMANCE MATERIALS

(Dollars in millions)

Net sales

Operating earnings
Operating earnings margin

Change in net sales from prior period due to:

Local Price and Product Mix

Currency

Volume

Portfolio and Other

Total change

2016

2015

2014

$

$

5,249

1,297

$

$

25%

5,305

1,216

$

$

23%

6,059

1,267

21%

2016

2015

(3)%

(1)%

3 %

— %

(1)%

(4)%

(6)%

1 %

(3)%

(12)%

2016 versus 2015    Full year 2016 segment net sales of $5.3 billion decreased 1 percent, as lower local price, driven by pricing 
pressure for raw materials pass-through, and a negative impact from currency were partially offset by increased volume for polymers 
in global automotive markets, primarily in Asia Pacific.

2016 operating earnings and operating earnings margin increased as cost saving and increased volumes were partially offset by a
$63 million negative impact from currency.  The net benefit of lower product costs was offset by the absence of $49 million of 
benefits from the prior year discussed below.

2015 versus 2014    Full year 2015 segment net sales of $5.3 billion decreased $0.8 billion, or 12 percent,  primarily due to the 
negative impact of currency, lower ethylene pricing and the portfolio impact of the sale of Glass Laminating Solutions/Vinyls
(GLS/Vinyls) in June 2014 (see Note 3 to the Consolidated Financial Statements for additional information). Partially offsetting
the declines are increased ethylene volumes due to the prior year scheduled outage at the ethylene unit in Orange, Texas and 
increased demand for polymers in automotive markets, primarily in the U.S. and Europe in the second half of 2015. 

2015 operating earnings decreased as cost reductions and continued productivity improvements were more than offset by the 
negative impact of currency of $132 million and lower selling prices. 2015 operating earnings includes $49 million of benefits,
comprised  of  a  net  benefit  from  a  joint  venture,  the  sale  of  a  business  and  the  realization  of  tax  benefits  associated  with  a 
manufacturing site. Operating earnings margin increased due primarily to cost reductions and continued productivity improvements.

36

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

PROTECTION SOLUTIONS

(Dollars in millions)

Net sales

Operating earnings
Operating earnings margin

Change in net sales from prior period due to:

Local Price and Product Mix

Currency

Volume

Portfolio and Other

Total change

$

$

2016

2,954

668

$

$

23%

2015

3,039

641
21%

$

$

2014

3,304

672
20%

2016

2015

(1)%

— %

(2)%

— %

(3)%

(1)%

(4)%

1 %

(4)%

(8)%

2016 versus 2015    Full year 2016 segment net sales of $3.0 billion decreased 3 percent, due to lower volume and unfavorable 
mix.  Volume declines in Nomex® thermal-resistant fiber, Kevlar® high-strength material, and Tyvek® protective material, were
driven by weakness in the oil and gas industry, military, and industrial market demand.  Volume declines were partially offset by
volume growth in solid surfaces.

2016 operating earnings and operating earnings margin increased as cost savings were partially offset by lower sales.

2015 versus 2014    Full year 2015 segment net sales of $3.0 billion decreased $0.3 billion, or 8 percent, primarily due to the 
negative impact of currency and the portfolio impact of the Sontara® divestiture.  Increased demand for Tyvek® protective material, 
including medical packaging was partially offset by decreased demand for Nomex® thermal resistant fiber and Kevlar® high 
strength materials driven by a weakened oil and gas industry and military spending delays.

2015 operating earnings decreased $31 million, or 5 percent, as cost reductions and continued productivity improvements were 
more than offset by the negative impact of currency of $53 million and lower sales. 2015 operating earnings margin increased 
from prior year due to cost reductions and continued productivity improvements.

37

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

Liquidity & Capital Resources

(Dollars in millions)
Cash, cash equivalents and marketable securities
Total debt

December 31,

2016

2015

$

5,967 $
8,536

6,206
8,807

Pursuant to its cash discipline policy, the company seeks first to maintain a strong balance sheet and second, to return excess cash 
to shareholders unless the opportunity to invest for growth is compelling.  The company continually reviews its sources of liquidity
and debt portfolio and occasionally may make adjustments to one or both to ensure adequate liquidity and an optimum debt maturity
schedule.

The company's credit ratings impact its access to the debt capital markets and cost of capital.  The company remains committed 
to a strong financial position and strong investment-grade rating.  The company's long-term and short-term credit ratings are as
follows:

Standard & Poor's

Moody’s Investors Service

Fitch Ratings

Long-term
A-

A3

A

Short-term
A-2

Outlook
Credit Watch Negative

P-2

F1

Negative

Rating Watch Negative

The company believes its ability to generate cash from operations and access to capital markets will be adequate to meet anticipated 
cash requirements to fund working capital, capital spending, dividend payments, share repurchases, debt maturities and other cash
needs and that its current strong financial position, liquidity and credit ratings continue to provide access as needed to the capital
markets. The company's liquidity needs can be met through a variety of sources, including cash provided by operating activities,
cash and cash equivalents, marketable securities, commercial paper, syndicated credit lines, bilateral credit lines, long-term debt 
markets, bank financing, committed receivable repurchase facilities and asset sales.

The company has access to approximately $7.9 billion in unused credit lines with several major financial institutions including
unused commitments of $4 billion under the Term Loan Facility described below and a $3 billion revolving credit facility to support 
its commercial paper program. These unused credit lines provide additional support to meet short-term liquidity needs and general 
corporate purposes including letters of credit. 

In March 2016, the company entered into a credit agreement that provides for a three-year, senior unsecured term loan facility in
the aggregate principal amount of $4.5 billion (the Term Loan Facility). DuPont may make up to seven term loan borrowings 
within one year of the closing date and amounts repaid or prepaid are not available for subsequent borrowings. The proceeds from
the borrowings under the Term Loan Facility will be used for the company's general corporate purposes including debt repayment,
working capital and share repurchases. The Term Loan Facility matures in March 2019 at which time all outstanding borrowings, 
including accrued but unpaid interest, become immediately due and payable. As of December 31, 2016, the company had borrowed 
$0.5 billion and had unused commitments of $4 billion under the Term Loan Facility.

In addition, in March 2016, the company amended the existing revolving credit facility to reduce the aggregate principal amount
of commitments from $4 billion to $3 billion consistent with lower expected commercial paper borrowings.

The Term Loan Facility and the amended revolving credit facility contain customary representations and warranties, affirmative 
and negative covenants, and events of default that are typical for companies with similar credit ratings and generally consistent 
with those applicable to DuPont’s long-term public debt. The Term Loan Facility and the amended revolving credit facility contain
a financial covenant requiring that the ratio of Total Indebtedness to Total Capitalization for DuPont and its consolidated subsidiaries
not exceed 0.6667. At December 31, 2016, the company was in compliance with this financial covenant.

38

 
Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

The Term Loan Facility and the amended revolving credit facility impose additional affirmative and negative covenants on DuPont
and its subsidiaries after the closing of the proposed merger with Dow, subject to certain limitations, including to:

• 

• 

not sell, lease or otherwise convey to DowDupont, its shareholders or its non-DuPont subsidiaries, any assets or properties 
of DuPont or its subsidiaries unless the aggregate amount of revenues attributable to all such assets and properties so 
conveyed after the merger does not exceed 30 percent of the consolidated revenues of DuPont and its subsidiaries as of 
December 31, 2015 (the Disposition Limitation); and
not guarantee any indebtedness or other obligations of DowDuPont, Dow or ther respective subsidiaries (other than of 
DuPont and its subsidiaries).

The Term Loan Facility and the amended revolving credit facility will terminate, and the loans and other amounts thereunder 
would become due and payable, upon the sale, transfer, lease or other disposition of all or substantially all of the assets of the 
Agriculture line of businesses to DowDuPont, its shareholders or any of its non-DuPont subsidiaries.

In February 2016, in line with seasonal agricultural working capital requirements, the company entered into a committed receivable 
repurchase facility of up to $1 billion (the 2016 repurchase facility) that expired on November 30, 2016.  Under the facility, the 
company  sold  a  portfolio  of  available  and  eligible  outstanding  customer  notes  receivables  within  the Agriculture  segment  to
participating institutions and simultaneously agreed to repurchase at a future date.  In January 2017, the company entered into a
new committed receivable repurchase facility of up to $1.3 billion (the 2017 repurchase facility) which expires on November 30,
2017.  The 2017 repurchase facility has substantially similar terms and conditions as the 2016 repurchase facility and includes the 
2016 repurchase facility change of control language conformed to the Disposition Limitation covenant described above.  See 
further  discussion  of  the  2017  repurchase  facility  in  Item  9B,  Other  Information  and  Note  23  to  the  Consolidated  Financial 
Statements.

a

The company's cash, cash equivalents and marketable securities at December 31, 2016 and 2015 are $6.0 billion and $6.2 billion,
respectively.  Cash,  cash  equivalents  and  marketable  securities  held  outside  of  the  U.S.  of  $5.8  billion  and  $4.2  billion  at 
December 31,  2016  and  2015,  respectively,  are  generally  utilized  to  fund  local  operating  activities  and  capital  expenditure 
requirements and are expected to support non-U.S. liquidity needs for the next 12 months and the foreseeable future thereafter.
The company expects domestic liquidity needs, for at least the next 12 months and the foreseeable future thereafter, will be met 
through existing cash, cash equivalents and marketable securities held in the U.S. and the various sources of liquidity discussed 
above. Therefore, the company believes that it has sufficient sources of domestic liquidity to support its assumption that undistributed 
earnings at December 31, 2016 can be considered reinvested indefinitely.

(Dollars in millions)

2016

2015

2014

Cash provided by operating activities

$

3,300 $

2,316 $

3,712

Cash provided by operating activities increased $1.0 billion primarily due to a higher earnings contribution of approximately $0.5 
billion, lower year-over-year income tax payments and lower working capital. 

Cash provided by operating activities decreased $1.4 billion in 2015 compared to 2014 primarily due to the absence of Chemours
in the second half of 2015 compared with a full year of results in 2014 for an impact of approximately $1.0 billion and a lower
cash earnings contribution from continuing operations of approximately $0.3 billion.

(Dollars in millions)

Cash used for investing activities

2016

2015

2014

$

(1,514) $

(1,828) $

(337)

Cash used for investing activities in 2016 decreased by $0.3 billion compared to 2015.  The change was primarily due to lower 
purchases  of  property,  plant  and  equipment,  lower  net  purchases  of  marketable  securities  and  higher  proceeds  from  sales  of 
businesses and other assets.  This is partially offset by cash outflows relating to foreign currency contract settlements. The absence
in 2016 of property, plant and equipment expenditures related to Chemours accounted for $0.2 billion of the reduction.

39

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Cash used for investing activities in 2015 increased by $1.5 billion compared to 2014. The change was primarily due to lower 
proceeds received from the sale of businesses in 2015 compared to 2014 and increased purchases of marketable securities in 2015
compared to 2014.  This was partially offset by lower purchases of property, plant and equipment, mainly due to the absence of 
Chemours in the second half of 2015 which accounted for $0.3 billion.  See Note 19 to the Consolidated Financial Statements for
further discussion of marketable securities outstanding at December 31, 2015 and 2014.

Purchases of property, plant and equipment totaled $1.0 billion, $1.6 billion and $2.0 billion in 2016, 2015, and 2014, respectively. 
The company expects 2017 purchases of property, plant and equipment to be about $1.1 billion.

(Dollars in millions)

Cash used for financing activities

2016

2015

2014

$

(2,328) $

(1,823) $

(5,074)

The $0.5 billion increase in cash used for financing activities in 2016 was primarily due to lower borrowings as a result of the 
prior year distribution of approximately $3.9 billion which Chemours financed through external borrowings and paid to the company 
prior to its separation. This was partially offset by lower share repurchases and lower dividends paid to stockholders.

aa

The $3.3 billion decrease in cash used for financing activities in 2015 was primarily due to the distribution of Chemours borrowings
to the company as part of the separation, partially offset by a reduction in short term borrowings, and an increase in the repurchase
of common stock.

u

Dividends paid to common and preferred shareholders were $1.3 billion, $1.5 billion, and $1.7 billion in 2016, 2015, and 2014,
respectively.  Dividends per share of common stock were $1.52, $1.72, and $1.84 in 2016, 2015, and 2014, respectively.  In January
2017, the Board of Directors declared a first quarter common stock dividend of $0.38 per share.  With the first quarter 2017 
dividend, the company has paid quarterly consecutive dividends since the company’s first dividend in the fourth quarter 1904. 

In the first quarter 2015, DuPont announced its intention to buy back about $4 billion of shares using the distribution proceeds 
received from Chemours. In connection with the completion of the spin-off of Chemours, the Board of Directors authorized the 
use of the distribution proceeds to buy back shares of the company's common stock as follows: $2 billion to be purchased and 
retired by December 31, 2015 with the remainder to be purchased and retired by December 31, 2016. During 2015, the company 
purchased and retired 35 million shares through a $2 billion accelerated share repurchase (ASR) agreement. The company had 
limited opportunity to repurchase shares in 2016, primarily due to the planned merger with Dow. However, during 2016, the
company  purchased  and  retired  13.2  million  shares  in  the  open  market  at  a  cost  of  $916  million. As  of  January  1,  2017,  the
authorization under this buyback program has expired. 

In January 2014, the company's Board of Directors authorized a $5 billion share buyback plan.  During 2014, the company purchased 
and retired 30.1 million shares for $2 billion under two separate ASR agreements as well as open market purchases. In 2015, the
company repurchased and retired 4.6 million shares in the open market for a total cost of $353 million.  As a result, the company 
has completed $2.4 billion of repurchases as of December 31, 2016. There is no required completion date for purchases under this
plan.  

a

See Note 16 to the Consolidated Financial Statements for additional information relating to the above share buyback plans.

40

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

(Dollars in millions)

Cash provided by operating activities
Purchases of property, plant and equipment
Free cash flow

2016

2015

2014

$

$

3,300 $
(1,019)
2,281 $

2,316 $
(1,629)

687 $

3,712
(2,020)
1,692

Free cash flow is a measurement not recognized in accordance with generally accepted accounting principles in the U.S. (GAAP) 
and should not be viewed as an alternative to GAAP measures of performance. All companies do not calculate non-GAAP financial
measures in the same manner and, accordingly, the company's free cash flow definition may not be consistent with the methodologies 
used by other companies. The company defines free cash flow as cash provided by operating activities less purchases of property,yy
plant and equipment, and therefore indicates operating cash flow available for payment of dividends, other investing activities and 
other financing activities. Free cash flow is useful to investors and management to evaluate the company's cash flow and financial 
performance, and is an integral financial measure used in the company's financial planning process.

For further information relating to the change in cash provided by operating activities, see discussion above under cash provided 
by operating activities.

41

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Critical Accounting Estimates
The  company's  significant  accounting  policies  are  more  fully  described  in  Note 1  to  the  Consolidated  Financial  Statements. 
Management believes that the application of these policies on a consistent basis enables the company to provide the users of the 
financial statements with useful and reliable information about the company's operating results and financial condition.

The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and 
assumptions that affect the reported amounts, including, but not limited to, receivable and inventory valuations, impairment of
tangible  and  intangible  assets,  long-term  employee  benefit  obligations,  income  taxes,  restructuring  liabilities,  environmental 
matters and litigation. Management's estimates are based on historical experience, facts and circumstances available at the time 
and various other assumptions that are believed to be reasonable. The company reviews these matters and reflects changes in 
estimates as appropriate. Management believes that the following represents some of the more critical judgment areas in the 
application of the company's accounting policies which could have a material effect on the company's financial position, liquidity
or results of operations.

Long-term Employee Benefits
Accounting for employee benefit plans involves numerous assumptions and estimates. Discount rate and expected return on plan 
assets are two critical assumptions in measuring the cost and benefit obligation of the company's pension and other post employment 
benefit (OPEB) plans. Management reviews these two key assumptions annually as of December 31st. These and other assumptions
are updated periodically to reflect the actual experience and expectations on a plan specific basis as appropriate. As permitted by
GAAP, actual results that differ from the assumptions are accumulated on a plan by plan basis and to the extent that such differences
exceed 10 percent of the greater of the plan's benefit obligation or the applicable plan assets, the excess is amortized over the 
average remaining service period of active employees.

t

About 80 percent of the company's benefit obligation for pensions and essentially all of the company's OPEB obligations are 
attributable to the benefit plans in the U.S.  In the U.S. the discount rate is developed by matching the expected cash flow of the 
benefit plans to a yield curve constructed from a portfolio of high quality fixed-income instruments provided by the plans' actuaries 
as of the measurement date. Effective in 2016, the company began to measure the service and interest cost components utilizing
a full yield curve approach by applying the specific spot rates along the yield curve used in the determination of the benefit 
obligation to the relevant projected cash flows.  The company made this change as it believes it is a more precise measurement 
of service and interest costs by improving the correlation between projected benefit cash flows to the corresponding spot yield
curve rates. The company considers this a change in estimate, and, accordingly, has accounted for it on a prospective basis.  This 
change does not affect the measure of the total benefit obligation.  Historically, the service and interest cost components were 
estimated utilizing a single weighted-average discount rate derived from the yield curve and cash flow for measurement of the 
benefit obligation at the beginning of the period.  For non-U.S. benefit plans, the company utilizes prevailing long-term high
quality corporate bond indices to determine the discount rate, applicable to each country, at the measurement date. 

f

tt

Within the U.S., the company establishes strategic asset allocation percentage targets and appropriate benchmarks for significant aa
asset classes with the aim of achieving a prudent balance between return and risk. Strategic asset allocations in other countries are 
selected in accordance with the laws and practices of those countries. Where appropriate, asset-liability studies are also taken into 
consideration. The long-term expected return on plan assets in the U.S. is based upon historical real returns (net of inflation) for 
the asset classes covered by the investment policy, expected performance, and projections of inflation and interest rates over the 
long-term period during which benefits are payable to plan participants. Consistent with prior years, the long-term expected return 
on plan assets in the U.S. reflects the asset allocation of the plan and the effect of the company's active management of the plan's
assets.  

n

42

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

In determining annual expense for the principal U.S. pension plan, the company uses a market-related value of assets rather thanaa
its fair value. The market-related value of assets is calculated by averaging market returns over 36 months. Accordingly, there
may be a lag in recognition of changes in market valuation. As a result, changes in the fair value of assets are not immediately 
reflected in the company's calculation of net periodic pension cost. The following table shows the market-related value and fair 
value of plan assets for the principal U.S. pension plan:

(Dollars in billions)

Market-related value of assets

Fair value of plan assets
1. 

2016 1

2015

2014

$

13.5 $

13.5

15.1 $

14.4

15.9

15.8

During 2016, the plan's trust fund paid about $550 million to a group of separated, vested plan participants who elected a limited-time opportunity to receive
a lump sum payout. See further discussion under "Long Term Employee Benefits" beginning on page 47.

For plans other than the principal U.S. pension plan, pension expense is determined using the fair value of assets. 

The following table highlights the potential impact on the company's pre-tax earnings due to changes in certain key assumptions
with respect to the company's pension and OPEB plans, based on assets and liabilities at December 31, 2016:

(Dollars in millions)

Discount rate

Expected rate of return on plan assets

1/2 Percentage
Point
Increase

1/2 Percentage
Point
Decrease

$

51 $

80

(55)
(80)

In October 2014, the Society of Actuaries released final reports of new mortality tables and a mortality improvement scale for 
measurement of retirement program obligations in the U.S. The Society of Actuaries published other mortality improvement scales
in October 2015 and October 2016. The company adopted these tables in measuring the 2015 and 2016 long-term employee benefit 
obligations, respectively. The effect of these adoptions is amortized into net periodic benefit cost for the years following the 
adoption. 

Additional information with respect to pension and OPEB expenses, liabilities and assumptions is discussed under "Long-term
Employee Benefits" beginning on page 47 and in Note 17 to the Consolidated Financial Statements.

Environmental Matters 
DuPont accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the 
liability can be made.  The company has recorded a liability of $457 million as of December 31, 2016; these accrued liabilities
exclude claims against third parties and are not discounted.  As remediation activities vary substantially in duration and cost from 
site to site, it is difficult to develop precise estimates of future site remediation costs. The company's estimates are based on a 
number of factors, including the complexity of the geology, the nature and extent of contamination, the type of remedy, the outcome 
of discussions with regulatory agencies and other Potentially Responsible Parties (PRPs) at multi-party sites and the number of
and financial viability of other PRPs.  Therefore, considerable uncertainty exists with respect to environmental remediation costs
and, under adverse changes in circumstances, the potential liability may range up to $900 million above the amount accrued as 
of December 31, 2016.

t

t

43

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Legal Contingencies
The company's results of operations could be affected by significant litigation adverse to the company, including product liability
claims, patent infringement and antitrust claims, and claims for third party property damage or personal injury stemming from
alleged environmental torts.  The company records accruals for legal matters when the information available indicates that it is 
probable that a liability has been incurred and the amount of the loss can be reasonably estimated.  Management makes adjustments 
to these accruals to reflect the impact and status of negotiations, settlements, rulings, advice of counsel and other information and 
events that may pertain to a particular matter.  Predicting the outcome of claims and lawsuits and estimating related costs and
exposure involves substantial uncertainties that could cause actual costs to vary materially from estimates.  In making determinations 
of likely outcomes of litigation matters, management considers many factors.  These factors include, but are not limited to, the 
nature of specific claims including unasserted claims, the company's experience with similar types of claims, the jurisdiction in
which the matter is filed, input from outside legal counsel, the likelihood of resolving the matter through alternative dispute
resolution mechanisms and the matter's current status.  Considerable judgment is required in determining whether to establish a
litigation accrual when an adverse judgment is rendered against the company in a court proceeding.  In such situations, the company 
will not recognize a loss if, based upon a thorough review of all relevant facts and information, management believes that it is 
probable that the pending judgment will be successfully overturned on appeal.  A detailed discussion of significant litigation 
matters is contained in Note 15 to the Consolidated Financial Statements.

mm

Indemnification Assets 
Pursuant to the Separation Agreement discussed in Note 3 to the Consolidated Financial Statements, the company is indemnified 
by Chemours against certain litigation, environmental, workers' compensation and other liabilities that arose prior to the separation. 
The term of this indemnification is indefinite and includes defense costs and expenses, as well as monetary and non-monetary 
settlements and judgments.  In connection with the recognition of liabilities related to these indemnified matters, the company
records an indemnification asset when recovery is deemed probable.  In assessing the probability of recovery, the company considers 
the contractual rights under the Separation Agreement and any potential credit risk.  Future events, such as potential disputes
related to recovery as well as solvency of Chemours, could cause the indemnification assets to have a lower value than anticipated 
and recorded.  The company evaluates the recovery of the indemnification assets recorded when events or changes in circumstances 
indicate the carrying values may not be fully recoverable.  

aa

Income Taxes 
The breadth of the company's operations and the global complexity of tax regulations require assessments of uncertainties and 
judgments in estimating taxes the company will ultimately pay. The final taxes paid are dependent upon many factors, including 
negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of disputes arising from
federal, state and international tax audits in the normal course of business. The resolution of these uncertainties may result in
adjustments to the company's tax assets and tax liabilities. It is reasonably possible that net reductions to the company’s global 
unrecognized tax benefits could be in the range of $70 million to $90 million within the next 12 months with the majority due to
the settlement of uncertain tax positions with various tax authorities.  

Deferred income taxes result from differences between the financial and tax basis of the company's assets and liabilities and area
adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred 
tax assets when it is more likely than not that a tax benefit will not be realized. Significant judgment is required in evaluating the
need for and magnitude of appropriate valuation allowances against deferred tax assets. The realization of these assets is dependent 
on generating future taxable income, as well as successful implementation of various tax planning strategies. For example, changes
in facts and circumstances that alter the probability that the company will realize deferred tax assets could result in recording a 
valuation allowance, thereby reducing the deferred tax asset and generating a deferred tax expense in the relevant period. In some 
situations these changes could be material.

At December 31, 2016, the company had a net deferred tax asset balance of $2.9 billion, net of valuation allowance of $1.3 billion. 
Realization of these assets is expected to occur over an extended period of time. As a result, changes in tax laws, assumptions with 
respect  to  future  taxable  income,  and  tax  planning  strategies  could  result  in  adjustments  to  these  assets.    See  Note  6  to  the
Consolidated Financial Statements for additional details related to the deferred tax asset balance.

44

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Valuation of Assets
The assets and liabilities of acquired businesses are measured at their estimated fair values at the dates of acquisition. The excess 
of  the  purchase  price  over  the  estimated  fair  value  of  the  net  assets  acquired,  including  identified  intangibles,  is  recorded  as 
goodwill.  The  determination  and  allocation  of  fair  value  to  the  assets  acquired  and  liabilities  assumed  is  based  on  various 
assumptions and valuation methodologies requiring considerable management judgment, including estimates based on historical
information,  current  market  data  and  future  expectations.  The  principal  assumptions  utilized  in  the  company's  valuation 
methodologies include revenue growth rates, operating margin estimates, royalty rates, and discount rates. Although the estimates 
are deemed reasonable by management based on information available at the dates of acquisition, those estimates are inherently 
uncertain.

Assessment of the potential impairment of  goodwill, other intangible assets, property, plant and equipment, and investments in
affiliates and other assets is an integral part of the company's normal ongoing review of operations.  Testing for potential impairment 
of these assets is significantly dependent on numerous assumptions and reflects management's best estimates at a particular point 
in time.  The dynamic economic environments in which the company's diversified businesses operate, and key economic and 
business assumptions with respect to projected selling prices, market growth and inflation rates, can significantly affect the outcome 
of impairment tests.  Estimates based on these assumptions may differ significantly from actual results.  Changes in factors and 
assumptions used in assessing potential impairments can have a significant impact on the existence and magnitude of impairments, 
as well as the time in which such impairments are recognized. In addition, the company continually reviews its diverse portfolio
of assets to ensure they are achieving their greatest potential and are aligned with the company's growth strategy.  Strategic decisions 
involving a particular group of assets may trigger an assessment of the recoverability of the related assets. Such an assessment 
could result in impairment losses.

mm

Based on the results of the company's annual goodwill impairment test, completed in the third quarter 2016, we determined that 
the fair value of each of the reporting units exceeded its carrying value by more than 20 percent, and therefore there were no
indications of impairment. The company's methodology for estimating the fair value of its reporting units is using the income 
approach based on the present value of future cash flows.  The income approach has been generally supported by additional market 
transaction analyses. There can be no assurance that the company's estimates and assumptions regarding forecasted cash flow,
revenue and operating income growth rates made for purposes of the annual goodwill impairment test will prove to be accurate
predictions of the future.  The company believes the current assumptions and estimates utilized are both reasonable and appropriate.

During 2016, the company recorded a $158 million impairment charge related to indefinite-lived intangible trade names within
the Industrial Biosciences segment as a result of the realignment of brand marketing strategies and a determination to phase out 
the use of certain acquired trade names.  See Note 4 to the Consolidated Financial Statements for additional details related to this
charge.  

During 2016, the company recorded an asset impairment charge of $435 million related to its uncompleted ERP system.  The 
company intends to complete the ERP system project, however, given the uncertainties related to timing as well as potential 
developments and changes to technologies in the market place at the time of restart, use of the ERP system can no longer be 
considered probable. See Note 4 to the Consolidated Financial Statements for additional details related to this charge.

45

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Off-Balance Sheet Arrangements
Certain Guarantee Contracts
Information with respect to the company's guarantees is included in Note 15 to the Consolidated Financial Statements. Historically, 
the company has not had to make significant payments to satisfy guarantee obligations; however, the company believes it has the
financial resources to satisfy these guarantees.

Contractual Obligations 
Information related to the company's significant contractual obligations is summarized in the following table:

(Dollars in millions)
Long-term debt obligations1

Expected cumulative cash requirements
    for interest payments through maturity
Capital leases1
Operating leases
Purchase obligations2

Information technology infrastructure & services
Raw material obligations3
Utility obligations
License agreements4
Other

Total purchase obligations
Other liabilities1,5,6

Workers' compensation

Environmental remediation

Legal settlements
Other7

Total other long-term liabilities
Total contractual obligations8

Payments Due In

Total at
December 
31,
2016

2017

2018 - 
 2019

2020 -
 2021

2022 and
beyond

$

8,137 $

4 $

2,327 $

2,506 $

3,300

2,875

9

1,203

187

1,070

125

1,456

122

2,960

86

457

17

153

713

351

—

263

93

480

105

281

79

1,038

15

165

6

43

229

561

2

440

92

289

14

462

23

880

37

137

4

25

203

333

3

281

2

202

4

366

15

589

16

80

4

19

119

$

15,897 $

1,885 $

4,413 $

3,831 $

1,630

4

219

—

99

2

347

5

453

18

75

3

66

162

5,768

1.

2.

3.

4.

5.

6.

7.

8.

Included in the Consolidated Financial Statements.
Represents enforceable and legally binding agreements in excess of $1 million to purchase goods or services that specify fixed or minimum quantities; fixed,
minimum or variable price provisions; and the approximate timing of the agreement.
Includes raw material obligations related to supply agreements with Koch Industries, Inc. (INVISTA).
Represents remaining minimum payments under DuPont Pioneer license agreements.
Pension and OPEB obligations have been excluded from the table above. Expected 2017 funding for the principal U.S. pension plan and non-U.S. plans
with plan assets is disclosed below within Long Term Employee Benefits. Contributions beyond 2017 are expected to be made, however, the amount of 
contributions are dependent on the future economic environment, investment returns on pension trust assets, as well as rules and regulations of the respective
country in which the plans operate.  The company’s remaining pension plans with no plan assets and other post employment benefit plans are paid from
operating cash flows. The benefit payments for these plans are excluded from the table above as the timing and amounts of benefit payments are uncertain.
The estimated benefit payments in 2017 for these plans are disclosed below within Long Term Employee Benefits. Refer to Note 17 to the Consolidated 
Financial Statements for further information regarding the pension and other post employment benefit plans.  
The company's contractual obligations do not reflect an offset for recoveries associated with indemnifications by Chemours in accordance with the Separation 
Agreement.  Refer to Notes 3 and 15 to the Consolidated Financial Statements for additional detail related to the indemnifications.
Primarily represents employee-related benefits other than pensions and other post employment benefits.
Due to uncertainty regarding the completion of tax audits and possible outcomes, the timing of certain payments of obligations related to unrecognized tax 
benefits cannot be made and have been excluded from the table above. See Note 6 to the Consolidated Financial Statements for additional detail.

n

ff

The company expects to meet its contractual obligations through its normal sources of liquidity and believes it has the financial 
resources to satisfy these contractual obligations.

46

 
 
 
 
 
 
 
 
 
 
Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Long-term Employee Benefits
The company has various obligations to its employees and retirees. The company maintains retirement-related programs in many
countries that have a long-term impact on the company's earnings and cash flows. These plans are typically defined benefit pension
plans, as well as medical, dental and life insurance benefits for pensioners and survivors and disability benefits for employees
(other post employment benefits or OPEB plans). Approximately 80 percent of the company's worldwide benefit obligation for 
pensions and essentially all of the company's worldwide OPEB obligations are attributable to the U.S. benefit plans.

Pension coverage for employees of the company's non-U.S. consolidated subsidiaries is provided, to the extent deemed appropriate, 
through separate plans. The company regularly explores alternative solutions to meet its global pension obligations in the most
cost  effective  manner  possible  as  demographics,  life  expectancy  and  country-specific  pension  funding  rules  change.  Where
permitted by applicable law, the company reserves the right to change, modify or discontinue its plans that provide pension, medical,
dental, life insurance and disability benefits.

Benefits under defined benefit pension plans are based primarily on years of service and employees' pay near retirement.  In 
November 2016, the company announced changes to the U.S. pension and OPEB plans. The company will freeze the pay and 
service amounts used to calculate pension benefits for active employees who participate in the U.S. pension plans at the earlier of 
the effective date of the first of the Intended Business Separations or November 30, 2018 (the Effective Date).  See further discussion 
of the Intended Business Separations under "DuPont Dow Merger of Equals" beginning on page 2.  Therefore, as of the Effective 
Date, active employees in the U.S. plans will not accrue additional benefits for future service and eligible compensation received.
In addition to the changes to the U.S. pension plans, eligible employees who will be under the age of 50 at the Effective Date will
not receive post-retirement medical, dental and life insurance benefits.  As a result of these changes, the company recognized a 
pre-tax curtailment gain of $382 million during the fourth quarter of 2016.   The majority of employees hired in the U.S. on or
after January 1, 2007 are not eligible to participate in the pension and post-retirement medical, dental and life insurance plans, but 
receive benefits in the defined contribution plans.

a

In the fourth quarter 2016, about $550 million of lump-sum payments were made from the principal U.S. pension plan trust fund 
to a group of separated, vested plan participants who were extended a limited-time opportunity and voluntarily elected to receive 
their pension benefits in a single lump-sum payment.

Pension benefits are paid primarily from trust funds established to comply with applicable laws and regulations. Unless required 
by  law,  the  company  does  not  make  contributions  that  are  in  excess  of  tax  deductible  limits. The  actuarial  assumptions  and 
procedures utilized are reviewed periodically by the plans' actuaries to provide reasonable assurance that there will be adequate 
funds for the payment of benefits.  The company contributed $230 million to the principal U.S. pension plan in 2016 and the 
company expects to contribute about the same amount to this plan in 2017. 

Funding for each pension plan other than the principal U.S. pension plan is governed by the rules of the sovereign country in which 
it operates. Thus, there is not necessarily a direct correlation between pension funding and pension expense. In general, however,
improvements in plans' funded status tends to moderate subsequent funding needs. The company contributed $121 million to its 
pension plans other than the principal U.S. pension plan in 2016.

U.S. pension benefits that exceed federal limitations are covered by separate unfunded plans and these benefits are paid to pensioners
and survivors from operating cash flows.  The company's remaining pension plans with no plan assets are paid from operating
cash flows.  The company made benefit payments of $184 million to its unfunded plans in 2016.

The company's OPEB plans are unfunded and the cost of the approved claims is paid from operating cash flows. Pre-tax cash 
requirements to cover actual net claims costs and related administrative expenses were $218 million, $237 million and $233 million
for 2016, 2015 and 2014, respectively. Changes in cash requirements reflect the net impact of higher per capita health care costs, 
demographic changes, plan amendments and changes in participant premiums, co-pays and deductibles.

In 2017, the company expects to contribute $95 million for pension plans other than the principal U.S. pension plan, $85 million 
to its remaining plans with no plan assets, and $275 million for its OPEB plans.

47

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

The company's income can be significantly affected by pension and defined contribution benefits as well as OPEB costs. The
following table summarizes the extent to which the company's income over each of the last 3 years was affected by pre-tax charges 
related to long-term employee benefits:

(Dollars in millions)
Long-term employee benefit plan charges 1

2016

2015

2014

$

442 $

616 $

715

1.

The long-term employee benefit plan charges include discontinued operations of $(5), $(245) and $96 for 2016, 2015 and 2014, respectively.

The above charges for pension and OPEB are determined as of the beginning of each year.  The decrease in long-term employee 
benefit expense in 2016 is driven by the curtailment gain recognized in 2016 related to the changes to the U.S. long term employee
benefits described above.  The decrease in 2015 is primarily due to a curtailment gain, which is presented within income from 
discontinued operations, partially offset by a decrease in discount rate. See "Long-term Employee Benefits" under the Critical 
Accounting Estimates section beginning on page 42 of this report for additional information on determining annual expense.

The company's key assumptions used in calculating its pension and other post employment benefits are the expected return on 
plan assets, the rate of compensation increases and the discount rate (see Note 17 to the Consolidated Financial Statements).  For 
2017, long term employee benefit expense from continuing operations is expected to increase by about $340 million mainly due
to the curtailment gain recognized in 2016.   This amount does not include any potential settlement charges related to the company's
Pension Restoration Plan which provides lump sum payments to certain eligible retirees.

Environmental Matters
The  company  operates  global  manufacturing,  product  handling  and  distribution  facilities  that  are  subject  to  a  broad  array  of 
environmental laws and regulations.  Such rules are subject to change by the implementing governmental agency, and the company
monitors these changes closely.  Company policy requires that all operations fully meet or exceed legal and regulatory requirements.
In addition, the company implements voluntary programs to reduce air emissions, minimize the generation of hazardous waste,
decrease the volume of water use and discharges, increase the efficiency of energy use and reduce the generation of persistent,
bioaccumulative and toxic materials.  Management has noted a global upward trend in the amount and complexity of proposed 
chemicals regulation.  The costs to comply with complex environmental laws and regulations, as well as internal voluntary programs
and goals, are significant and will continue to be significant for the foreseeable future.

Pre-tax environmental expenses charged to income from continuing operations are summarized below:

(Dollars in millions)
Environmental operating costs
Environmental remediation costs

2016

2015

2014

$

$

370 $
60
430 $

380 $
65
445 $

380
35
415

About 75 percent of total pre-tax environmental expenses charged to income from continuing operations in 2016 resulted from 
operations in the U.S.  Based on existing facts and circumstances, management does not believe that year over year changes, if 
any, in environmental expenses charged to current operations will have a material impact on the company's financial position,
liquidity or results of operations. Annual expenditures in the near term are not expected to vary significantly from the range of 
such expenditures experienced in the past few years. Longer term, expenditures are subject to considerable uncertainty and may
fluctuate significantly. 

Environmental Operating Costs 
As a result of its operations, the company incurs costs for pollution abatement activities including waste collection and disposal, 
installation and maintenance of air pollution controls and wastewater treatment, emissions testing and monitoring, and obtaining
permits.  The  company  also  incurs  costs  related  to  environmental  related  research  and  development  activities  including
environmental field and treatment studies as well as toxicity and degradation testing to evaluate the environmental impact of 
products and raw materials. 

48

            
ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

Part II

OPERATIONS, continued 

Remediation Accrual 
Changes in the remediation accrual balance are summarized below:

(Dollars in millions)

Balance at December 31, 2014
Remediation payments1
Net increase in remediation accrual2
Balance at December 31, 2015
Remediation payments1
Net increase in remediation accrual2
Balance at December 31, 2016
1. 
2.   

Includes reductions in the accrual for payments made by indemnified parties. See below for further discussion.
Excludes related indemnification asset. See below for further discussion.

$

$

$

478
(104)
118

492
(143)
108

457

Considerable uncertainty exists with respect to environmental remediation costs, and, under adverse changes in circumstances,
the potential liability may range up to $900 million above the amount accrued as of December 31, 2016.  However, based on
existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation
activities at any individual site will have a material impact on the financial position, liquidity or results of operations of the company.

Pursuant to the Separation Agreement discussed in Note 3 to the Consolidated Financial Statements, the company is indemnified 
by Chemours for certain environmental matters, included in the liability of $457 million, that have an estimated liability of $250 
million as of December 31, 2016  and a potential exposure that ranges up to approximately $500 million above the amount accrued.  
As such, the company has recorded an indemnification asset of $250 million corresponding to the company's accrual balance
related to these matters at December 31, 2016. Within the table above, during 2016, the remediation payments made by Chemours 
are about $90 million and the indemnified portion of the net increase in the remediation accrual is about $50 million.

On December 15, 2016, DuPont reached a settlement in principle, valued at about $50 million, with the U.S. Departments of Justice
and the Interior and the Commonwealth of Virginia, to resolve remediation claims associated with mercury contamination in the
South River and South Fork Shenandoah River watershed.  If approved by the U.S. District Court for the Western District of 
Virginia, the settlement requires DuPont to make a cash payment of about $42 million and undertake certain remediation activities. 
The full value of the settlement is included in the remediation accrual balance at December 31, 2016.

As of December 31, 2016, the company has been notified of potential liability under the Comprehensive Environmental Response,
Compensation  and  Liability Act  (CERCLA  or  Superfund)  or  similar  state  laws  at  about  500  sites  around  the  U.S.,  including
approximately 100 sites for which DuPont does not believe it has liability based on current information. Active remediation is
under way at approximately 90 of these sites.  In addition, the company has resolved its liability at approximately 70 sites, either 
by completing remedial actions with other PRPs or by participating in "de minimis buyouts" with other PRPs whose waste, like 
the company's, represented only a small fraction of the total waste present at a site. The company received notice of potential
liability at one new site during 2016 compared with one and three similar notices in 2015 and 2014, respectively.

Environmental Capital Expenditures
Capital expenditures for environmental projects, either required by law or necessary to meet the company’s internal environmental 
goals, were $39 million in 2016. The company currently estimates expenditures for environmental-related capital projects to be 
about $55 million in 2017.

49

Part II

ITEM  7.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND  RESULTS  OF 

OPERATIONS, continued 

Climate Change
The company believes that climate change is an important global issue that presents risks and opportunities. Expanding upon 
significant global greenhouse gas (GHG) emissions and other environmental footprint reductions made in the period 1990-2010,
as of 2015 the company reduced its environmental footprint, achieving reductions of 7.5 percent in GHG emissions, 7.6 percent 
in water consumption, and 3.3 percent in energy intensity from non-renewable resources versus a 2010 baseline. In 2015, the 
company announced its 2020 Sustainability Goals, including a goal to achieve a 7 percent reduction in GHG emissions intensity 
(2015 baseline) and continuation of its goal to achieve a 10 percent improvement in energy intensity (2010 baseline). The company 
continuously evaluates opportunities for existing and new product and service offerings in light of the anticipated demands of a
low-carbon economy.

aa

The company is actively engaged in efforts to develop constructive public policies to reduce GHG emissions and encourage lower 
carbon forms of energy. Such policies may bring higher operating costs as well as greater revenue and margin opportunities. 
Legislative efforts to control or limit GHG emissions could affect the company's energy source and supply choices as well as
increase the cost of energy and raw materials derived from fossil fuels. Such efforts are also anticipated to provide the business
community with greater certainty for the regulatory future, help guide investment decisions, and drive growth in demand for low-
carbon and energy-efficient products, technologies, and services. Similarly, demand is expected to grow for products that facilitate 
adaptation to a changing climate. However, the current unsettled policy environment in the U.S., where many company facilities 
are located, adds an element of uncertainty to business decisions, particularly those relating to long-term capital investments. 

In addition, significant differences in regional or national approaches could present challenges in a global marketplace.  An effective 
global  climate  policy  framework  will  help  drive  the  market  changes  that  are  needed  to  stimulate  and  efficiently  deploy  new 
innovations in science and technology, while maintaining open and competitive global markets.

50

Part II

ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The company’s global operations are exposed to financial market risks relating to fluctuations in foreign currency exchange rates,
commodity prices, and interest rates.  The company has established a variety of programs including use of derivative instruments 
and other financial instruments to manage the exposure to financial market risks as to minimize volatility of financial results.  In 
the ordinary course of business, the company enters into derivative instruments to hedge its exposure to foreign currency, interest 
rate and commodity price risks under established procedures and controls.  For additional information on these derivatives and 
related exposures, see Note 19 to the Consolidated Financial Statements.  Decisions regarding whether or not to hedge a given
commitment are made on a case-by-case basis, taking into consideration the amount and duration of the exposure, market volatility
and economic trends. Foreign currency exchange contracts are also used, from time to time, to manage near-term foreign currency
cash requirements.

Foreign Currency Exchange Rate Risks
The  company  has  significant  international  operations  resulting  in  a  large  number  of  currency  transactions  that  result  from 
international sales, purchases, investments and borrowings.  The primary currencies for which the company has an exchange rate
exposure are the European euro (EUR), Chinese yuan, Brazilian real, and Japanese yen.  The company uses forward exchange 
contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its 
operations.  In addition to the contracts disclosed in Note 19 to the Consolidated Financial Statements, from time to time, the
company will enter into foreign currency exchange contracts to establish with certainty the U.S. dollar (USD) amount of future 
firm commitments denominated in a foreign currency. 

Certain  foreign  entities  of  the  company  held  USD  denominated  marketable  securities,  mainly  US  government  securities,  at 
December 31, 2015. The USD/EUR was the primary foreign exchange exposure for these nonfunctional currency denominated 
marketable securities.  These marketable securities were classified as “available-for-sale” and as such, fluctuations in foreign
exchange were recorded in accumulated other comprehensive loss (AOCL) within the Consolidated Statements of Equity. These
fluctuations were subsequently reclassified from AOCL to earnings in the period in which the marketable securities were sold.    

The following table illustrates the fair values of outstanding foreign currency contracts and nonfunctional currency denominated 
marketable securities at December 31, 2016 and 2015, and the effect on fair values of a hypothetical adverse change in the foreign
exchange rates that existed at December 31, 2016 and 2015. The sensitivities for foreign currency contracts and nonfunctional 
currency denominated marketable securities are based on a 10 percent adverse change in foreign exchange rates.

(Dollars in millions)

Foreign currency contracts

Marketable securities

2016

2015

2016

2015

$

61 $

—

(6) $

788

(567) $
—

(738)
(110)

Fair Value
Asset/(Liability)

Fair Value
Sensitivity

Since the company's risk management programs are highly effective, the potential loss in value for each risk management portfolio
described above would be largely offset by changes in the value of the underlying exposure.

i

f C i

C
Concentration of Credit Risk 
The company maintains cash and cash equivalents, marketable securities, derivatives and certain other financial instruments withtt
various financial institutions. These financial institutions are generally highly rated and geographically dispersed and the company
has a policy to limit the dollar amount of credit exposure with any one institution.

i

As part of the company's financial risk management processes, it continuously evaluates the relative credit standing of all of the 
financial institutions that service DuPont and monitors actual exposures versus established limits. The company has not sustained 
credit losses from instruments held at financial institutions.

The company's sales are not materially dependent on any single customer.  As of December 31, 2016, no one individual customer 
balance represented more than five percent of the company's total outstanding receivables balance. Credit risk associated with its 
receivables balance is representative of the geographic, industry and customer diversity associated with the company's global
businesses.

The company also maintains strong credit controls in evaluating and granting customer credit. As a result, it may require that 
customers provide some type of financial guarantee in certain circumstances. Length of terms for customer credit varies by industry
and region.

51

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

C

S

S

S

Part II

The financial statements and supplementary data required by this Item are included herein, commencing on page F-1 of this report.rr

ITEM  9.  CHANGES  IN AND  DISAGREEMENTS  WITH ACCOUNTANTS  ON ACCOUNTING AND  FINANCIAL 

DISCLOSURE

None.

ITEM 9A.  CONTROLS AND PROCEDURES

The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to 
be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded,
processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and 
procedures  also  give  reasonable  assurance  that  information  required  to  be  disclosed  in  such  reports  is  accumulated  and 
communicated to management to allow timely decisions regarding required disclosures.

As  of  December 31,  2016,  the  company's  Chief  Executive  Officer  (CEO)  and  Chief  Financial  Officer  (CFO),  together  with
management,  conducted  an  evaluation  of  the  effectiveness  of  the  company's  disclosure  controls  and  procedures  pursuant  to 
Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure 
controls and procedures are effective.

There has been no change in the company's internal control over financial reporting that occurred during the fourth quarter of 
2016 that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting.
The company has completed its evaluation of its internal controls and has concluded that the company's system of internal controls 
over financial reporting was effective as of December 31, 2016 (see page F-2).

ITEM 9B.  OTHER INFORMATION

On January 31, 2017, the company entered into a committed receivable repurchase facility of up to $1.3 billion (the 2017 repurchase
facility) that expires on November 30, 2017.  Under the 2017 repurchase facility, the company may sell a portfolio of available
and eligible outstanding customer notes receivables within the Agriculture segment to participating institutions and simultaneously 
agree to repurchase at a future date.  The 2017 repurchase facility is considered a secured borrowing with the customer notes 
receivables, inclusive of those that are sold and repurchased, equal to 105 percent of the outstanding amounts borrowed utilized 
as collateral.  Borrowings under the repurchase facility will have an interest rate of LIBOR + 0.75 percent.  

52

Part III 

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 

CO O

C O S

C S

GO

O

C

C

Information with respect to this Item is incorporated herein by reference to the Proxy, including information within the sections 
entitled,  "Election  of  Directors,"  "Governance  of  the  Company-Committees  of  the  Board,"  "Governance  of  the  Company-
Committee  Membership,"  "Section 16(a)  Beneficial  Ownership  Reporting  Compliance,"  and  “Stockholder  Nominations  for 
Election of Directors.”

h

h

The company has adopted a Code of Ethics for its CEO, CFO, and Controller that may be accessed from the company's website
at  www.dupont.com  by  clicking  on  "Investors"  and  then  "Corporate  Governance." Any  amendments  to,  or  waiver  from,  any 
provision of the code will be posted on the company's website at the above address.
provision of the code will be posted on the company's website at the above address.

d
li ki

d h

b i

d f

hi

ll

h

b

h

d

d

b

d

d

d

f

f

f

i

i

Executive Officers of the Registrant
The following is a list, as of  bFebruary 2, 2017 f h
li

h f ll

f

i

i

, of the company's Executive Officers:

ffi

i

Chair of the Board of Directors and Chief Executive Officer:
Edward D. Breen

Other Executive Officers:
Benito Cachinero-Sánchez

Senior Vice President - Human Resources

James C. Collins

Executive Vice President

C. Marc Doyle

Executive Vice President

Nicholas C. Fanandakis

Executive Vice President and Chief Financial Officer

Stacy L. Fox

Senior Vice President and General Counsel

Douglas Muzyka

Senior Vice President and Chief Science & Technology Officer

Executive
Officer
Since

2015

2011

2014

2015

2009

2014

2014

Age

60

58

54

47

60

63

62

h

The company's Executive Officers are elected or appointed for the ensuing year or for an indefinite term and until their successors
i
h
are elected or appointed.
d

i d fi i

il h i

d f

ffi

d

d

d

f

l

i

i

i

l

Edward D. Breen joined the DuPont Board of Directors in February 2015, was named Interim Chair of the Board and CEO in 
October 2015, and assumed his current role in November 2015.  Mr. Breen served as Chairman and CEO of Tyco International 
plc (Tyco) from July 2002 until September 2012.  Prior to joining Tyco, Mr. Breen held several senior management positions at 
Motorola from 2000 to 2002, including as President and Chief Operating Officer.  From December 1997 to January 2000, he
served as Chairman, President and Chief Executive Officer of General Instrument Corporation.  Between 1994 and 1997, Mr.
Breen  was  president  of  the  Broadband  Networks  Group  for  General  Instrument,  President  of  Eastern  Operations  for  the
Communications Division and served as Executive Vice President of Terrestrial Systems.  Mr. Breen currently serves as a director 
of Comcast Corporation. He also serves as a member of the advisory board of New Mountain Capital LLC, a private equity firm.

Benito Cachinero-Sánchez joined DuPont in April 2011 as Senior Vice President - Human Resources.  Prior to joining DuPont, 
he was Corporate Vice President of Human Resources at Automatic Data Processing (ADP).  Prior to ADP, he was Vice President, 
Human Resources for the Medical Devices & Diagnostics Group of Johnson & Johnson.

53

 
 
 
 
 
 
 
 
Part III

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE, continued

James C. Collins joined DuPont in 1984 as an engineer.  He has held positions in engineering, supervision and plant management 
at a variety of manufacturing sites.  In 1993, he joined the Agriculture Sales & Marketing Group where he served in a variety of 
roles across the globe supporting DuPont’s seed and crop protection businesses.  From 2004 to 2010, he was responsible for DuPont 
Crop Protection as Vice President and General Manager and then President.  In January 2011, he was appointed Vice President 
for Acquisition & Integration of Danisco, and was named President of DuPont Industrial Biosciences in May of that year.  Beginning
in September 2013, he assumed additional business and functional responsibilities as Senior Vice President.  In December 2014, 
he was named Executive Vice President and had responsibility for the Electronics & Communications, Industrial Biosciences, 
Performance Materials segments as well as regional management for Europe, Middle East, Africa and Canada and Corporate 
Communications.   In January 2016, Mr. Collins assumed responsibility for the Agriculture businesses.

C. Marc Doyle joined DuPont in 1995 as a research scientist within DuPont Central Research & Development.  He has held 
positions in business development, marketing and business management, including strategic planning manager, global displays 
business manager and regional business director of the Asia Pacific region for the Microcircuit Materials business.  In Februaryrr
2008, he became the Global Business Director for DuPont Photovoltaic Solutions within the DuPont Electronics & Communications 
business. He was named Global Market and Product Director for DuPont Protection Technologies in September 2011.  In this role, 
Mr. Doyle had been responsible for the Kevlar® and Nomex® product lines globally.  In June 2013 he was named President of 
DuPont Protection Technologies.  In July 2015, he was named Senior Vice President and assumed responsibility for the Safety & 
Protection businesses.  In January 2016, he was named Executive Vice President and assumed responsibility for the Electronics 
& Communications, Protection Solutions, Sustainable Solutions, Industrial Biosciences, Nutrition & Health, and Performance 
Materials businesses.  

Nicholas C. Fanandakis joined DuPont in 1979 as an accounting and business analyst. Since then, Mr. Fanandakis served in a
variety of plant, marketing, and product management and business director roles. Mr. Fanandakis served as Vice President and 
General Manager—DuPont Chemical Solutions Enterprise from 2003 until February 2007 when he was named Vice President—
Corporate Plans. In January 2008, Mr. Fanandakis was named Group Vice President—DuPont Applied BioSciences. In November 
2009, he was named Senior Vice President and Chief Financial Officer. In August 2010, he was named Executive Vice President 
and Chief Financial Officer.

Stacy L. Fox joined DuPont in October 2014 as Senior Vice President and General Counsel.  In January 2016, she assumed 
responsibility for Corporate Communications.  Prior to joining DuPont she served as Deputy Emergency Manager of the City of 
Detroit. Prior to that role, she was Senior Vice President of Strategy and General Counsel of Sunoco, Inc.  She also served as a 
member  of  the  Board  of  Directors  of  Sunoco  Partners  LLC.    Earlier,  she  served  as  Executive  Vice  President  of  Corporate
Transactions and Legal Affairs for Visteon. Ms. Fox is also a founder and principal of the Roxbury Group.

Douglas Muzyka joined the company in 1985 as a research scientist and held a variety of research and research management roles. 
In 1994, he was named Director of Technology and New Business Development for DuPont Nylon, Asia Pacific. In 1998, he was 
named Global Business Director for the Nylon Industrial Specialties business. In 2001, Mr. Muzyka was then named President 
and General Manager of DuPont Mexico. In January 2003, he was named President and Chief Executive Officer of DuPont Canada 
Inc. and in September 2003, concurrently Vice President and General Manager - DuPont Nutrition & Health. In July 2006, he
assumed the role of President - DuPont Greater China. In September 2010, he was named Senior Vice President and Chief Science 
and Technology Officer.  In January 2016, he assumed responsibility for engineering technologies and regional leadership.

ITEM 11.  EXECUTIVE COMPENSATION

Information with respect to this Item is incorporated herein by reference to the Proxy, including information within the sections 
entitled,  "Compensation  Discussion  and  Analysis,"  "Compensation  of  Executive  Officers,"  "Directors'  Compensation," 
"Compensation Committee Interlocks and Insider Participation" and "Compensation Committee Report."

54

Part III

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED

STOCKHOLDER MATTERS

Information with respect to this Item is incorporated herein by reference to the Proxy, including information within the section
entitled "Ownership of Company Stock."

Securities authorized for issuance under equity compensation plans as of December 31, 2016
(Shares in thousands, except per share)

Plan Category
Equity compensation plans approved by
    security holders

Equity compensation plans not 
    approved by security holders

Total

Number of Securities to
be Issued Upon Exercise
of Outstanding Options,
Warrants and Rights

Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights2

Number of Securities
Remaining Available
for Future Issuance
Under Equity
Compensation Plans3

20,447 1

$

13 4

20,460

$

58.11

—

58.11

36,854

— 5

36,854

1.

2.

3.

4.

5.

Includes stock-settled time-vested and performance-based restricted stock units granted and stock units deferred under the company's Equity and Incentive 
Plan, Stock Performance Plan, Variable Compensation Plan and the Stock Accumulation and Deferred Compensation Plan for Directors. Performance-based 
restricted stock units reflect the maximum number of shares to be awarded at the conclusion of the performance cycle (200 percent of the original grant).
The actual award payouts can range from 0 to 200 percent of the original grant.
Represents the weighted-average exercise price of the outstanding stock options only; the outstanding stock-settled time-vested and performance-based 
restricted stock units and deferred stock units are not included in this calculation.
Reflects shares available pursuant to the issuance of stock options, restricted stock, restricted stock units or other stock-based awards under the Equity and 
Incentive Plan, as amended and restated effective March 14, 2016 (see Note 18 to the Consolidated Financial Statements). The maximum number of shares
of stock reserved for the grant or settlement of awards under the Equity and Incentive Plan (Share Limit) shall be 110,000 and shall be subject to adjustment 
as provided therein; provided that each share in excess of 30,000 issued under the Equity and Incentive Plan pursuant to any award settled in stock, other 
than a stock option or stock appreciation right, shall be counted against the foregoing Share Limit as four and one-half shares for every one share actually
issued in connection with such award. (For example, if 32,000 shares of restricted stock are granted under the Equity and Incentive Plan, 39,000 shall be
charged against the Share Limit in connection with that award.)
Includes 13 deferred stock units resulting from base salary and short-term incentive (STIP) deferrals under the Management Deferred Compensation Plan 
(MDCP). Under the MDCP, a select group of management or highly compensated employees can elect to defer the receipt of their base salary, STIP or Long 
Term Incentive (LTI) award. LTI deferrals are included in footnote 1 to the above chart. The company does not match deferrals under the MDCP. There are
seven core investment options under the MDCP for base salary and STIP deferrals, including deferred stock units with dividend equivalents credited as 
additional stock units. In general, deferred stock units are distributed in the form of DuPont common stock and may be made in the form of lump sum at a 
specified future date prior to retirement or a lump sum or annual installments after separation from service. Shareholder approval of the MDCP was not 
required under the rules of the New York Stock Exchange. 
There is no limit on the number of shares that can be issued under the MDCP and no further shares are available for issuance under the other equity compensation 
arrangements described in footnote 4 to the above chart.

uu

d

55

Part III

ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information with respect to this Item is incorporated herein by reference to the Proxy, including information within the sections 
entitled,  "Governance  of  the  Company-Review  and Approval  of Transactions  with  Related  Persons"  and  "Governance  of  the 
Company-Corporate  Governance  Guidelines,"  "Governance  of  the  Company-Committees  of  the  Board,"  "Governance  of  the 
Company-Committee Membership" and "Election of Directors."

ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

Information with respect to this Item is incorporated herein by reference to the Proxy, including information within the section
entitled "Ratification of Independent Registered Public Accounting Firm."

56

ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) 

Financial Statements, Financial Statement Schedules and Exhibits:

Part IV

1. 

2. 

Financial Statements (See the Index to the Consolidated Financial Statements on page F-1 of this report).

Financial Statement Schedules

Schedule II—Valuation and Qualifying Accounts

(Dollars in millions)

Year Ended December 31,
Accounts Receivable—Allowance for Doubtful Receivables

2016

2015

2014

Balance at beginning of period

Additions charged to expenses
Deductions from reserves1
Balance at end of period
Inventory—Obsolescence Reserve

Balance at beginning of period

Additions charged to expenses
Deductions from reserves2
Balance at end of period
Deferred Tax Assets—Valuation Allowance

Balance at beginning of period

Net benefits to income tax expense

(Deductions) additions to other comprehensive (loss) income

Balance at end of period

$

$

$

$

$

$

225 $

119
(57)
287 $

237 $

298
(320)
215 $

1,529 $
(184)
(37)
1,308 $

235 $

58
(68)
225 $

180 $

391
(334)
237 $

1,704 $
(71)
(104)
1,529 $

262

58
(85)
235

212

386
(418)
180

1,711
(47)
40

1,704

1.      Deductions include write-offs, recoveries and currency translation adjustments.
2.      Deductions include disposals and currency translation adjustments.

Financial Statement Schedules listed under SEC rules but not included in this report are omitted because they are not applicable 
or the required information is shown in the Consolidated Financial Statements or notes thereto incorporated by reference.

57

 
 
 
 
ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES, continued

3. 

Exhibits

Part IV

The following list of exhibits includes both exhibits submitted with this Form 10-K as filed with the SEC and those incorporated 
by reference to other filings:

Exhibit
Number

3.1

3.2

4

10.1*

10.2*

10.3*

10.4*

10.5*

10.6*

10.7*

10.8*

10.9*

10.10*

10.11*

10.12*

10.13*

Description

Company's Restated Certificate of Incorporation (incorporated by reference to Exhibit 99.2 to the company’s Annual 
Report on Form 8-K (Commission file number 1-815) dated June 1, 2015).

Company’s Bylaws, as last amended effective October 22, 2015 (incorporated by reference to Exhibit 3.2 to the 
company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended September 30, 
2015).

The company agrees to provide the Commission, on request, copies of instruments defining the rights of holders of 
long-term debt of the company and its subsidiaries.

The DuPont Stock Accumulation and Deferred Compensation Plan for Directors, as last amended effective January 1, 
2009 (incorporated by reference to Exhibit 10.1 to the company's Annual Report on Form 10-K (Commission file 
number 1-815) for the year ended December 31, 2013).

Company’s Supplemental Retirement Income Plan, as last amended effective December 18, 1996 (incorporated by 
reference to Exhibit 10.2 to the company's Annual Report on Form 10-K (Commission file number 1-815) for the 
year ended December 31, 2011).

Company’s Pension Restoration Plan, as last amended effective June 29, 2015 (incorporated by reference to Exhibit 
10.3 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 
30, 2015).

Company’s Rules for Lump Sum Payments, as last amended effective May 15, 2014 (incorporated by reference to 
Exhibit 10.4 to the company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended 
June 30, 2015).

Company’s Stock Performance Plan, as last amended effective January 25, 2007 (incorporated by reference to Exhibit 
10.5 to the company's Annual Report on Form 10-K (Commission file number 1-815) for the year ended December 
31, 2011).

Company’s Equity and Incentive Plan, as amended and restated effective March 14, 2016 (incorporated by reference 
to Exhibit 10.06 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period 
ended June 30, 2016).

Form of 2013 Award Terms under the company’s Equity and Incentive Plan (incorporated by reference to Exhibit 
10.7 to the company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 
30, 2013).

Company’s Retirement Savings Restoration Plan, as last amended effective May 15, 2014 (incorporated by reference 
to Exhibit 10.08 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period 
ended June 30, 2014).

Company’s Retirement Income Plan for Directors, as last amended January 2011 (incorporated by reference to Exhibit 
10.9 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March
31, 2012).

Company's Senior Executive Severance Plan, as amended and restated effective December 10, 2015 (incorporated 
by reference to Exhibit 10.10 to the company's Annual Report on Form 10-K (Commission file number 1-815) for 
the year ended December 31, 2015). The company agrees to furnish supplementally a copy of any omitted schedules 
to the Commission upon request.

Supplemental Deferral Terms for Deferred Long Term Incentive Awards and Deferred Variable Compensation Awards 
(incorporated by reference to Exhibit 10.12 to the company's Annual Report on Form 10-K (Commission file number 
1-815) for the year ended December 31, 2013).

Form of 2014 Award Terms under the Company's Equity and Incentive Plan (incorporated by reference to Exhibit 
10.13 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March
31, 2014).

Company’s Management Deferred Compensation Plan, as last amended effective April 15, 2014 (incorporated by
reference to Exhibit 10.13 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for 
the period ended June 30, 2014).

58

ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES, continued

Part IV

10.14*

10.15*

10.16*

10.17*

10.18**

10.19

10.20**

10.21**

10.22**

12

21

23

31.1

31.2

32.1

32.2

Separation Agreement dated October 5, 2015, by and between E.I. du Pont Nemours and Company and Ellen J. 
Kullman (incorporated by reference to Exhibit 10.1 to the company's Current Report on Form 8-K (Commission file 
number 1-815) dated October 5, 2015).

Form of 2015 Award Terms under the Company's Equity and Incentive Plan (incorporated by reference to Exhibit 
10.15 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March 
31, 2015).

Form of 2016 Award Terms under the Company’s Equity and Incentive Plan, (incorporated by reference to Exhibit 
10.22 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March 
31, 2016).

Letter Agreement dated January 4, 2016, by and between the Company and Mr. James C. Borel (incorporated by 
reference to Exhibit 10.1 to the company's Current Report on Form 8-K (Commission file number 1-815) dated 
January 22, 2016).

Separation Agreement by and between the Company and The Chemours Company (incorporated by reference to 
Exhibit 2.1 to the company's Current Report on Form 8-K (Commission file number 1-815) dated July 8, 2015).

Tax Matters Agreement by and between the Company and The Chemours Company (incorporated by reference to 
Exhibit 2.2 to the company's Current Report on Form 8-K (Commission file number 1-815) dated July 8, 2015).

Agreement and Plan of Merger by and between the Company and The Dow Chemical Company, dated as of December 
11, 2015 (incorporated by reference to Exhibit 2.1 to the company's Current Report on Form 8-K (Commission file
number 1-815) dated December 11, 2015).

Master Repurchase Agreement by and among Cooperatieve Rabobank, U.A. (New York Branch), The Bank of Tokyo
Mitsubishi UFJ Ltd. (New York Branch) and PHI Financial Services, Inc. dated as of January 31, 2017.

Master Framework Agreement by and among Cooperatieve Rabobank, U.A. (New York Branch), The Bank of Tokyo 
Mitsubishi UFJ Ltd. (New York Branch) and PHI Financial Services, Inc. dated as of January 31, 2017.

Computation of Ratio of Earnings to Fixed Charges.

Subsidiaries of the Registrant.

Consent of Independent Registered Public Accounting Firm.

Rule 13a-14(a)/15d-14(a) Certification of the company’s Principal Executive Officer.

Rule 13a-14(a)/15d-14(a) Certification of the company’s Principal Financial Officer.

Section 1350  Certification  of  the  company’s  Principal  Executive  Officer.  The  information  contained  in  this 
Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in
any registration statement filed by the registrant under the Securities Act of 1933, as amended.

Section 1350  Certification  of  the  company’s  Principal  Financial  Officer.  The  information  contained  in  this
Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in
any registration statement filed by the registrant under the Securities Act of 1933, as amended.

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

*

**

Management contract or compensatory plan or arrangement.

DuPont hereby undertakes to furnish supplementally a copy of any omitted schedule or exhibit to such agreement to the U.S. Securities and Exchange
Commission upon request.

59

Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.

Signatures 

February 2, 2017

E. I. DU PONT DE NEMOURS AND COMPANY

By:

/s/ Nicholas C. Fanandakis

Nicholas C. Fanandakis
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

_____________________________________________

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the registrant in the capacities and on the dates indicated:

Signature

Title(s)

Date

/s/ E.D. Breen

E. D. Breen

/s/ L. Andreotti

L. Andreotti

/s/ R.A. Brown

R. A. Brown

/s/ A.M. Cutler

A. M. Cutler

/s/ E.I. du Pont, II

E. I. du Pont, II

/s/ J. L. Gallogly
J. L. Gallogly

/s/ M.A. Hewson

M. A. Hewson

/s/ L.D. Juliber
L. D. Juliber

/s/ U. M. Schneider
U. M. Schneider

/s/ L. M. Thomas
L. M. Thomas

/s/ P. J. Ward
P. J. Ward

February 2, 2017

February 2, 2017

February 2, 2017

February 2, 2017

February 2, 2017

February 2, 2017

February 2, 2017

February 2, 2017

February 2, 2017

February 2, 2017

February 2, 2017

Chair of the Board of Directors and
Chief Executive Officer and Director
(Principal Executive Officer)
Director

Director

Director

Director

Director

Director

Director

Director

Director

Director

60

 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E.I. du Pont de Nemours and Company

Index to the Consolidated Financial Statements

Consolidated Financial Statements:

Management's Reports on Responsibility for Financial Statements and Internal Control over 

Financial Reporting

Report of Independent Registered Public Accounting Firm

Consolidated Income Statements for the years ended December 31, 2016, 2015 and 2014
Consolidated Statements of Comprehensive Income for the years ended December 31, 2016, 2015 and 2014

Consolidated Balance Sheets as of December 31, 2016 and December 31, 2015

Consolidated Statements of Equity for the years ended December 31, 2016, 2015 and 2014

Consolidated Statements of Cash Flows for the years ended December 31, 2016, 2015 and 2014

Notes to the Consolidated Financial Statements

Page(s)

F-2

F-3

F-4
F-5

F-6

F-7

F-8

F-9

F-1

                                                               
 
Management's Reports on Responsibility for Financial Statements and
Internal Control over Financial Reporting

Management's Report on Responsibility for Financial Statements

Management is responsible for the Consolidated Financial Statements and the other financial information contained in this Annual
Report on Form 10-K. The financial statements have been prepared in accordance with generally accepted accounting principles
in the United States of America (GAAP) and are considered by management to present fairly the company's financial position, 
results of operations and cash flows. The financial statements include some amounts that are based on management's best estimates
and judgments. The financial statements have been audited by the company's independent registered public accounting firm, 
PricewaterhouseCoopers LLP.  The  purpose  of  their  audit  is  to  express  an  opinion  as  to  whether  the  Consolidated  Financial 
Statements included in this Annual Report on Form 10-K present fairly, in all material respects, the company's financial position, 
results of operations and cash flows in conformity with GAAP. Their report is presented on the following page.

Management's Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining an adequate system of internal control over financial reporting as 
defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The company's internal control over financial 
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation 
of financial statements for external purposes in accordance with GAAP. The company's internal control over financial reporting 
includes those policies and procedures that:

i. 

ii. 

pertain  to  the  maintenance  of  records  that,  in  reasonable  detail,  accurately  and  fairly  reflect  the  transactions  and 
dispositions of the assets of the company;

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements 
in accordance with generally accepted accounting principles and that receipts and expenditures of the company are 
being made only in accordance with authorization of management and directors of the company; and

iii. 

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition 
of the company's assets that could have a material effect on the financial statements.

Internal control over financial reporting has certain inherent limitations which may not prevent or detect misstatements. In addition, 
changes in conditions and business practices may cause variation in the effectiveness of internal controls.

Management assessed the effectiveness of the company's internal control over financial reporting as of December 31, 2016, based
on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-
Integrated Framework (2013). Based on its assessment and those criteria, management concluded that the company maintained 
effective internal control over financial reporting as of December 31, 2016.

PricewaterhouseCoopers LLP, an independent registered public accounting firm, has audited the effectiveness of the company's 
internal control over financial reporting as of, as stated in their report, which is presented on the following page.

Edward D. Breen
Chair of the Board and
Chief Executive Officer

February 2, 2017 

Nicholas C. Fanandakis
Executive Vice President
and Chief Financial Officer

F-2

                                                               
Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of
E. I. du Pont de Nemours and Company:

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of income, comprehensive 
income, equity and cash flows present fairly, in all material respects, the financial position of E. I. du Pont de Nemours and 
Company and its subsidiaries at December 31, 2016 and 2015, and the results of their operations and their cash flows for each of 
the three years in the period ended December 31, 2016 in conformity with accounting principles generally accepted in the United
States of America.  In addition, in our opinion, the financial statement schedule listed in the index appearing under Item 15(a) (2) 
presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated 
financial statements.  Also in our opinion, the Company maintained, in all material respects, effective internal control over financial 
reporting as of December 31, 2016, based on criteria established in Internal Control - Integrated Framework (2013) issued by the 
Committee of Sponsoring Organizations of the Treadway Commission (COSO).  The Company's management is responsible for 
these financial statements and financial statement schedule, for maintaining effective internal control over financial reporting and 
for its assessment of the effectiveness of internal control over financial reporting, included in "Management's Report on Internal 
Control over Financial Reporting" appearing on page F-2.  Our responsibility is to express opinions on these financial statements,
on the financial statement schedule and on the Company's internal control over financial reporting based on our integrated audits.  
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). 
Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements 
are free of material misstatement and whether effective internal control over financial reporting was maintained in all material
respects.  Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating
the  overall  financial  statement  presentation.    Our  audit  of  internal  control  over  financial  reporting  included  obtaining  an
understanding  of  internal  control  over  financial  reporting,  assessing  the  risk  that  a  material  weakness  exists,  and  testing  and
evaluating the design and operating effectiveness of internal control based on the assessed risk.  Our audits also included performing 
such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for 
our opinions.

k

r

ff

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability 
of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted 
accounting principles.  A company’s internal control over financial reporting includes those policies and procedures that (i) pertain
to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets
of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are 
being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that 
could have a material effect on the financial statements.

a

Because  of  its  inherent  limitations,  internal  control  over  financial  reporting  may  not  prevent  or  detect  misstatements.   Also, 
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because 
of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 2, 2017 

F-3

                                                               
E. I. du Pont de Nemours and Company
Consolidated Financial Statements

CONSOLIDATED INCOME STATEMENTS
(Dollars in millions, except per share)

For the year ended December 31,
Net sales

Cost of goods sold

Other operating charges

Selling, general and administrative expenses

Research and development expense
Other income, net

Interest expense

Employee separation / asset related charges, net
Income from continuing operations before income taxes

Provision for income taxes on continuing operations

Income from continuing operations after income taxes

Income from discontinued operations after income taxes

Net income

Less: Net income attributable to noncontrolling interests
Net income attributable to DuPont
Basic earnings per share of common stock:

Basic earnings per share of common stock from continuing operations

Basic earnings per share of common stock from discontinued operations
Basic earnings per share of common stock

Diluted earnings per share of common stock:

Diluted earnings per share of common stock from continuing operations

Diluted earnings per share of common stock from discontinued operations
Diluted earnings per share of common stock

Dividends per share of common stock

2016

2015

2014

$

24,594 $

25,130 $

14,469

15,112

686

4,319

1,641
(708)
370

552

3,265

744

2,521

4

2,525

12

459

4,615

1,898
(697)
342

810

2,591

696

1,895

64

1,959

6

$

$

$

$

$

$

2,513 $

1,953 $

2.86 $

—

2.87 $

2.85 $

—

2.85 $

1.52 $

2.10 $

0.07

2.17 $

2.09 $

0.07

2.16 $

1.72 $

28,406

17,023

645

4,891

1,958
(1,277)
377

476

4,313

1,168

3,145

491

3,636

11

3,625

3.42

0.54

3.95

3.39

0.53

3.92

1.84

See Notes to the Consolidated Financial Statements beginning on page F-9.

F-4

                                                               
E. I. du Pont de Nemours and Company
Consolidated Financial Statements

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 
(Dollars in millions, except per share)

For the year ended December 31,
Net income
Other comprehensive loss, net of tax:
      Cumulative translation adjustment
      Adjustments to pension benefit plans
      Adjustments to other benefit plans
      Net change in unrealized gains (losses) on securities
      Net gains (losses) on cash flow hedging derivative instruments

Total other comprehensive loss

Comprehensive income
      Comprehensive income attributable to noncontrolling interests, net of tax
Comprehensive income attributable to DuPont

$

2016

2015

2014

$

2,525 $

1,959 $

3,636

(510)
323
(379)
20
31
(515)
2,010
12
1,998 $

(1,605)
574
(240)
(19)
(18)
(1,308)
651
6
645 $

(876)
(2,199)
(232)
—
42
(3,265)
371
12
359

See Notes to the Consolidated Financial Statements beginning on page F-9.

F-5

                                                               
E. I. du Pont de Nemours and Company
Consolidated Financial Statements

CONSOLIDATED BALANCE SHEETS
(Dollars in millions, except per share)

December 31,
Assets
Current assets
Cash and cash equivalents
Marketable securities

Accounts and notes receivable, net
Inventories
Prepaid expenses

Total current assets

Property, plant and equipment
Less: Accumulated depreciation
Net property, plant and equipment
Goodwill
Other intangible assets
Investment in affiliates
Deferred income taxes
Other assets
Total
Liabilities and Equity
Current liabilities
Accounts payable
Short-term borrowings and capital lease obligations
Income taxes
Other accrued liabilities

Total current liabilities

Long-term borrowings and capital lease obligations
Other liabilities
Deferred income taxes
Total liabilities

Commitments and contingent liabilities
Stockholders' Equity
Preferred stock, without par value – cumulative; 23,000,000 shares authorized; 
    issued at December 31, 2016 and 2015:

$4.50 Series – 1,673,000 shares (callable at $120)
$3.50 Series – 700,000 shares (callable at $102)

Common stock, $.30 par value; 1,800,000,000 shares authorized; 
    issued at December 31, 2016 – 950,044,000; 2015 – 958,388,000
Additional paid-in capital
Reinvested earnings
Accumulated other comprehensive loss
Common stock held in treasury, at cost 
    (Shares: December 31, 2016 and 2015 – 87,041,000)

Total DuPont stockholders' equity

Noncontrolling interests

Total equity

Total

2016

2015

4,605 $
1,362

4,971
5,673
506

17,117
23,967
14,736
9,231
4,180
3,664
649
3,308
1,815
39,964 $

3,705 $
429
101
4,662
8,897
8,107
12,333
431
29,768

167
70

285
11,190
14,924
(9,911)

(6,727)
9,998
198
10,196
39,964 $

5,300
906

4,643
6,140
398

17,387
24,130
14,346
9,784
4,248
4,144
688
3,799
1,116
41,166

3,398
1,165
173
5,580
10,316
7,642
12,591
417
30,966

167
70

288
11,081
14,510
(9,396)

(6,727)
9,993
207
10,200
41,166

$

$

$

$

See Notes to the Consolidated Financial Statements beginning on page F-9.

F-6

 
 
 
 
 
CONSOLIDATED STATEMENTS OF EQUITY
(Dollars in millions, except per share)

E. I. du Pont de Nemours and Company
Consolidated Financial Statements

Preferred
Stock

Common
Stock

Additional
Paid-in
Capital

Reinvested
Earnings

Accumulated
Other
Compre-
hensive
Loss

Treasury
Stock

Non-
controlling
Interests

Total
Equity

2014

Balance January 1, 2014

$

237 $

304 $

11,072 $

16,633 $

(5,290) $

(6,727) $

57 $

16,286

Sale of a majority interest in a consolidated
subsidiary
Net income

Other comprehensive (loss) income

Common dividends ($1.84 per share)

Preferred dividends

Common stock issued - compensation plans

Common stock repurchased

Common stock retired

3,625

(1,695)

(10)

(3,266)

3

(9)

434

(332)

(1,659)

(2,000)

2,000

(5)

11

1

(6)

(5)

3,636

(3,265)

(1,701)

(10)

437

(2,000)

—

Balance December 31, 2014

$

237 $

298 $

11,174 $

16,894 $

(8,556) $

(6,727) $

58 $

13,378

2015

Consolidation of a joint venture

Net income

Other comprehensive loss

Common dividends ($1.72 per share)

Preferred dividends

(1)

1,953

(1,542)

(10)

(1,308)

151

6

(4)

Common stock issued - compensation plans

2

359

Common stock repurchased

Common stock retired

Spin-off of Chemours

(12)

(451)

(1,890)

(2,353)

2,353

(895)

468

(4)

150

1,959

(1,308)

(1,546)

(10)

361

(2,353)

—

(431)

Balance December 31, 2015

$

237 $

288 $

11,081 $

14,510 $

(9,396) $

(6,727) $

207 $

10,200

2016

Sale of a majority interest in a consolidated
subsidiary

Net income

Other comprehensive loss

Common dividends ($1.52 per share)

Preferred dividends

Common stock issued - compensation plans

Common stock repurchased

Common stock retired

(4)

267

2,513

(1,331)

(10)

(515)

(154)

(758)

(916)

916

(5)

12

(16)

(9)

2,525

(515)

(1,347)

(10)

268

(916)

—

1

(4)

Balance December 31, 2016

$

237 $

285 $

11,190 $

14,924 $

(9,911) $

(6,727) $

198 $

10,196

See Notes to the Consolidated Financial Statements beginning on page F-9.

F-7

                                                               
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Consolidated Financial Statements

CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in millions)

Operating activities

Net income

Adjustments to reconcile net income to cash provided by operating activities:

$

2,525 $

1,959 $

Depreciation

Amortization of intangible assets
Net periodic pension benefit cost

Contributions to pension plans
Gain on sales of businesses and other assets

Asset related charges
Other operating activities – net

(Increase) decrease in operating assets:
Accounts and notes receivable

Inventories and other operating assets
(Decrease) increase in operating liabilities:

Accounts payable and other operating liabilities

Accrued interest and income taxes

Cash provided by operating activities

Investing activities

Purchases of property, plant and equipment

Investments in affiliates

Payments for businesses – net of cash acquired

Proceeds from sales of businesses and other assets - net

Purchases of short-term financial instruments

Proceeds from maturities and sales of short-term financial instruments

Foreign currency exchange contract settlements

Other investing activities – net

Cash used for investing activities

Financing activities

Dividends paid to stockholders

Net increase (decrease) in short-term (less than 90 days) borrowings

Long-term and other borrowings:

Receipts

Payments

Repurchase of common stock

Proceeds from exercise of stock options
Cash transferred to Chemours at spin-off
Other financing activities – net

Cash used for financing activities

Effect of exchange rate changes on cash
Decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental cash flow information:
Cash paid during the year for

Interest, net of amounts capitalized

Income taxes

$

$

939

319
572

(535)
(436)

682
366

(270)

(54)

(704)

(104)

3,300

(1,019)

(19)

—

316

(2,633)

2,181

(385)

45

(1,514)

(1,335)

387

813

(1,440)
(916)

181
—
(18)
(2,328)
(153)
(695)
5,300
4,605 $

1,104

362
591

(308)
(59)

147
106

(448)

164

(1,063)

(239)

2,316

(1,629)

(76)

(152)

156

(1,897)

1,121

615

34

(1,828)

(1,546)

(1)

3,679

(1,537)
(2,353)

274
(250)
(89)
(1,823)
(275)
(1,610)
6,910
5,300 $

3,636

1,254

363
406

(311)
(726)

174
192

(88)

(318)

(1,064)

194

3,712

(2,020)

(42)

—

1,092

(936)

950

430

189

(337)

(1,696)

(11)

104

(1,794)
(2,000)

327
—
(4)
(5,074)
(332)
(2,031)
8,941
6,910

386 $

735

341 $

885

394

1,016

See Notes to the Consolidated Financial Statements beginning on page F-9.

F-8

                                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements
(Dollars in millions, except per share)

1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The company follows generally accepted accounting principles in the United States of America (GAAP). The significant accounting
policies described below, together with the other notes that follow, are an integral part of the Consolidated Financial Statements.

Preparation of Financial Statements
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that 
affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Basis of Consolidation
The Consolidated Financial Statements include the accounts of the company and subsidiaries in which a controlling interest is
maintained.  For those consolidated subsidiaries in which the company's ownership is less than 100 percent, the outside stockholders' 
interests are shown as noncontrolling interests. Investments in affiliates over which the company has significant influence but not 
a controlling interest are accounted for under the equity method.

t

The company is also involved with certain joint ventures accounted for under the equity method of accounting that are variable
interest entities (VIEs).  The company is not the primary beneficiary, as the nature of the company's involvement with the VIEs
does not provide it the power to direct the VIEs significant activities.  Future events may require these VIEs to be consolidated if 
the company becomes the primary beneficiary.  At December 31, 2016 and 2015, the maximum exposure to loss related to the 
unconsolidated VIEs is not considered material to the Consolidated Financial Statements.

Basis of Presentation
Certain reclassifications of prior year's data have been made to conform to current year's presentation, including recasting the 
segment financial information as a result of the change in reportable segments which impacted the Industrial Biosciences segment, 
the DuPont Protection Solutions segment and Other. Refer to Note 21 for further information. As noted below under “Recent 
Accounting Pronouncements”, effective January 1, 2016, the company adopted Accounting Standards Update (ASU) No. 2015-17, 
Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes, which requires that deferred tax liabilities and assets 
be classified as noncurrent in a classified statement of financial position on a retrospective basis. In conjunction with the adoption
of ASU No. 2015-17, the company also retrospectively reclassified deferred charges previously recorded in the current deferred 
income taxes line item to prepaid expenses on the Consolidated Balance Sheets.

On July 1, 2015, the company completed the separation of its Performance Chemicals segment through the spin-off of all of the 
issued and outstanding stock of The Chemours Company (Chemours).  In accordance with GAAP, the financial position and results
of operations of the Performance Chemicals segment are presented as discontinued operations and, as such, have been excluded 
from continuing operations and segment results for all periods presented.  The sum of the individual earnings per share amounts
from continuing operations and discontinued operations may not equal the total company earnings per share amounts due to 
rounding.  The assets and liabilities related to the Performance Chemicals segment are presented as assets of discontinued operations 
and  liabilities  of  discontinued  operations  in  the  Consolidated  Balance  Sheets  for  all  periods  presented.   The  cash  flows  and 
comprehensive  income  related  to  the  Performance  Chemicals  segment  have  not  been  segregated  and  are  included  in  the 
Consolidated Statements of Cash Flows and Comprehensive Income, respectively, for all periods presented.  Amounts related to 
the Performance Chemicals segment are consistently included or excluded from the Notes to the Consolidated Financial Statements
based on the respective financial statement line item.  See Note 3 for additional information.

Revenue Recognition
The company recognizes revenue when the earnings process is complete. The company's revenues are from the sale of a wide 
range of products to a diversified base of customers around the world. Revenue for product sales is recognized upon delivery,
when title and risk of loss have been transferred, collectability is reasonably assured and pricing is fixed or determinable. Amajority 
of product sales are sold FOB (free on board) shipping point or, with respect to non United States of America (U.S.) customers,
an equivalent basis.  Accruals are made for sales returns and other allowances based on the company's experience. The company 
accounts for cash sales incentives as a reduction in sales and noncash sales incentives as a charge to cost of goods sold or selling
expense, depending on the nature of the incentive. Amounts billed to customers for shipping and handling fees are included in net 
sales and costs incurred by the company for the delivery of goods are classified as cost of goods sold in the Consolidated Income 
Statements. Taxes on revenue-producing transactions are excluded from net sales.

A

F-9

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

The  company  periodically  enters  into  prepayment  contracts  with  customers  in  the Agriculture segment  and  receives  advance 
payments for product to be delivered in future periods. These advance payments are recorded as deferred revenue (classified as
other accrued liabilities) or debt, depending on the nature of the program. Revenue associated with advance payments is recognized 
as shipments are made and title, ownership and risk of loss pass to the customer.

Licensing and royalty income is recognized in accordance with agreed upon terms, when performance obligations are satisfied,
the amount is fixed or determinable and collectability is reasonably assured.

Cost of Goods Sold
Cost of goods sold primarily includes the cost of manufacture and delivery, ingredients or raw materials, direct salaries, wages 
and benefits and overhead.

Other Operating Charges
Other operating charges includes product claim charges and recoveries, non-capitalizable costs associated with capital projects
and other operational expenses.  

Research and Development
Research and development costs are expensed as incurred. Research and development expense includes costs (primarily consisting
of  employee  costs,  materials,  contract  services,  research  agreements,  and  other  external  spend)  relating  to  the  discovery  and 
development of new products, enhancement of existing products and regulatory approval of new and existing products.

Selling, General and Administrative Expenses
Selling, general and administrative expenses primarily include selling and marketing expenses, commissions, functional costs,
and business management expenses. 

Cash and Cash Equivalents
Cash equivalents represent investments with maturities of three months or less from time of purchase. They are carried at cost 
plus accrued interest. 

Marketable Securities
Marketable securities represent investments in fixed and floating rate financial instruments with maturities greater than three
months and up to twelve months at time of purchase.  Investments classified as held-to-maturity are recorded at amortized cost.  
The carrying value approximates fair value due to the short-term nature of the investments.  Investments classified as available-
for-sale  are  carried  at  estimated  fair  value  with  unrealized  gains  and  losses  recorded  as  a  component  of  accumulated  other 
comprehensive income (loss).    

Fair Value Measurements
Under the accounting guidance for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes
the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 
measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is
significant to the fair value measurement.

The company uses the following valuation techniques to measure fair value for its assets and liabilities:

Level 1

Level 2

Level 3

–

–

–

Quoted market prices in active markets for identical assets or liabilities;

Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for 
identical or similar items in markets that are not active, inputs other than quoted prices that are observable 
such as interest rate and yield curves, and market-corroborated inputs);

Unobservable  inputs  for  the  asset  or  liability,  which  are  valued  based  on  management's  estimates  of 
assumptions that market participants would use in pricing the asset or liability.

F-10

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Inventories
The company's inventories are valued at the lower of cost or net realizable value.  Elements of cost in inventories include raw
materials, direct labor and manufacturing overhead. Stores and supplies are valued at cost or net realizable value, whichever is 
lower; cost is generally determined by the average cost method.

As of December 31, 2016 and 2015, approximately 55, 30 and 15 percent of the company’s inventories were accounted for under 
the first-in, first-out (FIFO), average cost and last-in, first-out (LIFO) methods, respectively.  Inventories accounted for under the 
FIFO method are primarily comprised of products with shorter shelf lives such as seeds, certain food-ingredients and enzymes.

The company establishes allowances for obsolescence of inventory based upon quality considerations and assumptions about 
future demand and market conditions.    

Property, Plant and Equipment
Property, plant and equipment is carried at cost and is depreciated using the straight-line method. Substantially all equipment and 
buildings are depreciated over useful lives ranging from 15 to 25 years. Capitalizable costs associated with computer software for 
internal use are amortized on a straight-line basis over 5 to 7 years. When assets are surrendered, retired, sold or otherwise disposed 
of,  their  gross  carrying  values  and  related  accumulated  depreciation  are  removed  from  the  Consolidated  Balance  Sheets  and 
included in determining gain or loss on such disposals.

t

Maintenance and repairs are charged to operations; replacements and improvements are capitalized.

Goodwill and Other Intangible Assets
Goodwill  represents  the  future  economic  benefits  arising  from  other  assets  acquired  in  a  business  combination  that  are  not 
individually identified and separately recognized. Goodwill and indefinite-lived intangible assets are tested for impairment at least 
annually; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset mayaa
be impaired.  Impairment exists when carrying value exceeds fair value. The company's fair value methodology is primarily based
on discounted cash flow techniques. 

t

Definite-lived intangible assets, such as purchased and licensed technology, patents and customer lists are amortized over their 
estimated useful lives, generally for periods ranging from 1 to 20 years or amortized based on units of production. The company
continually evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed 
from the Consolidated Balance Sheets.

Impairment of Long-Lived Assets
The company evaluates the carrying value of long-lived assets to be held and used when events or changes in circumstances 
indicate the carrying value may not be recoverable. The carrying value of a long-lived asset group is considered impaired when
the total projected undiscounted cash flows from the assets are separately identifiable and are less than its carrying value. In that 
event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The
company's fair value methodology is an estimate of fair market value which is made based on prices of similar assets or other 
valuation methodologies including present value techniques. Long-lived assets to be disposed of other than by sale are classified 
as held for use until their disposal. Long-lived assets to be disposed of by sale are classified as held for sale and are reported at 
the lower of carrying amount or fair market value less cost to sell. Depreciation is discontinued for long-lived assets classified as 
held for sale.

rr
ff

Royalty Expense
The company’s Agriculture segment currently has certain third party biotechnology trait license agreements, which require up-
front and variable payments subject to the licensor meeting certain conditions.  These payments are reflected as prepaid expenses
and other assets and are amortized to cost of goods sold as seeds containing the respective trait technology are utilized over the 
life of the license.  The company evaluates the carrying value of the prepaid royalties when events or changes in circumstances
indicate the carrying value may not be recoverable. 

Environmental
Accruals for environmental matters are recorded in operating expenses when it is probable that a liability has been incurred and 
the amount of the liability can be reasonably estimated. Accrued liabilities do not include claims against third parties and are not 
discounted.

F-11

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Costs related to environmental remediation and restoration are charged to expense. Other environmental costs are also charged to
expense unless they increase the value of the property or reduce or prevent contamination from future operations, in which case, 
they are capitalized.

Litigation
The company accrues for liabilities related to litigation matters when the information available indicates that it is probable that a 
liability has been incurred and the amount of the liability can be reasonably estimated. Legal costs such as outside counsel fees
and expenses are charged to expense in the period incurred.

Insurance/Self-Insurance
The company self-insures certain risks where permitted by law or regulation, including workers' compensation, vehicle liability
and  employee  related  benefits.  Liabilities  associated  with  these  risks  are  estimated  in  part  by  considering  historical  claims 
experience, demographic factors and other actuarial assumptions. For other risks, the company uses a combination of insurance 
and  self-insurance,  reflecting  comprehensive  reviews  of  relevant  risks.   A  receivable  for  an  insurance  recovery  is  generally
recognized when the loss has occurred and collection is considered probable.

Income Taxes
The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this 
approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities 
are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change 
in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the company's assets 
and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded 
to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Provision has been made for 
income taxes on unremitted earnings of subsidiaries and affiliates, except for subsidiaries in which earnings are deemed to be 
indefinitely reinvested. Investment tax credits or grants are accounted for in the period earned (the flow-through method). Interest 
accrued related to unrecognized tax benefits is included in miscellaneous income and expenses, net, within other income, net. 
Income tax related penalties are included in the provision for income taxes.

a

Foreign Currency Translation
The company's worldwide operations utilize the U.S. dollar (USD) or local currency as the functional currency, where applicable. 
The company identifies its separate and distinct foreign entities and groups the foreign entities into two categories: 1) extension 
of the parent (USD functional currency) and 2) self-contained (local functional currency). If a foreign entity does not align with
either category, factors are evaluated and a judgment is made to determine the functional currency.

For foreign entities where the USD is the functional currency, all foreign currency-denominated asset and liability amounts are
re-measured into USD at end-of-period exchange rates, except for inventories, prepaid expenses, property, plant and equipment,
goodwill and other intangible assets, which are re-measured at historical rates. Foreign currency income and expenses are re-
measured at average exchange rates in effect during the year, except for expenses related to balance sheet amounts re-measured 
at historical exchange rates. Exchange gains and losses arising from re-measurement of foreign currency-denominated monetary
assets and liabilities are included in income in the period in which they occur.

For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are 
translated into USD at end-of-period exchange rates and the resultant translation adjustments are reported, net of their related tax 
effects, as a component of accumulated other comprehensive income (loss) in equity. Assets and liabilities denominated in other
than the local currency are re-measured into the local currency prior to translation into USD and the resultant exchange gains or 
losses are included in income in the period in which they occur. Income and expenses are translated into USD at average exchange 
rates in effect during the period.

The company changes the functional currency of its separate and distinct foreign entities only when significant changes in economic 
facts and circumstances indicate clearly that the functional currency has changed. As a result of the separation of its Performance 
Chemicals segment, coupled with the company’s redesign initiative, the functional currency at certain of the company’s foreign
entities was re-evaluated which, in some cases, resulted in a change in the foreign entities' functional currency during 2015.

F-12

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Venezuelan Foreign Currency 
Venezuela is considered a highly inflationary economy under GAAP and the USD is the functional currency for the company's 
subsidiaries in Venezuela.  The official exchange rate continues to be set through the National Center for Foreign Commerce 
(CENCOEX, previously CADIVI). Based on its evaluation of the restrictions and limitations affecting the availability of specific 
exchange rate mechanisms, management concluded in the second quarter of 2014 that the Alternative Currency Exchange System 
(SICAD 2) auction process would be the most likely mechanism available.   As a result, in the second quarter of 2014, the companyaa
changed from the official exchange rate to the SICAD 2 exchange rate, which resulted in a pre-tax charge of $58. The charge is 
recorded within other income, net in the company's Consolidated Income Statements for the year ended December 31, 2014.

During the first quarter of 2015, the Venezuelan government enacted additional changes to the country's foreign exchange systems 
including the introduction of the Foreign Exchange Marginal System (SIMADI) auction process.  Management has concluded 
that the SIMADI auction process would be the most likely exchange mechanism available.  As a result, effective in the first quarter 
of  2015,  the  company  changed  from  the  SICAD  2  to  the  SIMADI  exchange  rate,  to  re-measure  its  Bolivar  Fuertes  (VEF)
denominated net monetary assets which resulted in a pre-tax charge of $3.  The charge is recorded within other income, net in the 
company's Consolidated Income Statements for the year ended December 31, 2015.  The remaining net monetary assets and non-
monetary assets are immaterial at December 31, 2016 and 2015, respectively.

a

t

Hedging and Trading Activities
Derivative instruments are reported in the Consolidated Balance Sheets at their fair values. For derivative instruments designated 
as fair value hedges, changes in the fair values of the derivative instruments will generally be offset in the income statement by 
changes in the fair value of the hedged items. For derivative instruments designated as cash flow hedges, the effective portion of 
any hedge is reported in accumulated other comprehensive income (loss) until it is cleared to earnings during the same period in
which the hedged item affects earnings. The ineffective portion of all hedges is recognized in current period earnings. Changes
in the fair values of derivative instruments that are not designated as hedges are recorded in current period earnings.

aa
t
n

In the event that a derivative designated as a hedge of a firm commitment or an anticipated transaction is terminated prior to the 
maturation of the hedged transaction, gains or losses realized at termination are deferred and included in the measurement of the 
hedged transaction. If a hedged transaction matures, or is sold, extinguished, or terminated prior to the maturity of a derivative 
designated as a hedge of such transaction, gains or losses associated with the derivative through the date the transaction matured 
are included in the measurement of the hedged transaction and the derivative is reclassified as for trading purposes. Derivatives
designated as hedges of anticipated transactions are reclassified as for trading purposes if the anticipated transaction is no longer 
probable.

u

t

Cash flows from derivative instruments accounted for as either fair value hedges or cash flow hedges are reported in the same
category as the cash flows from the items being hedged. Cash flows from all other derivative instruments are generally reported
as investing activities in the Consolidated Statements of Cash Flows.  See Note 19 for additional discussion regarding the company's
objectives and strategies for derivative instruments.

Recent Accounting Pronouncements
Accounting Pronouncements Implemented in 2016
In November 2015, the Financial Accounting Standards Board (FASB) issued ASU No. 2015-17, Income Taxes (Topic 740),
Balance Sheet Classification of Deferred Taxes. The amendments under the new guidance require that deferred tax liabilities and
assets be classified as noncurrent in a classified statement of financial position. The guidance is effective for financial statements 
issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application 
is permitted for all entities as of the beginning of an interim or annual reporting period. The amendments in this ASU may be
applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The company adopted 
this guidance effective January 1, 2016 on a retrospective basis. As a result of the adoption, $368 and $37 of deferred tax assets 
and liabilities, respectively, were reclassified from current to noncurrent assets and liabilities, respectively, as of December 31, 
2015.

nn

F-13

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820), Disclosures for Investments in Certain 
Entities that Calculate Net Asset Value per Share or its Equivalent. This guidance removes the requirement to categorize within
the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. 
The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair 
value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the 
entity has elected to measure the fair value using that practical expedient. The guidance is effective for fiscal years beginning after 
December 15, 2015, and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively
to all periods presented and early adoption is permissible. The company adopted this guidance effective January 1, 2016. The 
guidance only impacts disclosure and did not impact the company's Consolidated Financial Statements.

ff
t

New Accounting Pronouncements to be Implemented
In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than
Inventory.  The new guidance requires that entities recognize the income tax consequences of an intra-entity transfer of an asset 
other than inventory when the transfer occurs, rather than when the asset is sold to an outside party. The guidance is effective for 
annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods.
Early adoption is permitted as of the beginning of an annual reporting period (as of the first interim period if an entity issues
interim financial statements). The new guidance requires adoption on a modified retrospective basis through a cumulative-effect
adjustment directly to retained earnings as of the beginning of the period of adoption. The company is currently evaluating the
impact this guidance will have on the Consolidated Financial Statements and related disclosures.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts
and Cash Payments. The new guidance makes eight targeted changes to how cash receipts and cash payments are presented and 
classified in the statement of cash flows. The guidance is effective for fiscal years beginning after December 15, 2017, and interim 
periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts 
the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that 
interim period. An entity that elects early adoption must adopt all of the amendments in the same period. The new guidance requires 
adoption on a retrospective basis unless it is impracticable to apply, in which case the company would be required to apply the
amendments prospectively as of the earliest date practicable. The company is currently evaluating the impact this guidance will
have on the Consolidated Financial Statements and related disclosures.

t

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee 
Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects
of accounting for shared-based payment transactions, including income tax consequences, forfeitures and classification on the 
statement of cash flows. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods
within those annual periods. The company will adopt this standard on January 1, 2017.  The primary effects of adoption for the 
company relate to changes in classification within the Consolidated Statements of Cash Flows and recognition of tax effects related 
to share-based payments.  The new guidance requires all tax related cash flows resulting from share-based payments to be reported 
as cash provided by operating activities in the Consolidated Statements of Cash Flows.  This is a change from the current requirement 
to  present  excess  tax  benefits  as  cash  inflows  from  financing  activities  and  tax  deficiencies  as  cash  outflows  from  operating 
activities.  As permitted by the standard, the company has elected to adopt this reclassification on a retrospective basis.  The 
updated guidance also requires all tax effects related to share-based payments to be recognized within the provision for income
taxes in the Consolidated Income Statements.  Previously excess tax benefits and tax deficiencies were recognized in additional
paid-in capital in the Consolidated Balance Sheets.  The standard does not permit retrospective adoption of this update.  As such,
the company will adopt this update on a prospective basis.  The remaining updates required by this standard are not expected to
have a material impact to the company’s Consolidated Financial Statements.  

F-14

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The amendments under the new guidance will require 
lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability, other than leases that meet 
the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified 
as either operating or finance. Classification will be based on criteria that are largely similar to those applied in current lease 
accounting. Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model and 
the new revenue recognition standard. The new leasing standard will be effective for fiscal years beginning after December 15,
2018, and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified 
retrospective  transition,  requiring  application  at  the  beginning  of  the  earliest  comparative  period  presented. The  company  is
currently evaluating the impact of adopting this guidance on its financial position and results of operations.  The company is the 
lessee under various agreements for facilities and equipment that are currently accounted for as operating leases as discussed in
Note 15.  

In May 2014, the FASB and the International Accounting Standards Board (IASB) jointly issued ASU No. 2014-09, Revenue 
from Contracts with Customers (Topic 606), which was further updated in March, April, May, and December 2016. The new
guidance clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International
Financial Reporting Standards (IFRS). The core principle of the guidance is that an entity should recognize revenue to depict the 
transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be 
entitled in exchange for those goods and services. The new standard also will result in additional disclosure requirements to describe
the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. In July 2015, the 
FASB approved a deferral of the ASU effective date from annual and interim periods beginning after December 15, 2016 to annual 
and interim periods beginning after December 15, 2017.  The standard permits the use of either the retrospective or modified 
retrospective (cumulative-effect) transition method of adoption.  The company continues to evaluate the impact of the new standard 
on its Consolidated Financial Statements and disclosures.  Based on the analysis conducted to date, the company does not believe 
the impact upon adoption will be material to its Consolidated Financial Statements.  The company plans to adopt the standard in
the first quarter of 2018 under the modified retrospective transition method.

t

2.  PLANNED MERGER WITH DOW 
On December 11, 2015, DuPont and The Dow Chemical Company (Dow) announced entry into an Agreement and Plan of Merger 
(the Merger Agreement), under which the companies will combine in an all-stock merger of equals subject to satisfaction of 
customary closing conditions, including receipt of regulatory approval. The combined company will be named DowDuPont Inc. 
(DowDuPont). Following the consummation of the merger, DuPont and Dow intend to pursue, subject to the receipt of approval
by  the  board  of  directors  of  DowDuPont,  the  separation  of  the  combined  company’s  agriculture  business,  specialty  products
business  and  material  science  business  through  a  series  of  tax-efficient  transactions  (collectively,  the  Intended  Business 
Separations).

Subject to the terms and conditions of the Merger Agreement, each share of common stock, par value $0.30 per share, of DuPont 
(DuPont Common Stock) issued and outstanding immediately prior to the Effective Time, excluding any shares of DuPont Common 
Stock that are held in treasury, will be converted into the right to receive 1.2820 shares common stock, par value $0.01 per share,
of DowDuPont (DowDuPont Common Stock), for each share of DuPont Common Stock with cash in lieu of any fractional share 
of DowDuPont. Each share of DuPont Preferred Stock-$4.50 Series and DuPont Preferred Stock-$3.50 Series, in each case issued 
and outstanding immediately prior to the Effective Time, shall remain issued and outstanding and be unaffected by the merger.

Subject to the terms and conditions set forth in the Merger Agreement, at the Effective Time, each share of common stock, par 
value $2.50 per share, of Dow (the Dow Common Stock) issued and outstanding immediately prior to the Effective Time, excluding 
any shares of Dow Common Stock that are held in treasury, will be converted into the right to receive one share of  DowDuPont 
Common Stock.  On December 30, 2016, (the Dow Preferred Conversion Date) each share of Cumulative Convertible Perpetual 
Preferred Stock, Series A, par value $1.00 per share, of Dow (the Dow Preferred) issued and outstanding immediately prior thereto,
converted to 24.2010 shares of Dow Common Stock.  As a result, on the Dow Preferred Conversion Date, Dow issued 96,804,000
shares of Common Stock. 

Based on the aforementioned 1.2820 exchange ratio set forth in the Merger Agreement and the conversion of the Dow Preferred 
to Dow Common Stock, it is expected that DuPont common stockholders and Dow common stockholders will own approximately
48 percent and 52 percent, respectively, of the outstanding shares of DowDuPont Common Stock immediately following the
Effective Time.

F-15

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Conditions to the Mergerg
The completion of the merger is subject to the satisfaction or waiver of certain conditions, including (i) the receipt of certain
domestic and foreign approvals under competition laws; (ii) DuPont and Dow reasonably determining that the merger does not 
constitute an acquisition of a 50 percent or greater interest in DuPont and Dow, respectively, under the principles of Section 355
(e) of the Internal Revenue Code; (iii) the absence of governmental restraints or prohibitions preventing the consummation of thet
merger; and (iv) the approval of the shares of DowDuPont Common Stock to be issued in the merger for listing on the NYSE. The 
obligation of each of DuPont and Dow to consummate the merger is also conditioned on, among other things, the receipt of a tax 
opinion from the tax counsel as to the tax-free nature of the merger, and the truth and correctness of the representations and 
warranties made by the other party as of the closing date (subject to certain “materiality” and “material adverse effect” qualifiers).

Additional information about the Merger Agreement and the Intended Business Separations is set forth in the company’s Current 
Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the SEC) on December 11, 2015; the company’s
2015 Annual Report filed with the SEC on February 4, 2016 and the registration statement on Form S-4 (File No. 333-209869) 
(as amended, the Registration Statement) filed by DowDuPont and declared effective by the SEC on June 9, 2016. The Registration
Statement constitutes a prospectus of DowDuPont and includes a joint proxy statement of Dow and DuPont. The joint proxy
statement relates to the separate special meetings of the companies’ respective common stock shareholders of record as of the 
close of business on June 2, 2016, to adopt the Merger Agreement and related matters. DuPont's special meeting of stockholders 
was held on July 20, 2016, which resulted in a vote for adoption of the Merger Agreement and approval of related matters.

Consummation of the merger is contingent on satisfaction of customary closing conditions, including the receipt of regulatory
approval from the U.S., European Union, China, Brazil and Canada. Subject to satisfaction of these customary closing conditions,
including the receipt of regulatory approvals, closing would be expected to occur in first half of 2017.

g

g

Certain Other Terms of the Merger Agreement
The Merger Agreement contains mutual customary representations and warranties made by each of DuPont and Dow, and also
contains mutual customary pre-closing covenants, including covenants, among others, (i) to operate its businesses in the ordinarya
course consistent with past practice and to refrain from taking certain actions without the other party’s consent, (ii) not to solicit, 
initiate, knowingly encourage or knowingly take any other action designed to facilitate, and, subject to certain exceptions, not to 
participate in any discussions or negotiations, or cooperate in any way with respect to, any inquiries or the making of, any proposal
of an alternative transaction, (iii) subject to certain exceptions, not to withdraw, qualify or modify the support of its Board of 
Directors for the Merger Agreement and the merger, as applicable, and (iv) to use their respective reasonable best efforts to obtain 
governmental, regulatory and third party approvals, including by agreeing to any required divestiture of assets or business.

d

The Merger Agreement contains certain termination rights for each of DuPont and Dow, including in the event that (i) the merger
is not consummated on or before March 15, 2017, subject to each party having the right to unilaterally extend the termination date
of the Merger Agreement until June 15, 2017 (the Outside Date) in the event that the regulatory closing conditions have not been 
satisfied or (ii)  if any restraint having the effect of preventing the consummation of the merger shall have become final and non-
appealable or if any governmental entity that must grant a requisite regulatory approval has denied approval of the merger. 

The Merger Agreement further provides that, upon termination of the Merger Agreement under specified circumstances, including 
(i) a change in the recommendation of the Board of Directors of DuPont and Dow or (ii) a termination of the Merger Agreement 
by DuPont and Dow, because of a material breach by the other party or because the merger is not consummated by the Outside 
Date, in each case set forth in this clause (ii) at a time when there was an offer or proposal for an alternative transaction with respect 
to  such  party  and  such  party  enters  into  or  consummates  an  alternative  transaction  within  12  months  following  such  date  of 
termination, DuPont and Dow, as the case may be, will pay to the other party a termination fee equal to $1,900 in cash.

During the years ended December 31, 2016 and 2015, the company incurred $386 and $10, respectively, of costs in connection
with the planned merger with Dow and the Intended Business Separations, including costs relating to integration and separation
planning.   These  costs  were  recorded  in  selling,  general  and  administrative  expenses  in  the  company's  Consolidated  Income 
Statements and primarily include financial advisory, legal, accounting, consulting and other advisory fees and expenses.

F-16

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

3.  DIVESTITURES AND OTHER TRANSACTIONS
DuPont (Shenzhen) Manufacturing Limited
In  March  2016,  the  company  recognized  the  sale  of  its 100  percent ownership  interest  in  DuPont  (Shenzhen)  Manufacturing 
Limited to the Feixiang Group. The sale of the entity, which held certain buildings and other assets, resulted in a pre-tax gain
of $369 ($214 net of tax). The gain was recorded in other income, net in the company's Consolidated Income Statements for the 
year ended December 31, 2016 and reflected as a Corporate item.

Performance Chemicals
On July 1, 2015 (the Distribution Date), DuPont completed the separation of its Performance Chemicals segment through the spin-
off of all of the issued and outstanding stock of Chemours (the Separation).  To effect the spin-off, DuPont distributed to its
stockholders one share of Chemours common stock, par value $0.01 per share, for every five shares of DuPont common stock, 
par value $0.30 per share, (the Distribution) outstanding as of 5:00 p.m. June 23, 2015, the record date for the Distribution.  In
lieu of fractional shares of Chemours, stockholders of DuPont received cash, which generally was taxable.  In connection with 
the Separation, the company and Chemours entered into a Separation Agreement, discussed below, and a Tax Matters Agreement 
and certain ancillary agreements, including an employee matters agreement, agreements related to transition and site services, and 
intellectual property cross licensing arrangements.  In addition, the companies have entered into certain supply agreements. In then
first quarter 2016, the company agreed in principle to prepay $190 for certain goods and services expected to be delivered by
Chemours.  As of December 31, 2016, the balance of the prepayment was $60 recorded within prepaid expenses on the Consolidated 
Balance Sheet, which is expected to be fully utilized through delivery of goods and services during 2017.

Separation Agreement
The company and Chemours entered into a Separation Agreement that sets forth, among other things, the agreements between the
company  and  Chemours  regarding  the  principal  transactions  necessary  to  effect  the  Separation  and  also  sets  forth  ancillary 
agreements that govern certain aspects of the company’s relationship with Chemours after the separation. Among other matters, 
the  Separation Agreement  and  the  ancillary  agreements  provide  for  the  allocation  between  DuPont  and  Chemours  of  assets, 
employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) 
attributable to periods prior to, at and after the completion of the Separation.  

Pursuant  to  the  Separation  Agreement,  Chemours  indemnifies  DuPont  against  certain  litigation,  environmental,  workers' 
compensation and other liabilities that arose prior to the distribution. The term of this indemnification is indefinite and includes 
defense costs and expenses, as well as monetary and non-monetary settlements and judgments.  In connection with the recognition
of  liabilities  related  to  these  matters,  the  company  records  an  indemnification  asset  when  recovery  is  deemed  probable.   At 
December 31, 2016, the indemnified assets are $81 within accounts and notes receivable, net and $444 within other assets along
with the corresponding liabilities of $81 within other accrued liabilities and $444 within other liabilities on the Consolidated 
Balance Sheet.

The results of operations of the Performance Chemicals segment are presented as discontinued operations as summarized below:

For the year ended December 31,
Net sales

Cost of goods sold
Other operating charges
Selling, general and administrative expenses
Research and development expense

$

Other income, net
Interest expense
Employee separation / asset related charges, net
(Loss) income from discontinued operations before income taxes

(Benefit from) provision for income taxes

(Loss) income from discontinued operations after income taxes

$

2016

2015

2014

— $
—
36
—
—
(3)
—
—
(33)
(28)
(5) $

2,810 $
2,215
386
(87)
40
(27)
32
59
192

106

86 $

6,317
4,680
422
453
109
(46)
—
21
678

202

476

F-17

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

During the years ended December 31, 2016, 2015 and 2014, the company incurred $35, $306, and $175 of costs, respectively, in 
connection with the transaction primarily related to professional fees associated with preparation of regulatory filings and separation
activities within finance, tax, legal, and information system functions.  Income from discontinued operations during the years 
ended December 31, 2016, 2015 and 2014, includes $35, $260 and $142 of these costs, respectively.  Income from continuing 
operations during the years ended December 31, 2015 and 2014, includes $26 and $33 of these costs, respectively, recorded in 
other operating charges in the company's Consolidated Income Statements.  Income from continuing operations during the year 
ended December 31, 2015 also included $20 of transaction costs incurred for a premium associated with the early retirement of 
DuPont debt.  The company exchanged notes received from Chemours in May 2015 (as part of a dividend payment) for DuPont 
debt that it then retired.  These costs were reported in interest expense in the company's Consolidated Income Statements.

During the year ended December 31, 2015, in connection with the separation, the company recorded an other post employment 
benefit plan curtailment gain of $274 and a pension curtailment gain of $7.  See Note 17 for further discussion.

Income from discontinued operations during the year ended December 31, 2015, included a restructuring charge of $59, consisting
of severance and related benefit costs associated with the Performance Chemicals segment to achieve fixed cost and operational 
productivity improvements for Chemours post-spin.

In connection with the spin-off, the company received a dividend from Chemours in May 2015 of $3,923 comprised of a cash 
distribution of $3,416 and a distribution in-kind of $507 of 7 percent senior unsecured notes due 2025 (Chemours Notes Received). 
Chemours  financed  the  dividend  payment  through  issuance  of  approximately  $4,000  of  debt,  including  the  Chemours  Notes 
Received (Chemours' Debt).  Net assets of $431 were transferred to Chemours on July 1, 2015, including the $4,000 of Chemours' 
Debt. 

The following table presents the depreciation, amortization and purchases of property, plant and equipment of the discontinued 
operations related to Performance Chemicals:

For the year ended December 31,
Depreciation

Amortization of intangible assets

Purchases of property, plant and equipment

$

2015

2014

126 $

2

235

248

3

525

Glass Laminating Solutions/Vinyls
In June 2014, the company sold Glass Laminating Solutions/Vinyls (GLS/Vinyls), a part of the Performance Materials segment, 
to Kuraray Co. Ltd.  The sale resulted in a pre-tax gain of $391 ($273 net of tax). The gain was recorded in other income, net in
the company's Consolidated Income Statements for the year ended December 31, 2014.

Performance Coatings
In February 2013, the company sold its Performance Coatings business to Flash Bermuda Co. Ltd., a Bermuda exempted limited 
liability company formed by affiliates of The Carlyle Group (collectively referred to as "Carlyle"). 

The results of discontinued operations related to Performance Coatings are summarized below:

For the year ended December 31,
Net sales
Income (loss) from discontinued operations before income taxes1,2
Benefit from income taxes3

Income (loss) from discontinued operations after income taxes

2016

2015

2014

$
$

$

— $
6 $
(3)
9 $

— $
(23) $
(1)
(22) $

—
—
(15)
15

1. 
2. 

3. 

The year ended December 31, 2016 includes a pre-tax benefit of $6 primarily related to a postretirement settlement gain.
The year ended December 31, 2015 includes a pre-tax net charge of $(23) related to a postretirement settlement charge and other employee related settlement 
adjustments.
The year ended December 31, 2014 includes a tax benefit of $(15) related to a change in estimate of income taxes resulting from the filing of various tax 
returns impacted by the sale of Performance Coatings. 

F-18

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

4.  EMPLOYEE SEPARATION/ASSET RELATED CHARGES, NET
La Porte Plant, La Porte, Texas
In March 2016, DuPont announced its decision to not re-start the Agriculture segment’s insecticide manufacturing facility at the 
La Porte site located in La Porte, Texas.  The facility manufactures Lannate® and Vydate® insecticides and has been shut down
since November 2014.  As a result of this decision, during the year ended December 31, 2016, a pre-tax charge of $68 was recorded 
in employee separation / asset related charges, net which included $41 of asset related charges, $11 of contract termination costs, 
and $16 of employee severance and related benefit costs.         

2016 Global Cost Savings and Restructuring Program
In December 2015, DuPont committed to take structural actions across all businesses and staff functions globally to operate more 
efficiently by further consolidating businesses and aligning staff functions more closely with them as part of a 2016 global cost 
savings and restructuring plan.  As a result, during the year ended December 31, 2015, a pre-tax charge of $798 was recorded,
consisting of $793 of employee separation / asset related charges, net and $5 in other income, net in the company's Consolidated 
Income Statements.  The charges consisted of $656 in severance and related benefit costs, $109 in asset related charges, and $33
in contract termination charges.  

During the year ended December 31, 2016, in connection with the restructuring actions, the company recorded a net pre-tax benefit ff
to earnings of $(85), consisting of $(88) in employee separation / asset related charges, net, and a $3 charge to other income, net 
in the company's Consolidated Income Statements.  The net benefit was comprised of a reduction of $(154) in severance and related 
benefit costs, offset by $53 of asset related charges, and $16 of contract termination costs.  This was primarily due to a reduction 
in severance and related benefit costs partially offset by the identification of additional projects in certain segments.  The reduction
in severance and related benefit costs was driven by elimination of positions at a lower cost than expected as a result of redeployments 
and attrition as well as lower than estimated individual severance costs. 

The restructuring actions associated with this charge impacted approximately 10 percent of DuPont’s workforce and are substantially 
complete. 

The 2016 restructuring program (benefits) charges related to the segments, as well as corporate expenses, were as follows:

For the year ended December 31,

Agriculture

Electronics & Communications

Industrial Biosciences
Nutrition & Health

Performance Materials

Protection Solutions

Other
Corporate Expenses

$

$

2016

2015

23 $
(2)
(5)
(7)
(4)
(13)
11
(88)
(85) $

161

93

60
47

61

44

2
330
798

At December 31, 2016 and 2015, total liabilities related to the restructuring program were $122 and $680, respectively.  

F-19

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Account balances and activity for the restructuring program are summarized below:

Severance
and Related
Benefit
Costs

Asset 
Related 
Charges                                                                

Other Non-
Personnel
              1

Balance at December 31, 2015

  Payments

  Net translation adjustment

Other adjustments

Asset write-offs

Balance at December 31, 2016

$

$

648 $
(393)
(1)
(154)
—
100 $

— $

—

—

53
(53)
— $

32 $ 680
(26)
—

(419)

(1)

16

(85)

— (53)
22 $ 122

1.  

Other non-personnel charges consist of contractual obligation costs.

2014 Restructuring Program
In June 2014, DuPont announced its global, multi-year initiative to redesign its global organization and operating model to reduce 
costs and improve productivity and agility across all businesses and functions. DuPont commenced a restructuring plan to realign
and rebalance staff function support, enhance operational efficiency, and to reduce residual costs associated with the separation of 
its Performance Chemicals segment.  At December 31, 2016 and 2015, total liabilities related to the 2014 restructuring program 
were $9 and $78, respectively.  During the year ended December 31, 2016 a benefit of $(21) was recorded in employee separation / 
asset related charges, net in the company's Consolidated Income Statements to reduce the accrual for severance costs. 

dd

During the year ended December 31, 2015, a net benefit of $(21) was recorded to adjust the estimated costs associated with the 
2014 restructuring program in employee separation / asset related charges, net in the company's Consolidated Income Statements.  
This was primarily due to lower than estimated individual severance costs and workforce reductions achieved through non-severance 
programs, offset by the identification of additional projects in certain segments. 

During the year ended December 31, 2014 a pre-tax charge of $541 was recorded, consisting of $476 in employee separation / asset 
related charges, net and $65 in other income, net in the company's Consolidated Income Statements.  The charges consisted of $301
of severance and related benefit costs, $17 of other non-personnel charges, and $223 of asset related charges, including $65 of
charges associated with the restructuring actions of a joint venture within the Performance Materials segment. 

The 2014 restructuring program (benefits) charges related to the segments, as well as corporate expenses, were as follows:

For the year ended December 31,

Agriculture
Electronics & Communications

Industrial Biosciences
Nutrition & Health
Performance Materials
Protection Solutions
Other

Corporate Expenses

2016

2015

2014

$

$

(1) $
(2)
(1)
(2)
(1)
(1)
—
(13)
(21) $

3 $

(15)
1
3
1
(4)
1
(11)
(21) $

134
84

20
15
99
45
10

134
541

F-20

 
 
 
              
         
         
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Asset Impairments
In the fourth quarter 2015, the company elected to defer further testing and deployment of a multi-year, phased implementation of 
an enterprise resource planning (ERP) system; which had not been placed in service as of year-end 2016.  At December 31, 2016,
the company had capitalized costs associated with the ERP system of $435.  In connection with IT strategy reviews conducted 
during the fourth quarter of 2016, the company reviewed considerations around the timing of restarting testing and deployment of 
the ERP system.  As a result, the company intends to complete and place in service the ERP system, however, given the uncertainties 
related to implementation timing as well as potential developments and changes to technologies in the market place at the time of 
restart, use of this ERP system can no longer be considered probable.  As a result, due to the specificity of the design related to the
ERP system, the company determined that the uncompleted ERP system has a fair value of zero and recorded a pre-tax charge of 
$435 in employee separation / asset related charges, net in the company's Consolidated Income Statements during the year ended 
December 31, 2016.

The company recognized a $158 pre-tax impairment charge in employee separation / asset related charges, net in the company's
Consolidated Income Statements during the year ended December 31, 2016 related to indefinite-lived intangible trade names within
the Industrial Biosciences segment. In connection with business strategy reviews and brand realignment conducted during the third 
quarter 2016, the company decided to phase out the use of certain acquired trade names within the segment resulting in a change
from an indefinite life to a finite useful life for these assets. As a result of these changes, the carrying value of the trade name assets
exceeded the fair value.

The basis of the fair value for the charges was calculated utilizing an income approach (relief from royalty method) using Level 3
inputs within the fair value hierarchy, as described in Note 1. The key assumptions used in the calculation included projected 
revenue, royalty rates and discount rates. These key assumptions involve management judgment and estimates relating to future 
operating performance and economic conditions that may differ from actual cash flows. After the recognition of the impairment 
charge, the remaining net book value of the trade names was $28, which represented fair value. 

During the first quarter 2015, a $38 pre-tax impairment charge was recorded in employee separation / asset related charges, net
within the Other segment in the company's Consolidated Income Statements.  The majority relates to a cost basis investment in
which the assessment resulted from the venture's revised operating plan reflecting underperformance of its European wheat based
ethanol facility and deteriorating European ethanol market conditions.  One of the primary investors communicated that they would 
not fund the revised operating plan of the investee.  As a result, the carrying value of DuPont's 6 percent cost basis investment in
this venture exceeds its fair value by $37, such that an impairment charge was recorded.

F-21

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

5.  OTHER INCOME, NET

Royalty income
Interest income

Equity in earnings (loss) of affiliates, net
Net gains on sales of businesses and other assets1
Net exchange (losses) gains
Miscellaneous income and expenses, net2

Other income, net

2016

2015

2014

$

$

170 $
107

99

435
(106)
3
708 $

138 $
129

49

92

30

259
697 $

156
129
(36)
710

196

122
1,277

1. 

Includes a pre-tax gain of $369 ($214 net of tax) for the year ended December 31, 2016 related to the sale of DuPont (Shenzhen) Manufacturing Limited. 
See Note 3 for additional information.  

2.  Miscellaneous income and expenses, net, includes interest items, gains related to litigation settlements, gains/losses on available-for-sale securities and other 

items.

The following table summarizes the impacts of the company's foreign currency hedging program on the company's results from
operations for the years ended December 31, 2016, 2015 and 2014.  The company routinely uses foreign currency exchange
contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The
objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-
tax basis, the effects of exchange rate changes on net monetary asset positions.  The hedging program gains are largely taxable in 
the U.S., whereas the offsetting exchange losses on the re-measurement of the net monetary asset positions are often not tax 
deductible in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income, net and the related 
tax impact is recorded in provision for income taxes on continuing operations on the Consolidated Income Statements.

)
Subsidiary/Affiliate Monetary Position Gain (Loss)

y

y

(

$

$

$

$

$

$

198 $
(126)

72 $

(304) $
110
(194) $

(106) $
(16)
(122) $

(404) $
(61)
(465) $

434 $
(157)
277 $

30 $

(218)
(188) $

(411)
(207)
(618)

607
(212)
395

196
(419)
(223)

Pretax exchange gain (loss)

Local tax expenses
Net after-tax impact from subsidiary exchange gain (loss)

)
Hedging Program Gain (Loss)

g g

g

(

Pretax exchange (loss) gain

Tax benefits (expenses)
Net after-tax impact from hedging program exchange (loss) gain

)
Total Exchange Gain (Loss)
g

(

Pretax exchange (loss) gain
Tax expenses
Net after-tax exchange loss

F-22

 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

6.  PROVISION FOR INCOME TAXES

Current tax expense on continuing operations:

U.S. federal

U.S. state and local

International

Total current tax expense on continuing operations

Deferred tax expense on continuing operations:

U.S. federal

U.S. state and local

International

Total deferred tax expense on continuing operations

2016

2015

2014

$

40 $

218 $

11

592

643

27
(29)
103

101

7

466

691

139

4
(138)
5

656

38

449

1,143

91
(42)
(24)
25

Provision for income taxes on continuing operations

$

744 $

696 $

1,168

The significant components of deferred tax assets and liabilities at December 31, 2016 and 2015, are as follows:

2016

2015

Asset

Liability

Asset

Liability

Depreciation

Accrued employee benefits

Other accrued expenses

Inventories

Unrealized exchange gains/losses
Tax loss/tax credit carryforwards/backs

Investment in subsidiaries and affiliates

Amortization of intangibles

Other

Valuation allowance

Net deferred tax asset

$

— $

742 $

— $

4,529

617

163

—
1,808

126

210

257
(1,308)
6,402 $

2,877

410

222

144

346
—

230

1,345

86

—
3,525 $

  $

4,812

624

89

—
2,124

133

187

215
(1,529)
6,655 $

3,382

$

$

An analysis of the company's effective income tax rate (EITR) on continuing operations is as follows:

Statutory U.S. federal income tax rate
Exchange gains/losses1
Domestic operations
Lower effective tax rates on international operations-net
Tax settlements
Sale of a business

U.S. research & development credit

2016

2015

2014

35.0%
1.6
(3.7)
(9.3)
(0.1)
(0.1)
(0.6)
22.8%

35.0%
8.0
(2.8)
(11.1)
(0.7)
(0.2)
(1.3)
26.9%

953

374

61

99

224
—

154

1,331

77

—
3,273

35.0%
8.1
(2.8)
(11.4)
(0.6)
(0.4)
(0.8)
27.1%

1. 

Principally reflects the impact of foreign exchange losses on net monetary assets for which no corresponding tax benefit is realized. Further information
about the company's foreign currency hedging program is included in Note 5 and Note 19 under the heading Foreign Currency Risk.

F-23

 
 
 
 
         
 
         
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Consolidated income from continuing operations before income taxes for U.S. and international operations was as follows:

U.S. (including exports)

International

Income from continuing operations before income taxes

2016

2015

2014

$

$

1,457 $

1,808

3,265 $

1,397 $

1,194

2,591 $

2,537

1,776

4,313

The increase in international pre-tax earnings from continuing operations from 2015 to 2016 is primarily driven by the gain on
the sale of DuPont (Shenzhen) Manufacturing Limited in 2016 in addition to the absence of 2015 employee separation / asset 
related charges, net.

The decrease in pre-tax earnings from continuing operations from 2014 to 2015 is primarily driven by lower worldwide sales 
volume, the absence of 2014 gains on sales of businesses primarily in the U.S., higher employee separation / asset related charges,
net, as well as the results of the company’s hedging program.

r

In 2016 and 2015, the U.S. recorded a net exchange (loss) gain associated with the hedging program of $(304) and $434, respectively.  
While the taxation of the amounts reflected on the chart above does not correspond precisely to the jurisdiction of taxation (due dd
to taxation in multiple countries, exchange gains/losses, etc.), it represents a reasonable approximation of the income before income 
taxes split between U.S. and international jurisdictions. See Note 19 for additional information regarding the company's hedging
program.

Under the tax laws of various jurisdictions in which the company operates, deductions or credits that cannot be fully utilized for 
tax purposes during the current year may be carried forward or back, subject to statutory limitations, to reduce taxable income or 
taxes payable in future or prior years. At December 31, 2016, the tax effect of such carryforwards/backs, net of valuation allowance
approximated $516. Of this amount, $285 has no expiration date, $3 expires after 2016 but before the end of 2021 and $228 expires
after 2021.

At December 31, 2016, unremitted earnings of subsidiaries outside the U.S. totaling $17,380 were deemed to be indefinitely 
reinvested. No deferred tax liability has been recognized with regard to the remittance of such earnings. It is not practicable to 
estimate the income tax liability that might be incurred if such earnings were remitted to the U.S.

Each year the company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which 
it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the 
tax authorities may be settled or appealed by the company. As a result, there is an uncertainty in income taxes recognized in the 
company's financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes.  
It is reasonably possible that net reductions to the company’s global unrecognized tax benefits could be in the range of $70 to $90
within the next 12 months with the majority due to the settlement of uncertain tax positions with various tax authorities.  

t

F-24

 
84

92

(15)

(3)
(23)
986

818

5

117

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

The  company  and/or  its  subsidiaries  file  income  tax  returns  in  the  U.S.  federal  jurisdiction,  and  various  states  and  non-U.S. 
jurisdictions. With few exceptions, the company is no longer subject to U.S. federal, state and local, or non-U.S. income tax 
examinations by tax authorities for years before 2004. A reconciliation of the beginning and ending amounts of unrecognized tax
benefits is as follows:

Total unrecognized tax benefits as of January 1

Gross amounts of decreases in unrecognized tax benefits as a result of tax positions
    taken during the prior period

Gross amounts of increases in unrecognized tax benefits as a result of tax positions 
    taken during the prior period

Gross amounts of increases in unrecognized tax benefits as a result of tax positions 
    taken during the current period

2016

2015

2014

$

846 $

986 $

901

(41)

(98)

(50)

32

55

13

69

Amount of decreases in the unrecognized tax benefits relating to settlements with taxing 
    authorities

(314)

(58)

Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of 
    limitations
Exchange loss (gain)

Total unrecognized tax benefits as of December 31

Total unrecognized tax benefits that, if recognized, would impact the effective tax rate

Total amount of interest and penalties recognized in the Consolidated Income Statements

Total amount of interest and penalties recognized in the Consolidated Balance Sheets

(30)
2

550 $

429 $

20 $

98 $

(30)
(36)
846 $

651 $
(8) $
105 $

$

$

$

$

F-25

 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

7.  EARNINGS PER SHARE OF COMMON STOCK
Set forth below is a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the 
periods indicated:

Numerator:

Income from continuing operations after income taxes attributable to DuPont $

Preferred dividends

Income from continuing operations after income taxes available to DuPont
common stockholders

Income from discontinued operations after income taxes

Net income available to common stockholders

Denominator:

$

$

$

2016

2015

2014

2,509 $
(10)

1,889 $
(10)

3,135
(10)

2,499 $

1,879 $

3,125

4 $

64 $

490

2,503 $

1,943 $

3,615

Weighted-average number of common shares outstanding – Basic

872,560,000

893,992,000

914,752,000

Dilutive effect of the company's equity compensation plans
Weighted-average number of common shares outstanding – Diluted

4,476,000
877,036,000

5,535,000
899,527,000

7,121,000
921,873,000

The weighted-average number of common shares outstanding in 2016 and 2015 decreased as a result of the company's repurchase 
and retirement of its common stock, partially offset by the issuance of new shares from the company's equity compensation plans
(see Notes 16 and 18, respectively). 

The following average number of stock options are antidilutive and therefore, are not included in the diluted earnings per share 
calculation:

Average number of stock options

2016
4,794,000

2015
4,715,000

2014

3,000

The change in the average number of stock options that were antidilutive in 2016 and 2015 was due to changes in the company's 
average stock price.

8.  ACCOUNTS AND NOTES RECEIVABLE, NET

December 31,
Accounts receivable – trade1
Notes receivable – trade1,2
Other3

2016

2015

$

$

3,610 $
206
1,155
4,971 $

3,435
301
907
4,643

1.

2.

3.

Accounts and notes receivable – trade are net of allowances of $287 at 2016 and $225 at 2015. Allowances are equal to the estimated uncollectible amounts. 
That estimate is based on historical collection experience, current economic and market conditions, and review of the current status of customers' accounts.
Notes receivable – trade primarily consists of receivables within the Agriculture segment for deferred payment loan programs for the sale of seed products
to customers. These loans have terms of one year or less and are primarily concentrated in North America. The company maintains a rigid pre-approval 
process for extending credit to customers in order to manage overall risk and exposure associated with credit losses. As of December 31, 2016 and 2015, 
there were no significant past due notes receivable, nor were there any significant impairments related to current loan agreements.
Other includes receivables in relation to fair value of derivative instruments, indemnification assets, value added tax, general sales tax and other taxes.

Accounts and notes receivable are carried at amounts that approximate fair value.

F-26

 
 
 
 
          
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

9.  INVENTORIES

Finished products
Semi-finished products

Raw materials, stores and supplies

Adjustment of inventories to a LIFO basis

10.  PROPERTY, PLANT AND EQUIPMENT

December 31,
Buildings

Equipment

Land
Construction1

2016

2015

3,113 $
2,009

719

5,841
(168)
5,673 $

3,779
1,780

783

6,342
(202)
6,140

2016

2015

4,495 $

17,534

514

1,424

23,967 $

4,468

17,410

506

1,746

24,130

$

$

$

$

1. 

The decrease in construction is the result of an impairment charge of $435 related to the company's uncompleted ERP system.  See Note 4 for additional 
information.

11.  GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
The following table summarizes changes in the carrying amount of goodwill for the years ended December 31, 2016 and 2015, 
by reportable segment:

Balance as of
December 31,
2016

Goodwill
Adjustments
and
Acquisitions

Balance as of
December 31,
2015

Goodwill
Adjustments
and
Acquisitions

Balance as of
December 31,
2014

Agriculture

$

343 $

7 $

336 $

18 $

Electronics & Communications

Industrial Biosciences
Nutrition & Health

Performance Materials

Protection Solutions

Other
Total

149

1,175
2,053

381

34

45
4,180 $

$

—
(34)
(39)
(2)
—

—
(68) $

149

1,209
2,092

383

34

45
4,248 $

—
(9)
(101)
8

—

—
(84) $

318

149

1,218
2,193

375

34

45
4,332

Changes in goodwill in 2016
performed impairment tests for goodwill and determined that no goodwill impairments existed.

 and 2015 primarily relate to currency translation adjustments

 p

d

.  In 2016 and 2015, the company

F-27

        
         
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Other Intangible Assets
The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major 
class:

December 31, 2016

December 31, 2015

Gross

Accumulated
Amortization

Net

Gross

Accumulated
Amortization

Net

Intangible assets subject to amortization 
    (Definite-lived)

Customer lists

Patents

Purchased and licensed technology
Trademarks/tradenames1
Other2

Intangible assets not subject to amortization 
    (Indefinite-lived)

In-process research and development
Microbial cell factories3
Pioneer germplasm4
Trademarks/tradenames1

$

1,574 $

446

964

53

171

3,208

73
306

1,053

545

1,977

Total

$

5,185 $

(586) $
(259)
(579)
(15)
(82)
(1,521)

988 $

1,621 $

187

385

38

89

454

1,173

26

180

1,687

3,454

—
—

—

—

—
(1,521) $

73
306

1,053

545

1,977

72
306

1,048

747

2,173

3,664 $

5,627 $

(529) $
(220)
(649)
(13)
(72)
(1,483)

—
—

—

—

—
(1,483) $

1,092

234

524

13

108

1,971

72
306

1,048

747

2,173

4,144

1.

The decrease in indefinite-lived intangible trademarks / trade names is the result of a $158 impairment charge recorded during the year ended December 31,
2016 associated with certain acquired trade names. The remaining net book value of the trade names are reflected in definite-lived trademarks / trade names 
at December 31, 2016. See Note 4 for additional information.
Primarily consists of sales and grower networks, marketing and manufacturing alliances and noncompetition agreements.

2.
3. Microbial cell factories, derived from natural microbes, are used to sustainably produce enzymes, peptides and chemicals using natural metabolic processes.
The company recognized the microbial cell factories as an intangible asset upon the acquisition of Danisco. This intangible asset is expected to contribute 
to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life. 
Pioneer germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. The 
company recognized germplasm as an intangible asset upon the acquisition of Pioneer. This intangible asset is expected to contribute to cash flows beyond 
the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.

4.

The aggregate pre-tax amortization expense from continuing operations for definite-lived intangible assets was $319, $360 and 
$360 for 2016, 2015 and 2014, respectively. The estimated aggregate pre-tax amortization expense from continuing operations 
for 2017, 2018, 2019, 2020 and 2021 is $208, $211, $213, $187 and $138, respectively.

F-28

 
 
 
 
 
 
 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

12.  OTHER ACCRUED LIABILITIES

December 31,
Deferred revenue
Compensation and other employee-related costs

Employee benefits (Note 17)

Discounts and rebates

Derivative instruments (Note 19)

Accrual for restructuring programs (Note 4)
Miscellaneous

2016

2015

$

2,223 $
813

353

299

173

131
670

2,519
699

364

284

91

758
865

$

4,662 $

5,580

Deferred revenue principally includes advance customer payments within the Agriculture segment. Miscellaneous other accrued 
liabilities  principally  includes  accruals  for  plant  and  operating  expenses,  interest  costs,  environmental  remediation  costs, 
commissions costs, and royalties.

13.  SHORT-TERM AND LONG-TERM BORROWINGS
The following table summarizes the company's short-term borrowings and capital lease obligations:

December 31,
Commercial paper
Other loans - various currencies
Long-term debt payable within one year
Capital lease obligations

2016

2015

386 $
39
4
—
429 $

—
49
1,115
1
1,165

$

$

The estimated fair value of the company's short-term borrowings, including interest rate financial instruments, was determined 
using Level 2 inputs within the fair value hierarchy, as described in Note 1. Based on quoted market prices for the same or similar 
issues, or on current rates offered to the company for debt of the same remaining maturities, the fair value of the company's short-
term borrowings was $430 and $1,190 at December 31, 2016 and 2015, respectively.

Unused bank credit lines were approximately $7,900 and $4,900 at December 31, 2016 and 2015, respectively. These lines are
available to support short-term liquidity needs and general corporate purposes including letters of credit and have a remaining life
of up to two years. Outstanding letters of credit were $188 and $203 at December 31, 2016 and 2015, respectively. These letters
of credit support commitments made in the ordinary course of business.

The weighted-average interest rate on short-term borrowings outstanding at December 31, 2016 and 2015 was 2.2 percent and 4.1 
percent, respectively. The decrease in the interest rate for 2016 was primarily due to lower long-term debt maturities within one 
year.

F-29

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

The following table summarizes the company's long-term borrowings and capital lease obligations: 

December 31,
U.S. dollar:

Medium-term notes due 2038 – 20411
1.95% notes due 20162
2.75% notes due 20162
5.25% notes due 20162
6.00% notes due 20183
5.75% notes due 2019

4.625% notes due 2020

3.625% notes due 2021

4.25% notes due 2021

2.80% notes due 2023

6.50% debentures due 2028

5.60% notes due 2036

4.90% notes due 2041

4.15% notes due 2043
Term loan due 2019
Other loans2,4

Other loans- various currencies2

Less short-term portion of long-term debt

Less debt issuance costs

Capital lease obligations

Total

2016

2015

$

111 $

—

—

—

111

348

223

541

1,290

1,314

500

999

999

499

499

998

999

499

1,250

1,250

299

396

494

749
500

22

29

8,137

4
8,133

35

8,098

9

$

8,107 $

299

396

494

749
—

25

32

8,777

1,115
7,662

32

7,630

12

7,642

1. 

2. 

3. 

4. 

Average interest rates on medium-term notes were 0.6 percent and 0.1 percent at December 31, 2016 and 2015, respectively.
Includes long-term debt due within one year.
During 2008, the interest rate swap agreement associated with these notes was terminated. The gain will be amortized over the remaining life of the bond,
resulting in an effective yield of 3.85 percent.
Average interest rates on other loans were 4.3 percent at December 31, 2016 and 2015.  

In connection with the spin-off of Chemours, as discussed in Note 3, the company received a dividend from Chemours in May
2015 of $3,923 comprised of a cash distribution of $3,416 and a distribution in-kind of $507 of 7 percent senior unsecured notes 
due 2025 (Chemours Notes Received).

In 2015, DuPont exchanged the Chemours Notes Received for $488 of company debt due in 2016 as follows: $152 of 1.95 percent 
notes,  $277 of 2.75 percent notes, and $59 of 5.25 percent notes.  The company paid a premium of $20, recorded in interest 
expense in the company's Consolidated Income Statements in 2015, in connection with the early retirement of the $488 of 2016
notes.  This debt for debt exchange was considered an extinguishment.

Maturities of long-term borrowings are $1,323, $1,004, $1,003 and $1,503 for the years 2018, 2019, 2020 and 2021, respectively,
and $3,300 thereafter.

The estimated fair value of the company's long-term borrowings, was determined using Level 2 inputs within the fair value hierarchy,
as described in Note 1. Based on quoted market prices for the same or similar issues, or on current rates offered to the company 
for  debt  of  the  same  remaining  maturities,  the  fair  value  of  the  company's  long-term  borrowings  was  $8,460  and  $7,860  at 
December 31, 2016 and 2015, respectively.

aa

F-30

 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Term Loan Facility
In March 2016, the company entered into a credit agreement that provides for a three-year, senior unsecured term loan facility in
the aggregate principal amount of $4,500 (the Term Loan Facility).  DuPont may make up to seven term loan borrowings within 
one year of the closing date and amounts repaid or prepaid are not available for subsequent borrowings.  The Term Loan Facility
matures in March 2019 at which time all outstanding borrowings, including accrued but unpaid interest, become immediately due
and payable.

Under the Term Loan Facility, DuPont can borrow funds at LIBOR plus a spread from 0.75 percent to 1.25 percent (LIBOR Loan
Rate) depending on DuPont's long term credit rating.  As of December 31, 2016, the company had borrowed $500 at the LIBOR 
Loan Rate and had unused commitments of $4,000 under the Term Loan Facility.

DuPont has the option of obtaining a same day loan under the Term Loan Facility at an interest rate based on the higher of a) the 
LIBOR Loan Rate, b) the federal funds effective rate plus 0.5 percent plus a margin from 0.00 percent to 0.25 percent depending
on DuPont's long term credit rating (Margin) or c) the prime rate plus Margin.

14.  OTHER LIABILITIES

December 31,
Employee benefits:

Accrued pension benefit costs (Note 17)

Accrued other post employment benefit costs (Note 17)

Accrued environmental remediation costs

Miscellaneous

2016

2015

$

$

8,100 $

2,554
337

1,342

8,478

2,524
367

1,222

12,333 $

12,591

Miscellaneous  includes  litigation  accruals,  tax  contingencies,  accrued  royalties,  non-current  portion  of  employee  separation 
accruals and certain obligations related to divested businesses.

15.  COMMITMENTS AND CONTINGENT LIABILITIES 
Guarantees
Indemnifications
In connection with acquisitions and divestitures, the company has indemnified respective parties against certain liabilities that 
may arise in connection with these transactions and business activities prior to the completion of the transaction. The term of these
indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. In addition, the 
company indemnifies its duly elected or appointed directors and officers to the fullest extent permitted by Delaware law, against 
liabilities incurred as a result of their activities for the company, such as adverse judgments relating to litigation matters. If the 
indemnified party were to incur a liability or have a liability increase as a result of a successful claim, pursuant to the terms of the 
indemnification, the company would be required to reimburse the indemnified party. The maximum amount of potential future
payments is generally unlimited.

rr

f

Obligations for Equity Affiliates & Others
The company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates, 
customers and suppliers.  At December 31, 2016, the company had directly guaranteed $354 of such obligations. This amount 
represents the maximum potential amount of future (undiscounted) payments that the company could be required to make under 
the guarantees.  The company would be required to perform on these guarantees in the event of default by the guaranteed party.

The company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees.  These 
default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical
default history for counterparties that do not have published credit ratings.  For counterparties without an external rating or available 
credit history, a cumulative average default rate is used.

r

F-31

 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

In certain cases, the company has recourse to assets held as collateral, as well as personal guarantees from customers and suppliers. 
Assuming liquidation, these assets are estimated to cover approximately 23 percent of the $167 of guaranteed obligations of 
customers and suppliers. Set forth below are the company's guaranteed obligations at December 31, 2016:

Obligations for customers and suppliers1:
Bank borrowings (terms up to 5 years)

Obligations for equity affiliates2:

Bank borrowings (terms up to 1 year)

Obligations for Chemours3:

Chemours' purchase obligations (final expiration - 2018)

Total
1. 
2.     Existing guarantees for equity affiliates' liquidity needs in normal operations.
3. 

Existing guarantees for customers and suppliers, as part of contractual agreements.

Guarantee for Chemours' raw material purchase obligations under agreement with third party supplier.

Short-Term

Long-Term

Total

$

$

149 $

18 $

161

15

325 $

—

11

29 $

167

161

26

354

Operating Leases
The company uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on
the lease agreement.

Future minimum lease payments (including residual value guarantee amounts) under non-cancelable operating leases are $263, 
$233, $207, $158 and $123 for the years 2017, 2018, 2019, 2020 and 2021, respectively, and $219 for subsequent years and are 
not reduced by non-cancelable minimum sublease rentals due in the future in the amount of $2.  Net rental expense under operating 
leases was $245, $271 and $249 in 2016, 2015 and 2014, respectively.

Litigation
The company is subject to various legal proceedings arising out of the normal course of its business including product liability, 
intellectual property, commercial, environmental and antitrust lawsuits.  It is not possible to predict the outcome of these various
proceedings.  Although considerable uncertainty exists, management does not anticipate that the ultimate disposition of these
matters will have a material adverse effect on the company's results of operations, consolidated financial position or liquidity.  
However, the ultimate liabilities could be material to results of operations in the period recognized.

a

tt

tt

PFOA
DuPont  used  PFOA  (collectively,  perfluorooctanoic  acids  and  its  salts,  including  the  ammonium  salt),  as  a  processing  aid  to
manufacture some fluoropolymer resins at various sites around the world including its Washington Works plant in West Virginia. 
At December 31, 2016, DuPont has an accrual balance of $117 related to the PFOA matters discussed below.  Pursuant to the 
Separation Agreement discussed in Note 3, the company is indemnified by Chemours for the PFOA matters discussed below. As
a result, the company has recorded an indemnification asset of $117 corresponding to the accrual balance as of December 31,
2016.

Since 2006, DuPont has undertaken obligations under agreements with the U.S. Environmental Protection Agency (EPA), including
a 2009 consent decree under the Safe Drinking Water Act (the order),  and voluntary commitments to the New Jersey Department 
of Environmental Protection (NJDEP).  These obligations and voluntary commitments include surveying, sampling and testing 
drinking water in and around certain company sites and offering treatment or an alternative supply of drinking water if tests indicate 
the presence of PFOA in drinking water at or greater than the national health advisory level, even if provisional, as established 
from time to time by EPA.  A provisional health advisory level was set in 2009 at 0.4 parts per billion (ppb) for PFOA in drinking
water considering episodic exposure.  In May 2016, EPA announced a health advisory level of 0.07 ppb for PFOA in drinking 
water  considering  lifetime  versus  episodic  exposure.    In  January  2017,  EPA  announced  it  had  amended  the  order  to  include 
Chemours, and to make the new health advisory level the trigger for additional actions by the companies, thus expanding the 
obligations to the EPA beyond the previously established testing and water supply commitments around the Washington Works
facility.  The company's accrual balance of $17 at December 31, 2016 related to these obligations and voluntary commitments 
reflects the impacts of the new health advisory level and expanded obligations under the amended order. 

F-32

 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

g

Drinking Water Actions
In August 2001, a class action, captioned Leach v DuPont, was filed in West Virginia state court alleging that residents living near 
the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the 
plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community 
health project.  The company funded a series of health studies which were completed in October 2012 by an independent science 
panel of experts (the C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available 
scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and 
human disease. 

The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-
induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed 
high cholesterol. 

In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic 
testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing 
three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for 
completion of its protocol. The company is obligated to fund up to $235 for a medical monitoring program for eligible class
members and, in addition, administrative costs associated with the program, including class counsel fees. In January 2012, the
company established and put $1 into an escrow account to fund medical monitoring as required by the settlement agreement. 
Under the settlement agreement, the balance in the escrow amount must be at least $0.5; as a result, transfers of additional funds 
may be required periodically. The court appointed Director of Medical Monitoring has established the program to implement the
medical panel's recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening
and testing has begun and associated payments to service providers are being disbursed from the escrow account; at December 31,
2016, less than $1 has been disbursed. While it is probable that the company will incur liabilities related to funding the medical 
monitoring program, such liabilities cannot be reasonably estimated due to uncertainties surrounding the level of participation by 
eligible class members and the scope of testing.

u

n

In addition, under the settlement agreement, the company must continue to provide water treatment designed to reduce the level
of PFOA in water to six area water districts, including the Little Hocking Water Association (LHWA), and private well users.

g

Multi-District Litigation
Leach class members may pursue personal injury claims against DuPont only for the six human diseases for which the C8 Science 
Panel determined a probable link exists.   At December 31, 2016 there were about 3,550 lawsuits, of which about 30 allege wrongful 
death, pending in various federal and state courts in Ohio and West Virginia. These lawsuits are consolidated in multi-district
litigation (MDL) in the U.S. District Court for the Southern District of Ohio (the Court). The approximate number of lawsuits
pending in the MDL remained constant year-over-year.  However, the company has refined the number pending at December 31,
2016, in connection with updates to the table below. DuPont, through Chemours, denies the allegations in these lawsuits and is
defending itself vigorously.

The table below approximates the number of lawsuits based on primary alleged disease.

Alleged Injury

Number of Claims

Kidney cancer
Testicular cancer
Ulcerative colitis
Preeclampsia
Thyroid disease

High cholesterol

210
70
300
200
1,430

1,340

F-33

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

In 2014, six cases from the MDL were selected for individual trial. In 2016, three of these cases, two kidney cancer and one 
ulcerative colitis, were settled for amounts immaterial individually and in the aggregate, and one case was voluntarily withdrawn 
by plaintiffs. The other two matters, (Barlett v DuPont, kidney cancer, and Freeman v DuPont, testicular cancer) were tried to jury 
verdicts in 2015 and 2016, respectively.  The Bartlett jury awarded compensatory damages of  $1.6 and no punitive damages.  The
company has appealed the Bartlett verdict to the U.S. Court of Appeals for the Sixth Circuit (the Sixth Circuit) which is expected 
to issue a ruling in the first half of 2017. In 2016, the Freeman jury awarded compensatory damages of $5.1 and $0.5 in punitive 
damages and attorneys’ fees.  Pending a post-trial motion, the company will appeal to the Sixth Circuit.

aa

In January 2016, the Court determined that 40 cases asserting cancer claims, to be identified by plaintiffs' attorneys, would be 
scheduled for trial through year-end 2017. In the first two matters selected for trial, (Vigneron v DuPont and Moody v DuPont)
plaintiffs make testicular cancer claims. After a fourth quarter 2016 trial, the Vigneron jury awarded compensatory damages of 
$2 and punitive damages of $10.5.  Pending post-trial motions, the company will appeal to the Sixth Circuit. The Moody trial 
began in January 2017 and the jury is expected to render a verdict in the first quarter 2017. The remaining 38 trials are scheduled 
to begin each week starting in May 2017.

dd

In 2016, the Court ordered the parties to participate in confidential, nonbinding mediation regarding global resolution of the MDL.  
This process continues.

At December 31, 2016, the company has established an accrual of $100 related to the MDL, representing the company’s estimate 
of the low end of the range of potential loss. While DuPont could incur liabilities in excess of the amount accrued, the upper end 
of the range of such loss cannot be reasonably estimated. The range of possible loss is unpredictable and involves significant 
uncertainty due to the uniqueness of individual plaintiff's claims and the company's defenses as to potential liability and damages
on an individual claims basis, and the timing and outcome of the appellate process, among other factors. This type of litigation
could take place over many years and interim results do not predict the final outcomes of cases. 

Additional Actions
In the first quarter 2016, a confidential settlement was reached in the Ohio action brought by the LHWA claiming, “imminent and
substantial  endangerment  to  health  and  or  the  environment”  under  the  Resource  Conservation  and  Recovery Act  (RCRA)  in 
addition to general claims of PFOA contamination of drinking water. The cost of the settlement was paid by Chemours.

Under the Separation Agreement, all liabilities associated with the PFOA matters discussed above, including liabilities related tod
judgments, including punitive damages, or settlements associated with the MDL, are subject to indemnification by Chemours.

Environmental
The company is also subject to contingencies pursuant to environmental laws and regulations that in the future may require the 
company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or
petroleum substances by the company or other parties. The company accrues for environmental remediation activities consistent 
with the policy set forth in Note 1.  Much of this liability results from the Comprehensive Environmental Response, Compensation
and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require the 
company to undertake certain investigative, remediation and restoration activities at sites where the company conducts or once 
conducted operations or at sites where company-generated waste was disposed.  The accrual also includes estimated costs related
to a number of sites identified by the company for which it is probable that environmental remediation will be required, but which 
are not currently the subject of enforcement activities.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend 
on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, 
as well as the presence or absence of potentially responsible parties.  At December 31, 2016, the Consolidated Balance Sheet 
included a liability of $457, relating to these matters and, in management's opinion, is appropriate based on existing facts and 
circumstances.  The average time frame, over which the accrued or presently unrecognized amounts may be paid, based on past 
history, is estimated to be 15-20 years.  Considerable uncertainty exists with respect to these costs and, under adverse changes in 
circumstances, the potential liability may range up to $900 above the amount accrued as of December 31, 2016.  Pursuant to the 
Separation Agreement discussed in Note 3, the company is indemnified by Chemours for certain environmental matters, included 
in the liability of $457, that have an estimated liability of $250 as of December 31, 2016  and a potential exposure that ranges up 
to  approximately  $500  above  the  amount  accrued.   As  such,  the  company  has  recorded  an  indemnification  asset  of  $250
corresponding to the company's accrual balance related to these matters at December 31, 2016.

F-34

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

16.  STOCKHOLDERS' EQUITY
Share Repurchase Program
2015 Share Buyback Plan
In the first quarter 2015, DuPont announced its intention to buy back shares of about $4,000 using the distribution proceeds received 
from Chemours.  In connection with the completion of the spin-off of Chemours, the Board of Directors authorized the use of the
distribution  proceeds  to  buy  back  shares  of  the  company's  common  stock  as  follows:  $2,000  to  be  purchased  and  retired  by 
December 31, 2015, which was completed during 2015, with the remainder to be purchased and retired by December 31, 2016.  
There were no share repurchases under this plan in the first and second quarters of 2016.  The company had limited opportunity
to repurchase shares in 2016, primarily due to the planned merger with Dow.  However, during the second half of 2016, the companya
purchased and retired 13.2 million shares in the open market for a total cost of $916.  As of December 31, 2016, in aggregate, the 
company has paid $2,916 and received and retired 48.2 million shares.  As of January 1, 2017, the authorization under this buyback 
program has expired.

2014 Share Buyback Plan
In January 2014, the company's Board of Directors authorized a $5,000 share buyback plan that replaced the 2011 plan.  During 
2014, the company purchased and retired 30.1 million shares for $2,000 under two separate accelerated share repurchase (ASR) 
agreements as well as open market purchases.  During 2015, the company repurchased and retired 4.6 million shares in the open 
market for a total cost of $353.  There were no share repurchases under this plan during 2016. As of December 31, 2016, in
aggregate, the company has purchased 34.7 million shares at a total cost of $2,353 under the plan. As a result, $2,647 buyback 
authority remains under this program.  There is no required completion date for the remaining stock purchases under the 2014
plan.

Common stock held in treasury is recorded at cost.  When retired, the excess of the cost of treasury stock over its par value is 
allocated between reinvested earnings and additional paid-in capital.

Set forth below is a reconciliation of common stock share activity for the years ended December 31, 2016, 2015 and 2014:

Shares of common stock
Balance January 1, 2014
Issued

Repurchased

Retired

Balance December 31, 2014

Issued
Repurchased

Retired

Balance December 31, 2015
Issued
Repurchased
Retired
Balance December 31, 2016

Issued
1,014,027,000
8,103,000

—
(30,110,000)
992,020,000

5,932,000
—
(39,564,000)
958,388,000
4,808,000
—
(13,152,000)
950,044,000

Held In Treasury

(87,041,000)
—
(30,110,000)
30,110,000
(87,041,000)
—
(39,564,000)
39,564,000
(87,041,000)
—
(13,152,000)
13,152,000
(87,041,000)

Noncontrolling Interest
In September 2015, the company obtained a controlling interest in a joint venture included in the Performance Materials segment.  
Accordingly, the company consolidated the entity at December 31, 2015 and recorded the fair value of the noncontrolling interest 
in the amount of $151 in the Consolidated Balance Sheet.

F-35

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Other Comprehensive Loss

The changes and after-tax balances of components comprising accumulated other comprehensive loss are summarized below:

2014
Balance January 1, 2014

Other comprehensive (loss) income

before reclassifications

Amounts reclassified from accumulated

other comprehensive loss

Net other comprehensive (loss) income
Balance December 31, 2014
2015
Other comprehensive (loss) income

before reclassifications

Amounts reclassified from accumulated

other comprehensive loss

Net other comprehensive (loss) income

Spin-off of Chemours

Balance December 31, 2015
2016
Other comprehensive (loss) income

before reclassifications

Amounts reclassified from accumulated

other comprehensive loss

Net other comprehensive (loss) income

Balance December 31, 2016
1. 

Cumulative
Translation
Adjustment 1

Net Gains (Losses)
on Cash Flow
Hedging
Derivative
Instruments

Pension Benefit
Plans

Other Benefit
Plans

Unrealized Gain
(Loss) on
Securities

Total

(43) $

(48) $

(5,695) $

494 $

2 $

(5,290)

(876)

—

(876) $
(919) $

33

9

42 $
(6) $

(2,601)

(131)

401
(2,200) $
(7,895) $

(101)
(232) $
262 $

—

—

— $
2 $

(3,575)

309
(3,266)
(8,556)

(1,605)

(25)

39

3

(17)

(1,605)

—

(1,605) $

191

(2,333) $

7
(18) $
—
(24) $

535

574 $

278
(7,043) $

(243)
(240) $
—

22 $

(2)
(19) $
(1)
(18) $

297
(1,308)
468
(9,396)

(510)

20

(271)

(81)

(8)

(850)

—
(510) $

(2,843) $

11
31 $

7 $

594
323 $
(6,720) $

(298)
(379) $
(357) $

28
20 $

2 $

335
(515)
(9,911)

$

$
$

$

$

$

$

The currency translation loss for the year ended December 31, 2016 is primarily driven by the strengthening  of the U.S. dollar (USD) against the European
Euro (EUR) partially offset by the weakening of the USD against the Brazilian real (BRL).  The currency translation loss for the years ended December 31,
2015 and 2014 is driven by the strengthening USD against primarily the EUR and BRL.  For the year ended December 31, 2015, the increase over prior 
year is also due to changes in certain foreign entity's functional currency as described in Note 1. 

r

The tax benefit (expense) on the net activity related to each component of other comprehensive loss were as follows:

For the year ended December 31,
Net gains (losses) on cash flow hedging derivative instruments $
Pension benefit plans, net
Other benefit plans, net
Benefit from (provision for) income taxes related to other
comprehensive (loss) income items

$

2016

2015

2014

(19) $
(163)
194

12 $

7 $

(317)
135

(175) $

(26)
1,274
155

1,403

F-36

 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

A summary of the reclassifications out of accumulated other comprehensive loss is provided as follows:

Net gains (losses) on cash flow hedging derivative
instruments, before tax:

$

Tax benefit

After-tax $

Amortization of pension benefit plans:

  Prior service (benefit) cost

  Actuarial losses

  Curtailment loss (gain)

  Settlement loss

Amortization of other benefit plans:

  Prior service benefit

  Actuarial losses
  Curtailment gain

Total before tax $

Tax benefit

After-tax $

Total before tax $

Tax expense

After-tax $

Net realized gains (losses) on investments, before tax:

Tax expense

After-tax $

Total reclassifications for the period, after-tax
1.

$

2016

2015

2014

18 $
(7)
11 $

(6)
822

40

62
918 $
(324)
594 $

(134)
78
(392)
(448) $
150
(298) $
28
—

28 $

335 $

12 $
(5)
7 $

(9)
768
(6)
76
829 $
(294)
535 $

(182)
78
(274)
(378) $
135
(243) $
(2)
—
(2) $
297 $

Consolidated
Statements of
Income
Classification

15 See (1) below
(6) See (2) below
9

2 See (3) below

601 See (3) below

4 See (3) below

7 See (3) below

614
(213) See (2) below
401

(214) See (3) below
57 See (3) below
— See (3) below

(157)

56 See (2) below

(101)

— See (4) below
— See (2) below

—

309

2.

3.

4.

Net sales and cost of goods sold
Provision for income taxes from continuing operations
These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost of the company's pension and other 
benefit plans. See Note 17 for additional information. 
Other income, net

aa

The  tax  benefit  (expense)  recorded  in  Stockholders'  Equity  was  $33,  $(138)  and  $1,461  for  the  years  2016,  2015  and  2014, 
respectively.  Included in these amounts were tax benefits of $21, $37 and $58 for the years 2016, 2015 and 2014, respectively,
associated with stock compensation programs.  The remainder consists of amounts recorded within other comprehensive loss as 
shown in the table above.

F-37

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

17.  LONG-TERM EMPLOYEE BENEFITS
The company offers various long-term benefits to its employees. Where permitted by applicable law, the company reserves the 
right to change, modify or discontinue the plans.

Defined Benefit Pensions
The  company  has  both  funded  and  unfunded  noncontributory  defined  benefit  pension  plans  covering  a  majority  of  the  U.S.
employees. The benefits under these plans are based primarily on years of service and employees' pay near retirement.   In November 
2016, the company announced changes to the U.S. pension  plans. The company will freeze the pay and service amounts used to 
calculate pension benefits for active employees who participate in the U.S. pension plans at the earlier of the effective date of the 
first of the Intended Business Separations or November 30, 2018 (the Effective Date).  See Note 2 for further discussion of the
Intended Business Separations.  Therefore, as of the Effective Date, active employees in the U.S. will not accrue additional benefits 
for future service and eligible compensation received.  These changes resulted in a $527 decline in the projected benefit obligation, 
which is reflected in actuarial loss (gain) in the below table, and recognition of a $25 pre-tax curtailment gain during the fourth
quarter of 2016.  The decline in the projected benefit obligation is primarily due to the decrease in expected future compensation.  
Most employees hired on or after January 1, 2007 are not eligible to participate in the U.S. defined benefit pension plans. 

The company's funding policy is consistent with the funding requirements of federal laws and regulations.  Pension coverage for
employees of the company's non-U.S. consolidated subsidiaries is provided, to the extent deemed appropriate, through separate 
plans.  Obligations  under  such  plans  are  funded  by  depositing  funds  with  trustees,  covered  by  insurance  contracts,  or  remain 
unfunded.

The workforce reductions in 2016 related to the 2016 global cost savings and restructuring plan triggered curtailments for certain 
of the company's pension plans, including the principal U.S. pension plan.  For the principal U.S. pension plan, the company 
recorded curtailment losses of $63 during 2016 driven by the changes in the benefit obligation based on the demographics of the
terminated positions partially offset by accelerated recognition of a portion of the prior  service benefit.  

In the fourth quarter 2016, about $550 of lump-sum payments were made from the principal U.S. pension plan trust fund to a 
group of separated, vested plan participants who were extended a limited-time opportunity and voluntarily elected to receive their 
pension benefits in a single lump-sum payment.  Since the company recognizes pension settlements only when the lump-sum
payments exceed the sum of the plan's service and interest cost components of net periodic pension cost for the year, these lump-mm
sum payments did not result in the recognition of a pension settlement charge.

Other Post Employment Benefits
The parent company and certain subsidiaries provide medical, dental and life insurance benefits to pensioners and survivors. The 
associated plans for retiree benefits are unfunded and the cost of the approved claims is paid from company funds. Essentially all 
of the cost and liabilities for these retiree benefit plans are attributable to the U.S. benefit plans.  The non-Medicare eligible retiree 
medical plan is contributory with pensioners and survivors' contributions adjusted annually to achieve a 50/50 target sharing of 
cost increases between the company and pensioners and survivors. In addition, limits are applied to the company's portion of the 
retiree medical cost coverage.  For Medicare eligible pensioners and survivors, the company provides a company-funded Health 
Reimbursement Arrangement (HRA).   In November 2016, the company announced that eligible employees who will be under 
the age of 50 at the Effective Date, as defined above, will not receive post-retirement medical, dental and life insurance benefits. 
As  a  result  of  these  changes,  the  company  recognized  a  pre-tax  curtailment  gain  of  $357  during  the  fourth  quarter  of  2016.  
Beginning January 1, 2015, eligible employees who retire on and after that date will receive the same life insurance benefit payment, 
regardless of age. The majority of U.S. employees hired on or after January 1, 2007 are not eligible to participate in the post-
retirement medical, dental and life insurance plans.

aa

As a result of the workforce reductions noted above, curtailments were triggered for the company’s other post employment benefit 
plans.  The company recorded curtailment gains of $35 during the year ended December 31, 2016.  The curtailment gains were
driven by accelerated recognition of a portion of the prior service benefit partially offset by the change in the benefit obligation 
based on the demographics of the terminated positions. 

The company also provides disability benefits to employees. Employee disability benefit plans are insured in many countries. 
However, primarily in the U.S., such plans are generally self-insured. Obligations and expenses for self-insured plans are reflected 
in the figures below.

F-38

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Summarized information on the company's pension and other post employment benefit plans is as follows:

Obligations and Funded Status at December 31,
Change in benefit obligation

Pension Benefits

Other Benefits

2016

2015

2016

2015

Benefit obligation at beginning of year

$

26,094  

$

29,669

$

2,758

$

2,889

Service cost

Interest cost

Plan participants' contributions

Actuarial loss (gain)
Benefits paid 1d
Amendments

Effect of foreign exchange rates

Acquisitions/divestitures/other activity

Spin-off of Chemours

Benefit obligation at end of year
Change in plan assets

Fair value of plan assets at beginning of year
Actual gain on plan assets

Employer contributions

Plan participants' contributions
Benefits paid1
Effect of foreign exchange rates
Acquisitions/divestitures/other activity

Spin-off of Chemours

Fair value of plan assets at end of year
Funded status

U.S. plan with plan assets
Non-U.S. plans with plan assets
All other plans 2

Total

Amounts recognized in the Consolidated Balance 
    Sheets consist of:

Other assets
Other accrued liabilities (Note 12)
Other liabilities (Note 14)

Net amount recognized

$

$

$

$

$

$

$

174  

800  

18  

460
(2,374)
—
(348)
7

—

24,831

17,497
1,219

535

18
(2,374)
(239)
—

—

16,656

(6,391)
(674)
(1,110)
(8,175)

3
(78)
(8,100)
(8,175)

$

$

$

$

$

$

$

232

1,084

19
(1,404)
(1,761)
—
(456)
(52)
(1,237)
26,094

20,446
88

308

19
(1,761)
(330)
(47)
(1,226)
17,497

(6,662)
(748)
(1,187)
(8,597)

11
(130)
(8,478)
(8,597)

$

$

$

$

$

$

$

11

87

36

153
(254)
(28)
1

65

—

2,829

$

— $
—

218

36
(254)
—
—

—

— $

— $
—
(2,829)
(2,829)

$

— $

(275)
(2,554)
(2,829)

$

15

112

45
(4)
(282)
—
(6)
—
(11)
2,758

—
—

237

45
(282)
—
—

—

—

—
—
(2,758)
(2,758)

—
(234)
(2,524)
(2,758)

1. 

2. 

2016 benefits paid includes about $550 of lump sum benefits associated with the limited-time opportunity provided to certain separated, vested participants
in the principal U.S. pension plan.  See further discussion above.
Includes pension plans maintained around the world where funding is not customary.

F-39

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

The pre-tax amounts recognized in accumulated other comprehensive loss are summarized below:

December 31,
Net loss
Prior service benefit

Pension Benefits

Other Benefits

2016

2015

2016

2015

$

$

(10,280) $
17
(10,263) $

(10,803) $
54
(10,749) $

(830) $
281
(549) $

(787)
811
24

The accumulated benefit obligation for all pension plans was $24,345 and $24,984 at December 31, 2016 and 2015, respectively.

Information for pension plans with projected benefit obligation in excess of plan assets
Projected benefit obligation
Accumulated benefit obligation
Fair value of plan assets

Information for pension plans with accumulated benefit obligations in excess of plan assets
Projected benefit obligation

Accumulated benefit obligation

Fair value of plan assets

$

$

2016

2015

24,779 $
24,297
16,601

25,769
24,715
17,162

2016

2015

23,946 $

23,591

15,838

25,515

24,508

16,930

F-40

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Components of net periodic benefit cost (credit) and amounts recognized in other 
    comprehensive loss
Net periodic benefit cost

Pension Benefits

2016

2015

2014

$

174 $

232 $

Service cost

Interest cost

Expected return on plan assets

Amortization of loss

Amortization of prior service (benefit) cost
Curtailment loss (gain)

Settlement loss

Net periodic benefit cost - Total

Less: Discontinued operations

Net period benefit cost - Continuing operations
Changes in plan assets and benefit obligations recognized in other 
    comprehensive loss

Net loss
Amortization of loss

Prior service benefit

Amortization of prior service benefit (cost)

Curtailment (loss) gain

Settlement loss
Effect of foreign exchange rates

Spin-off of Chemours

Total (benefit) loss recognized in other comprehensive loss

Noncontrolling interest

800
(1,320)
822
(6)
40

62

572 $
(5)
577 $

570 $
(822)
—

6
(40)
(62)
(138)
—
(486) $
—

(486) $
86 $

1,084
(1,554)
768
(9)
(6)
76

591 $
(5)
596 $

57 $

(768)
—

9

6
(76)
(119)
(382)
(1,273) $
—

(1,273) $
(682) $

$

$

$

$

241

1,162
(1,611)
601

2
4

7

406

40

366

4,131
(601)
(44)
(2)
(4)
(7)
—

—

3,473

1

3,474

3,880

Total (benefit) loss recognized in other comprehensive loss, attributable to DuPont $

Total recognized in net periodic benefit cost and other comprehensive loss

$

The estimated pre-tax net loss and prior service benefit for the defined benefit pension plans that will be amortized from accumulated 
other comprehensive loss into net periodic benefit cost during 2017 are $758 and $(4), respectively.  These amounts do not include 
any potential settlement charges related to the company's Pension Restoration Plan which provides lump sum payments to certain
eligible retirees.   

u

F-41

 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Components of net periodic benefit cost (credit) and amounts recognized in other      
    comprehensive loss
Net periodic benefit cost

Service cost

Interest cost

Amortization of loss

Amortization of prior service benefit

Curtailment gain
Net periodic benefit credit - Total

Less: Discontinued operations

Net periodic benefit (credit) cost - Continuing operations
Changes in plan assets and benefit obligations recognized in other 
    comprehensive loss

Net loss (gain)

Amortization of loss

Prior service benefit
Amortization of prior service benefit

Curtailment gain

Effect of foreign exchange rates

Total loss recognized in other comprehensive loss, attributable to DuPont

Total recognized in net periodic benefit cost and other comprehensive loss

Other Benefits

2016

2015

2014

$

$

$

$

$

$

11 $

87

78
(134)
(392)
(350) $
—
(350) $

153 $
(78)
(28)
134

392

—

573 $

223 $

15 $

112

78
(182)
(274)
(251) $
(272)

21 $

(4) $
(78)
—
182

274

1

375 $

124 $

17

121

57
(214)
—
(19)
3
(22)

280
(57)
(50)
214

—

—

387

368

The estimated pre-tax net loss and prior service benefit for the other post employment benefit plans that will be amortized from
accumulated other comprehensive loss into net periodic benefit cost during 2017 are $91 and $(69), respectively. 

Weighted-average assumptions used to determine benefit obligations at December 31,
Discount rate
Rate of compensation increase1

2016

2015

2016

2015

3.80%
3.80%

4.13%
3.94%

4.03%
—%

4.32%
—%

1. 

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant's
entire career at the company. 

d

Weighted-average assumptions used to determine net
    periodic benefit cost for the years ended December 31,
Discount rate
Expected return on plan assets
Rate of compensation increase

2016

2015

2014

2016

2015

2014

3.77%
7.74%
3.96%

3.93%
8.10%
4.01%

4.55%
8.35%
4.22%

3.87%
—%
—%

4.13%
—%
—%

4.60%
—%
—%

F-42

 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

For determining U.S. pension plans' net periodic benefit costs, the discount rate, expected return on plan assets and the rate of 
compensation increase were 4.04 percent, 8.00 percent and 4.15 percent for 2016.

For determining U.S. pension plans' net periodic benefit costs, the discount rate, expected return on plan assets and the rate of 
compensation increase were 4.29 percent, 8.50 percent and 4.20 percent for 2015.

For determining U.S. pension plans' net periodic benefit costs, the discount rate, expected return on plan assets and the rate of 
compensation increase were 4.90 percent, 8.75 percent and 4.50 percent for 2014.

In the U.S., the discount rate is developed by matching the expected cash flow of the benefit plans to a yield curve constructed 
from a portfolio of high quality fixed-income instruments provided by the plan's actuary as of the measurement date. Effective in
2016, the company changed its method to estimate the service and interest cost components of net periodic benefit cost for the 
U.S. benefit plans.  The company utilized a full yield curve approach in the estimation of service and interest rate components by 
applying specific spot rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash
flows.  For non-U.S. benefit plans, the company utilizes prevailing long-term high quality corporate bond indices to determine
the discount rate applicable to each country at the measurement date. 

The long-term rate of return on assets in the U.S. was selected from within the reasonable range of rates determined by historical 
real returns (net of inflation) for the asset classes covered by the investment policy, expected performance, and projections of 
inflation over the long-term period during which benefits are payable to plan participants. Consistent with prior years, the long-
term rate of return on plan assets in the U.S. reflects the asset allocation of the plan and the effect of the company's active management 
of the plan's assets.  For non-U.S. plans, assumptions reflect economic assumptions applicable to each country.

In October 2014, the Society of Actuaries released final reports of new mortality tables and a mortality improvement scale for 
measurement of retirement program obligations in the U.S. The Society of Actuaries published other mortality improvement scales
in October 2015 and October 2016. The company adopted these tables in measuring the 2015 and 2016 long-term employee benefit 
obligations, respectively. The effect of these adoptions is amortized into net periodic benefit cost for the years following the 
adoption. 

Assumed health care cost trend rates at December 31,
Health care cost trend rate assumed for next year
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)

Year that the rate reaches the ultimate trend rate

2016

2015

7%
5%

2023

7%
5%

2023

Assumed health care cost trend rates have a modest effect on the amount reported for the health care plan. A one-percentage point 
change in assumed health care cost trend rates would have the following effects:

Increase (decrease) on total of service and interest cost
Increase (decrease) on post-retirement benefit obligation

Point Increase

1-Percentage
Point Decrease

$

— $
11

—
(11)

F-43

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Plan Assets
All pension plan assets in the U.S. are invested through a single master trust fund. The strategic asset allocation for this trust fund 
is approved by management. The general principles guiding U.S. pension asset investment policies are those embodied in the 
Employee Retirement Income Security Act of 1974 (ERISA). These principles include discharging the company's investment 
responsibilities for the exclusive benefit of plan participants and in accordance with the "prudent expert" standard and other ERISA 
rules  and  regulations.  The  company  establishes  strategic  asset  allocation  percentage  targets  and  appropriate  benchmarks  for 
significant asset classes with the aim of achieving a prudent balance between return and risk. Strategic asset allocations in other 
countries are selected in accordance with the laws and practices of those countries. Where appropriate, asset liability studies are
utilized in this process. U.S. plan assets and a portion of non-U.S. plan assets are managed by investment professionals employed 
by the company. The remaining assets are managed by professional investment firms unrelated to the company. The company's 
pension investment professionals have discretion to manage the assets within established asset allocation ranges approved by 
management of the company. Additionally, pension trust funds are permitted to enter into certain contractual arrangements generally 
described as "derivatives". Derivatives are primarily used to reduce specific market risks, hedge currency and adjust portfolio
duration and asset allocation in a cost-effective manner.

rr

The weighted-average target allocation for plan assets of the company's U.S. and non-U.S. pension plans is summarized as follows:

Target allocation for plan assets at December 31,
U.S. equity securities
Non-U.S. equity securities
Fixed income securities
Hedge funds
Private market securities
Real estate
Cash and cash equivalents
Total

2016

2015

27%
24
33
2
8
4
2
100%

29%
22
32
2
9
3
3
100%

Global equity securities include varying market capitalization levels. U.S. equity investments are primarily large-cap companies.
Global  fixed  income  investments  include  corporate-issued,  government-issued  and  asset-backed  securities.  Corporate  debt 
investments include a range of credit risk and industry diversification. U.S. fixed income investments are weighted heavier thanaa
non-U.S fixed income securities. Other investments include cash and cash equivalents, hedge funds, real estate and private market 
securities such as interests in private equity and venture capital partnerships.

Fair value calculations may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the 
company  believes  its  valuation  methods  are  appropriate  and  consistent  with  other  market  participants,  the  use  of  different 
methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value 
measurement at the reporting date.

F-44

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

The tables below presents the fair values of the company's pension assets by level within the fair value hierarchy, as described in
Note 1, as of December 31, 2016 and 2015, respectively.

Asset Category
Cash and cash equivalents
U.S. equity securities1
Non-U.S. equity securities

Debt – government-issued

Debt – corporate-issued

Debt – asset-backed

Hedge funds

Private market securities

Real estate

Derivatives – asset position
Derivatives – liability position

Other

    Subtotal

Investments measured at net asset value

    Hedge funds
    Private market securities

    Real estate funds

Total investments measured at net asset value

Other items to reconcile to fair value of plan assets
    Pension trust receivables2
    Pension trust payables3
Total

$

$

$

Fair Value Measurements at December 31, 2016

Total

Level 1

Level 2

Level 3

$

1,505 $

1,480 $

25 $

4,071

3,278

2,067

2,475

721

1

67

275

53
(47)
4

4,033

3,126

864

273

39

—

—

175

7
—

—

20

151

1,203

2,163

682

1

25

2

46
(47)
4

—

18

1

—

39

—

—

42

98

—
—

—

14,470 $

9,997 $

4,275 $

198

434
1,416

444

2,294

264
(372

)

16,656

1. 

2. 

3. 

The company's pension plans directly held $732 (4 percent of total plan assets) of DuPont common stock at December 31, 2016.
Primarily receivables for investment securities sold.
Primarily payables for investment securities purchased.  

F-45

 
 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Fair Value Measurements at December 31, 2015

Total

Level 1

Level 2

Level 3

$

1,962 $

1,961 $

1 $

Asset Category
Cash and cash equivalents
U.S. equity securities1
Non-U.S. equity securities

Debt – government-issued
Debt – corporate-issued

Debt – asset-backed

Hedge funds

Private market securities

Real estate
Derivatives – asset position

Derivatives – liability position

    Subtotal

Investments measured at net asset value

    Debt - government issued
    Debt - corporate issued

    Hedge funds

    Private market securities

    Real estate funds

Total investments measured at net asset value
Other items to reconcile to fair value of plan assets
    Pension trust receivables2
    Pension trust payables3
Total

3,843

3,480

852
291

44

—

—

98
10

1

10,580 $

10

115

1,176
2,049

786

1

17

4
48
(60)
4,147 $

3,873

3,597

2,028
2,374

831

1

54

246
58
(59)
14,965 $

8
6

429

1,553

457

2,453

783
(704)
17,497

$

$

$

$

—

20

2

—
34

1

—

37

144
—

—

238

1. 

2. 

3. 

The company's pension plans directly held $664 (4 percent of total plan assets) of DuPont common stock at December 31, 2015.
Primarily receivables for investment securities sold.
Primarily payables for investment securities purchased.  

F-46

 
 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

The company's pension plans hold Level 3 assets which are primarily ownership interests in investment partnerships and trusts
that own private market securities and real estate. Fair value is generally based on the company's units of ownership and net asset 
value of the investment entity or the company's share of the investment entity's total equity. The table below presents a rollforward 
of activity for these assets for the years ended December 31, 2016 and 2015:

ff

Total

U.S. Equity
Securities

Non-U.S.
Equity
Securities

Debt-
Corporate
Issued

Debt-
Asset-
Backed

Private
Market
Securities

Real
Estate

Level 3 Assets

Beginning balance at December 31, 2014

$

286 $

Realized (loss) gain

Change in unrealized (loss) gain

Purchases, sales and settlements, net

Transfers in (out) of Level 3

(32)

(11)

(18)

13

29 $

(14)

5

—

—

4 $

—

(3)

—

1

15 $

(18)

15

10

12

1 $

37 $

—

—

—

—

—

(5)

5

—

Ending balance at December 31, 2015

$

238 $

20 $

2 $

34 $

1 $

37 $

Realized (loss) gain

Change in unrealized (loss) gain

Purchases, sales and settlements, net

Transfers in (out) of Level 3

(28)

19

(37)

6

(3)

1

—

—

—

(1)

—

—

(25)

27

(3)

6

—

—

(1)

—

—

2

3

—

Ending balance at December 31, 2016

$

198 $

18 $

1 $

39 $

— $

42 $

200

—

(23)

(33)

—

144

—

(10)

(36)

—

98

The following table presents additional information about the pension plan assets valued using net asset value as a practical 
expedient:

2016

2015

Fair Value

Unfunded
Commitments

Fair Value

Unfunded
Commitments

Redemption
Frequency

Redemption Notice
Period Range

Debt - government issued

$

Debt - corporate issued

— $

—

Hedge funds 1
Private market securities 2
Real estate funds 2

434

1,416

444

— $

—

—

693

244

8 $

6

— Monthly

— Monthly

3 days

3 days

429

1,553

457

— Monthly, Quarterly

Ranges from 3-45
days monthly, 3-90
days quarterly

632 Not applicable

Not applicable

361 Not applicable

Not applicable

Total

$

2,294 $

937 $

2,453 $

993

1.

2.

Less than 5 percent of hedge funds have gates in place at the investor level for year end redemptions.  Hedge funds also contain either no lock up or a lock 
up period of less than 1 year.
The remaining life of private market securities and real estate funds is an average of 15 years per investment.

Cash Flow
Contributions
No contributions to its principal U.S. pension plan were made in 2014 or 2015.   The company contributed $230 to the principal 
U.S. pension plan in 2016 and is expected to contribute about the same amount to this plan in 2017.  The company contributed 
$121, $184, and $218 to its pension plans other than the principal U.S. pension plan, its remaining plans with no plan assets and 
its other post employment benefit plans, respectively, in 2016.  The company contributed $164, $144, and $237 to its pension 
plans other than the principal U.S. pension plan, its remaining plans with no plan assets and its other post employment benefitt
plans, respectively, in 2015.  In 2017, the company expects to contribute $95 to its pension plans other than the principal U.S. 
pension plan, $85 to its remaining plans with no plan assets, and $275 to its other post employment benefit  plans.

a

F-47

    
    
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Estimated Future Benefit Payments
The following benefit payments, which reflect future service, as appropriate, are expected to be paid:

2017
2018
2019
2020
2021
Years 2022-2026

Pension
Benefits

Other Benefits

$

1,622 $
1,601
1,589
1,575
1,567
7,596

275
233
226
217
210
931

Defined Contribution Plan
The company provides defined contribution benefits to its employees. The most significant is the Retirement Savings Plan (the
Plan), which covers all U.S. full-service employees. This Plan includes a non-leveraged Employee Stock Ownership Plan 
(ESOP). Employees are not required to participate in the ESOP and those who do are free to diversify out of the ESOP. The 
purpose of the Plan is to provide retirement savings benefits for employees and to provide employees an opportunity to become 
stockholders of the company. The Plan is a tax qualified contributory profit sharing plan, with cash or deferred arrangement and 
any eligible employee of the company may participate. Currently, the company contributes 100 percent of the first 6 percent of 
the employee's contribution election and also contributes 3 percent of each eligible employee's eligible compensation regardless
of the employee's contribution.

The company's contributions to the Plan were $187, $219 and $262 for the years ended December 31, 2016, 2015 and 2014, 
respectively.  The company's matching contributions vest immediately upon contribution. The 3 percent nonmatching company 
contribution vests after employees complete three years of service. In addition, the company made contributions to other defined 
contribution plans of $33, $57 and $66 for the years ended December 31, 2016, 2015 and 2014, respectively.  Included in the 
company's contributions are amounts related to discontinued operations of $32 and $57 for the years ended December 31, 2015
and 2014, respectively.  The company expects to contribute about the same amount as 2016 to its defined contribution plans in 
2017.

18.  COMPENSATION PLANS
The total stock-based compensation cost included in continuing operations within the Consolidated Income Statements was $119,
$128 and $136 for 2016, 2015 and 2014, respectively. The income tax benefits related to stock-based compensation arrangements 
were $39, $42 and $45 for 2016, 2015 and 2014, respectively.

The company's Equity Incentive Plan, as amended and restated effective March 14, 2016, (EIP), provides for equity-based and 
cash incentive awards to certain employees, directors, and consultants. Under the amended EIP, the maximum number of shares 
reserved for the grant or settlement of awards is 110 million shares, provided that each share in excess of 30 million that is issued 
with respect to any award that is not an option or stock appreciation right will be counted against the 110 million share limit as 
four and one-half shares. At December 31, 2016, approximately 37 million shares were authorized for future grants under the EIP. PP
The company satisfies stock option exercises and vesting of time-vested restricted stock units (RSUs) and performance-based 
restricted stock units (PSUs) with newly issued shares of DuPont common stock. 

t

The company's Compensation Committee determines the long-term incentive mix, including stock options, RSUs and PSUs and 
may authorize new grants annually.

Stock Options
The exercise price of shares subject to option is equal to the market price of the company's stock on the date of grant. All options 
vest serially over a three-year period.  Stock option awards granted between 2009 and 2015 expire seven years after the grant date 
and options granted in 2016 expire ten years after the grant date. The plan allows retirement-eligible employees to retain any 
granted awards upon retirement provided the employee has rendered at least six months of service following grant date.

F-48

   
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

For purposes of determining the fair value of stock options awards, the company uses the Black-Scholes option pricing model and
the assumptions set forth in the table below. The weighted-average grant-date fair value of options granted in 2016, 2015 and 2014
was $13.40, $11.57 and $13.68, respectively.

Dividend yield
Volatility
Risk-free interest rate
Expected life (years)

2016

2015

2014

2.6%
28.27%
1.8%
7.2

2.5%
22.52%
1.4%
5.3

2.9%
31.33%
1.7%
5.3

The company determines the dividend yield by dividing the current annual dividend on the company's stock by the option exercise
price. A historical daily measurement of volatility is determined based on the expected life of the option granted. The risk-free 
interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of 
the option granted. Expected life is determined by reference to the company's historical experience.

Stock option awards as of December 31, 2016, and changes during the year then ended were as follows:

Number of
Shares
(in thousands)

Weighted
Average
Exercise Price
(per share)

Weighted
Average
Remaining
Contractual
Term (years)

Aggregate
Intrinsic
Value
(in thousands)

Outstanding, December 31, 2015

Granted

Exercised
Forfeited

Canceled

Outstanding, December 31, 2016

Exercisable, December 31, 2016

18,160 $

1,690
(3,638)
(281)
(122)
15,809 $

9,519 $

54.89

58.79

43.31
67.17

39.71

58.11

53.48

3.92 $

3.10 $

240,030

189,624

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the company's 
closing stock price on the last trading day of 2016 and the exercise price, multiplied by the number of in-the-money options) that 
would have been received by the option holders had all option holders exercised their in-the-money options at year end. This 
amount changes based on the fair market value of the company's stock. Total intrinsic value of options exercised for 2016, 2015
and 2014 were $86, $160 and $219, respectively. In 2016, the company realized a tax benefit of $28 from options exercised.

a

t

As of December 31, 2016, $19 of total unrecognized compensation cost related to stock options is expected to be recognized over
a weighted-average period of 1.52 years.

RSUs and PSUs
The company issues RSUs that serially vest over a three-year period and, upon vesting, convert one-for-one to DuPont common 
stock. A retirement-eligible employee retains any granted awards upon retirement provided the employee has rendered at least six
months of service following the grant date. Additional RSUs are also granted periodically to key senior management employees. 
These RSUs generally vest over periods ranging from two to five years. The fair value of all stock-settled RSUs is based upon the 
market price of the underlying common stock as of the grant date.

F-49

 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

The company also grants PSUs to senior leadership. In 2016, there were 365,177 PSUs granted. Vesting for PSUs granted in 2016 
is based upon total shareholder return (TSR) relative to peer companies. Vesting for PSUs granted in 2015 is equally based upon
change  in  operating  net  income  relative  to  target  and TSR  relative  to  peer  companies.    Operating  net  income  is  net  income 
attributable to DuPont excluding income from discontinued operations after taxes, significant after tax benefits (charges), and
non-operating pension and OPEB costs. Vesting for PSUs granted in 2014 is equally based upon corporate revenue growth relative 
to peer companies and TSR relative to peer companies. Performance and payouts are determined independently for each metric. 
The actual award, delivered as DuPont common stock, can range from zero percent to 200 percent of the original grant. The 
weighted-average grant-date fair value of the PSUs granted in 2016, subject to the TSR metric, was $56.15, and estimated using 
a Monte Carlo simulation. The weighted-average grant-date fair value of the PSUs, subject to the revenue metric, was based upon
the market price of the underlying common stock as of the grant date.

Non-vested awards of RSUs and PSUs as of December 31, 2016 and 2015 are shown below. The weighted-average grant-date fair 
value of RSUs and PSUs granted during 2016, 2015 and 2014 was $59.50, $71.66 and $64.64, respectively. 

Nonvested, December 31, 2015

Granted

Vested

Forfeited

Nonvested, December 31, 2016

Number of
Shares
(in thousands)

Weighted
Average
Grant Date
Fair Value
(per share)

3,936 $

1,701
(1,460)
(286)
3,891 $

59.54

59.50

56.89

62.06

63.11

As of December 31, 2016, there was $75 of unrecognized stock-based compensation expense related to nonvested awards.  That 
cost is expected to be recognized over a weighted-average period of 1.80 years.  The total fair value of stock units vested during
2016, 2015 and 2014 was $83, $64 and $75, respectively.

Other Cash-based Awards
Cash  awards  under  the  EIP  plan  may  be  granted  to  employees  who  have  contributed  most  to  the  company's  success,  with
consideration  being  given  to  the  ability  to  succeed  to  more  important  managerial  responsibility.  Such  awards  resulted  in 
compensation expense of $53, $31 and $34 for 2016, 2015 and 2014, respectively included in income from continuing operations 
within the Consolidated Financial Statements. The amounts of the awards are dependent on company earnings and are subject to 
maximum limits as defined under the governing plans.

In addition, the company has other variable compensation plans under which cash awards may be granted. These plans include 
the company's regional and local variable compensation plans and Pioneer's Annual Reward Program. Such awards resulted in 
compensation  expense  of  $248,  $150  and  $137  for  2016,  2015  and  2014,  respectively,  included  in  income  from  continuing 
operations within the Consolidated Financial Statements.

F-50

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

i

i

S

S

C

19.  FINANCIAL INSTRUMENTS
S
O j
Objectives and Strategies for Holding Derivative Instruments
i
In the ordinary course of business, the company enters into contractual arrangements (derivatives) to reduce its exposure to foreign
currency, interest rate and commodity price risks.  The company has established a variety of derivative programs to be utilized
for  financial  risk  management.  These  programs  reflect  varying  levels  of  exposure  coverage  and  time  horizons  based  on  an 
assessment of risk. 

f

i

i

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, 
consistent with the company's financial risk management policies and guidelines.  Derivative instruments used are forwards, 
options, futures and swaps.  The company has not designated any nonderivatives as hedging instruments.

The  company's  financial  risk  management  procedures  also  address  counterparty  credit  approval,  limits  and  routine  exposure 
monitoring  and  reporting.  The  counterparties  to  these  contractual  arrangements  are  major  financial  institutions  and  major 
commodity exchanges. The company is exposed to credit loss in the event of nonperformance by these counterparties.  The company
utilizes  collateral  support  annex  agreements  with  certain  counterparties  to  limit  its  exposure  to  credit  losses. The  company's 
derivative  assets  and  liabilities  are  reported  on  a  gross  basis  in  the  Consolidated  Balance  Sheets.  The  company  anticipates
performance by counterparties to these contracts and therefore no material loss is expected.  Market and counterparty credit risks
associated with these instruments are regularly reported to management.

The notional amounts of the company's derivative instruments were as follows:

Derivatives designated as hedging instruments:

Foreign currency contracts

Commodity contracts

Derivatives not designated as hedging instruments:

Foreign currency contracts

Commodity contracts

2016

2015

$

— $

422

9,896

7

10

356

8,065

70

Foreign Currency Risk
Foreign Currency Risk
The company's objective in managing exposure to foreign currency fluctuations is to reduce earnings and cash flow volatility
associated with foreign currency rate changes. Accordingly, the company enters into various contracts that change in value as 
foreign exchange rates change to protect the value of its existing foreign currency-denominated assets, liabilities, commitments 
and cash flows.  

The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency-
denominated monetary assets and liabilities of its operations. The primary business objective of this hedging program is to maintain 
an approximately balanced position in foreign currencies so that exchange gains and losses resulting from exchange rate changes, 
net of related tax effects, are minimized.  The company also uses foreign currency exchange contracts to offset a portion of the 
company's exposure to certain foreign currency-denominated revenues so that gains and losses on these contracts offset changes 
in the USD value of the related foreign currency-denominated revenues. The objective of the hedge program is to reduce earnings
and cash flow volatility related to changes in foreign currency exchange rates.

h

Interest Rate Risk
Interest Rate Risk
rrowing. 
i
The company uses interest rate swaps to manage the interest rate mix of the total debt portfolio and related overall cost of bo
i
f b
Interest rate swaps involve the exchange of fixed for floating rate interest payments to effectively convert fixed rate debt into
d b i
i
fl
ll
floating rate debt based on USD LIBOR.  Interest rate swaps allow the company to achieve a target range of floating rate debt.
The company had no interest rate swaps outstanding at December 31, 2016 and 2015.  
b
h

h i
f fi d f

ll
fi d
f fl

d b b
h d

d l
l
i

f h
i

l d b

d b

f li

di

hi

ff

fl

d

h

d

h

h

d

i

i

l

i

i

i

Commodity Price Risk
Commodity Price Risk
Commodity price risk management programs serve to reduce exposure to price fluctuations on purchases of inventory such as 
corn,  soybeans  and  soybean  meal.    The  company  enters  into  over-the-counter  and  exchange-traded  derivative  commodity
instruments to hedge the commodity price risk associated with agricultural commodity exposures.

F-51

 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

CCash Flow Hedges
FForeign Currency Contracts
The company uses foreign currency exchange instruments such as forwards and options to offset a portion of the company's 
exposure to certain foreign currency-denominated revenues so that gains and losses on these contracts offset changes in the USD
value of the related foreign currency-denominated revenues.  In addition, the company occasionally uses forward exchange contracts
to offset a portion of the company’s exposure to certain foreign currency-denominated transactions such as capital expenditures.

d

Commodity Contracts
The company enters into over-the-counter and exchange-traded derivative commodity instruments, including options, futures and 
swaps, to hedge the commodity price risk associated with agriculture commodity exposures.

While each risk management program has a different time maturity period, most programs currently do not extend beyond the
next two-year period.  Cash flow hedge results are reclassified into earnings during the same period in which the related exposure 
impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction is not probable of occurring. The 
following table summarizes the after-tax effect of cash flow hedges on accumulated other comprehensive loss for the
 years ended 
d d
December 31, 2016

d and 2015:

b

December 31,
Beginning balance

Additions and revaluations of derivatives designated as cash flow hedges

Clearance of hedge results to earnings, after-tax

Ending balance

2016

2015

$

$

(24) $
20

11

7 $

(6)
(25)
7
(24)

December 31, 2016

At December 31, 2016, an after-tax net loss of $10 is expected to be reclassified from accumulated other comprehensive loss into 
earnings over the next twelve months. 

i

i

i

i

i

i

i

Derivatives not Designated in Hedging Relationships
FForeign Currency Contracts
The company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-
denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes
are minimized.  The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the 
forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal 
earnings impact, after taxes.  The company also uses foreign currency exchange contracts to offset a portion of the company's 
exposure to certain foreign currency-denominated revenues so that gains and losses on the contracts offset changes in the USD 
value of the related foreign currency-denominated revenues.

d

Commodity Contracts
The company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity 
price fluctuations on purchases of inventory such as corn, soybeans and soybean meal.

F-52

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

f

i
h

Fair Values of Derivative Instruments
i
The table below presents the fair values of the company's derivative assets and liabilities within the fair value hierarchy, as d
in Note 1, as of 
f
i

l
December 31, 2016

f h
d and 2015.   

i hi h f i

d li bili i

bl b l

h f i

d i

hi

h

b

l

i

i

 described 
ib d

Balance Sheet Location

2016

2015

Fair Value at December 31
Using Level 2 Inputs

Asset derivatives:

Derivatives not designated as hedging instruments:

Foreign currency contracts1

Accounts and notes receivable, net

Total asset derivatives2
Cash collateral1

Liability derivatives:

Derivatives not designated as hedging instruments:

Foreign currency contracts

Commodity contracts

Total liability derivatives2

Other accrued liabilities

Other accrued liabilities

Other accrued liabilities

$

$

$

182 $

182 $

52 $

121

—

121

$

121 $

74

74

7

80

4

84

84

1. 
2. 

Cash collateral held as of December 31, 2016 and 2015 is related to foreign currency derivatives not related to hedging instruments.
The company's derivative assets and liabilities subject to enforceable master netting arrangements totaled $114 and $35 at December 31, 2016 and 2015.

Effect of Derivative Instruments
i

ff

f

i

Derivatives designated as hedging instruments:

Fair value hedges:

Interest rate swaps

Cash flow hedges:

Amount of Gain (Loss)
Recognized in OCL1
(Effective Portion)

))
Amount of Gain (Loss)
Recognized in Income2

2016

2015

2014

2016

2015

2014

Income Statement Classification

$ — $ — $ — $ — $ (1) $ (28) Interest expense3

Foreign currency contracts

—

(2)

27 — 10

11 Net sales

Foreign currency contracts
Commodity contracts

Derivatives not designated as hedging instruments:

Foreign currency contracts
Foreign currency contracts
Commodity contracts

Total derivatives

— — — — —
(22)
26
32
(13)
53
32

(18)
(18)

(35)
(37)

Income from discontinued
operations after income taxes

4

(30) Cost of goods sold
(43)

434

607 Other income, net4

— — — (304)
— — — (12)
— — — (11)
— — — (327)

(21) Cost of goods sold
586
$ 32 $ (37) $ 53 $(345) $ 416 $ 543

(3) — Net sales
(2)
429

1. 

2. 

3. 

4. 

OCI is defined as other comprehensive loss.
For cash flow hedges, this represents the effective portion of the gain (loss) reclassified from accumulated OCL into income during the period.  For the years
ended December 31, 2016, 2015 and 2014, there was no material ineffectiveness with regard to the company's cash flow hedges.
Gain (loss) recognized in income of derivative is offset to $0 by gain (loss) recognized in income of the hedged item. 
Gain (loss) recognized in other income, net, was partially offset by the related gain (loss) on the foreign currency-denominated monetary assets and liabilities
of the company's operations, see Note 5 for additional information.

uu

F-53

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
   
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Cash, Cash Equivalents and Marketable Securities
The company's cash, cash equivalents and marketable securities as of 
f

i i

bl

h

h

h

k

d

l

i

December 31, 2016 and 2015

 and 

b

 are comprised of the following:

i d f h f ll

i

December 31, 2016

December 31, 2015

Cash

Level 1:

Cash and
Cash
Equivalents
$

1,892 $

Marketable
Securities

Total
Estimated
Fair Value
— $ 1,892 $

Cash and
Cash
Equivalents

Marketable
Securities

1,938 $

— $

Total
Estimated
Fair Value
1,938

Money market funds
U.S. Treasury securities1

$

— $
—

— $
—

— $
—

550 $
—

— $
788

550
788

Level 2:
Certificate of deposit / time deposits2

$

2,713 $

1,362 $ 4,075 $

2,812 $

118 $

2,930

Total cash, cash equivalents and marketable securities $

4,605 $

1,362

$

5,300 $

906

1. 

2. 

Available-for-sale securities are reported at estimated fair value with unrealized gains and losses reported as component of accumulated other comprehensive
loss. Proceeds from the sale of available-for-sale securities were $788 and $75 in the years ended December 31, 2016, and 2015, respectively.
Held-to-maturity investments are reported at amortized cost.

The estimated fair value of the company's cash equivalents, which approximates carrying value as of December 31, 2016 and 
2015, was determined using Level 1 and Level 2 inputs within the fair value hierarchy.  Level 1 measurements were based on
observed net asset values and Level 2 measurements were based on current interest rates for similar investments with comparable
credit risk and time to maturity.

The estimated fair value of the held-to-maturity securities, which approximates carrying value as of December 31, 2016 and 2015, 
was determined using Level 2 inputs within the fair value hierarchy, as described below.  Level 2 measurements were based on
current interest rates for similar investments with comparable credit risk and time to maturity.  The carrying value approximates 
fair value due to the short-term nature of the investments.

The estimated fair value of the available-for-sale securities as of December 31, 2015 was determined using Level 1 inputs within 
the fair value hierarchy.  Level 1 measurements were based on quoted market prices in active markets for identical assets and 
liabilities.  The available-for-sale securities as of December 31, 2015 were held by certain foreign subsidiaries in which the USD 
is not the functional currency.  The fluctuations in foreign exchange were recorded in accumulated other comprehensive loss withint
the Consolidated Statements of Equity.  These fluctuations were subsequently reclassified from accumulated other comprehensive
loss to earnings in the period in which the marketable securities were sold and the gains and losses on these securities offset at
portion of the foreign exchange fluctuations in earnings for the company.  

F-54

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

20.  GEOGRAPHIC INFORMATION

United States

Canada
EMEA22
France

Germany

Italy
Other

Total EMEA

Asia Pacific

China
India

Japan

Other

Total Asia Pacific

Latin America

Brazil

Mexico

Other

Total Latin America

Total

2016

Net Sales1

2015

$

$

9,683 $

730 $

10,021 $

734 $

2014

10,556

826

535

909

527
3,768

575

959

546
3,963

$

5,739 $

6,043 $

2,200
704

840

2,057

2,067
615

843

2,092

$

5,801 $

5,617 $

1,392

583

666

1,401

622

692

$

$

2,641 $

24,594 $

2,715 $

25,130 $

678

1,180

655
4,806

7,319

2,325
603

961

2,267

6,156

2,051

682

816

3,549

28,406

1. 

2. 

Net sales, based on the location of the customer, are generally presented for locations with greater than two percent of total net sales.
Europe, Middle East, and Africa (EMEA).

F-55

 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Net Property1

2016

2015

2014

6,203 $

127 $

6,706 $

131 $

6,570

138

211

218

188

210

740

217

217

200

222

747

242

239

251

248

883

1,567 $

1,603 $

1,863

339

536

362

565

875 $

927 $

314

145
459 $

263

154
417 $

306

539

845

411

181
592

9,231 $

9,784 $

10,008

$

$

$

$

$

$

United States

Canada
EMEA22

Denmark

France

Spain

Luxembourg

Other

Total EMEA

Asia Pacific

China

Other

Total Asia Pacific

Latin America

Brazil

Other

Total Latin America

Total

1. 

2. 

Net property is presented for locations with greater than two percent of the total and includes property, plant and equipment less accumulated 
depreciation.
Europe, Middle East, and Africa (EMEA).

F-56

 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

21.  SEGMENT INFORMATION
The company consists of 7 businesses which are aggregated into 6 reportable segments based on similar economic characteristics,
the nature of the products and production processes, end-use markets, channels of distribution and regulatory environment. The 
company's  reportable  segments  are Agriculture,  Electronics &  Communications,  Industrial  Biosciences,  Nutrition  &  Health, 
Performance Materials and Protection Solutions.  The company includes certain businesses not included in the reportable segments,
such  as  pre-commercial  programs,  nonaligned  businesses  and  pharmaceuticals  in  Other.  Pre-commercial  programs  include 
approximately $420 for the investment in a cellulosic biofuel facility in Nevada, Iowa which includes all material, engineering, 
and technical design costs involved in construction of the facility.  The facility is expected to commence initial production activities 
in mid-2017. 

Major products by segment include: Agriculture (corn hybrids and soybean varieties, herbicides, fungicides and insecticides); 
Electronics & Communications (printing and packaging materials, photopolymers and electronic materials); Industrial Biosciences
(enzymes, bio-based materials and process technologies); Nutrition & Health (probiotics, cultures, emulsifiers, texturants, natural
sweeteners and soy-based food ingredients); Performance Materials (engineering polymers, packaging and industrial polymers, 
films  and  elastomers);  and  Protection  Solutions  (nonwovens,  aramids  and  solid  surfaces). The  company  operates  globally  in 
substantially all of its product lines.

tt

In general, the accounting policies of the segments are the same as those described in Note 1. Exceptions are noted as follows and 
are shown in the reconciliations below. Segment net assets includes net working capital, net property, plant and equipment, and
other noncurrent operating assets and liabilities of the segment.  Depreciation and amortization includes depreciation on researchaa
and development facilities and amortization of other intangible assets, excluding write-down of assets. 

Segment operating earnings is defined as income (loss) from continuing operations before income taxes excluding significant pre-
tax benefits (charges), non-operating pension and other post employment benefit (OPEB) costs, exchange gains (losses), corporate 
expenses and interest.  Non-operating pension and OPEB costs includes all of the components of net periodic benefit cost from 
continuing operations with the exception of the service cost component.  DuPont Sustainable Solutions, previously within the 
company's former Safety & Protection segment (now Protection Solutions) was comprised of two business units: clean technologies
and consulting solutions.  Effective January 1, 2016, the clean technologies business unit is reported within the Industrial Biosciences
segment, and the consulting solutions business unit is reported within Other. Reclassifications of prior year data have been made 
to conform to current year classifications.

F-57

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Agriculture

Electronics &
Communications

Industrial
Biosciences

Nutrition &
Health

Performance
Materials

Protection
Solutions

Other

Total

$

9,516 $

1,960 $

1,500 $

3,268 $

5,249 $

2,954 $

147 $

24,594

1,758

417

7

6,342

222

345

358

87

31

1,186

146

51

270

100

12

2,855

39

64

504

223

—

5,182

4

1,297

130

27

2,711

146

668

146

33

2,220

81

111

160

120

(215)

4,640

10

1,113

(11)

321

11

28

99

20,817

649

879

$

9,798 $

2,070 $

1,478 $

3,256 $

5,305 $

3,039 $

184 $

25,130

1,646

453

31

6,751

234

334

359

100

24

1,323

139

45

243

101

7

3,154

41

84

373

236

—

5,457

9

1,216

125

(8)

2,918

171

120

159

641

156

23

2,295

71

96

(235)

4,243

6

1,177

(30)

258

23

132

47

22,156

688

970

$

11,296 $

2,381 $

1,624 $

3,529 $

6,059 $

3,304 $

213 $

28,406

2,352

436

31

6,696

240

407

336

97

20

1,359

137

52

269

102

8

3,241

45

94

369

264

—

5,942

7

1,267

139

(77)

3,125

238

112

134

672

168

28

2,339

78

98

(233)

5,032

8

1,214

(47)

316

16

(37)

23,018

761

203

1,100

2016

Net sales

Operating earnings

Depreciation and 
    amortization

Equity in earnings (losses) of 
    affiliates, net

Segment net assets

Affiliate net assets

Purchases of property,
    plant and equipment

2015

Net sales

Operating earnings

Depreciation and 
    amortization

Equity in earnings (losses) of 
    affiliates, net

Segment net assets

Affiliate net assets

Purchases of property,
    plant and equipment

2014

Net sales

Operating earnings

Depreciation and 
    amortization

Equity in earnings (losses) of 
    affiliates, net

Segment net assets

Affiliate net assets

Purchases of property,
    plant and equipment

F-58

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Reconciliation to Consolidated Financial Statements

Segment operating earnings to income from continuing operations before income taxes
Total segment operating earnings

Significant pre-tax (charges) benefits not included in segment operating earnings

Non-operating pension and OPEB costs
Net exchange (losses) gains

Corporate expenses
Interest expense

Income from continuing operations before income taxes

Segment net assets to total assets at December 31,
Total segment net assets
Corporate assets1
Liabilities included in segment net assets
Assets related to discontinued operations2
Total assets

$

$

$

2016

2015

2014

4,640 $
(168)
(40)
(106)
(691)
(370)
3,265 $

4,243 $
(38)
(374)
30
(928)
(342)
2,591 $

5,032

434
(128)
196
(844)
(377)
4,313

2016

2015

2014

20,817 $

22,156 $

11,306

7,841

—

11,163

7,847

—

23,018

12,889

8,356

6,227

$

39,964 $

41,166 $

50,490

1. 

2. 

Pension assets are included in corporate assets.
See Note 1 for additional information on the presentation of Performance Chemicals which met the criteria for discontinued operations.

Other items
2016

Depreciation and amortization

Equity in earnings of affiliates, net
Affiliate net assets

Purchases of property, plant and equipment
2015

Depreciation and amortization

Equity in earnings of affiliates, net
Affiliate net assets

Purchases of property, plant and equipment
2014

Depreciation and amortization
Equity in (losses) earnings of affiliates, net
Affiliate net assets

Purchases of property, plant and equipment

Segment
Totals

Adjustments1

Consolidated
Totals

$

$

$

1,113 $

145 $

99
649

879

—
—

140

1,177 $

289 $

47
688

970

1,214 $
(37)
761

1,100

2
—

659

403 $
1
1

920

1,258

99
649

1,019

1,466

49
688

1,629

1,617
(36)
762

2,020

1. 

Adjustments include amounts related to Corporate in all periods presented, and to the Performance Chemicals business in 2015 and 2014, as it met the criteria
for discontinued operations during 2015. See Note 1 for additional information on the presentation of discontinued operations and See Note 3 for depreciation, 
amortization and purchases of property, plant and equipment related to Performance Chemicals for the years ended December 31, 2015 and 2014.

aa

F-59

 
 
 
 
 
 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

Additional Segment Details
2016 included the following significant pre-tax benefits (charges) which are excluded from segment operating earnings:

Agriculture1,2,3,4
Electronics & Communications2,4
Industrial Biosciences2,4,5
Nutrition & Health2,4
Performance Materials2,4
Protection Solutions2,4
Other2

$

$

(37)
4
(152)
9

5
14
(11)
(168)

1.

2.

3.

4.

5.

Included $30 of net insurance recoveries recorded in other operating charges for recovery of costs for customer claims related to the use of the Imprelis®
herbicide.  Included a benefit of $23 in other operating charges for reduction in the accrual for customer claims related to the use of the Imprelis® herbicide.
The company recorded a $(3) net restructuring charge in employee separation / asset related charges, net for the year ended December 31, 2016, associated 
with the 2016 global cost savings and restructuring program.  See Note 4 for additional information. 
Includes a $(68) restructuring charge recorded in employee separation / asset related charges, net for the year ended December 31, 2016, related to the
decision not to re-start the insecticide manufacturing facility at the La Porte site located in La Porte, Texas.  See Note 4 for additional information.
The company recorded a $8 restructuring benefit recorded in employee separation/asset related charges, net, for adjustments to the previously recognized 
severance costs related to the 2014 restructuring program. See Note 4 for additional information.
The company recorded a $(158) charge in employee separation / asset related charges, net, for the year ended December 31, 2016, related to the write-down
of indefinite lived intangible assets. See Note 4 for additional information.

2015 included the following significant pre-tax benefits (charges) which are excluded from segment operating earnings:

Agriculture1,2,5
Electronics & Communications1,5
Industrial Biosciences1,5
Nutrition & Health1,5
Performance Materials1,5
Protection Solutions1,3,5
Other1,4,5

$

$

148
(78)
(61)
(50)
(62)
105
(40)
(38)

1.

2.

3.

4.

5.

Included a $10 net restructuring benefit recorded in employee separation/asset related charges, net, associated with the 2014 restructuring program. These
adjustments were primarily due to the identification of additional projects in certain segments, offset by lower than estimated individual severance costs and 
workforce reductions achieved through non-severance programs. See Note 4 for additional information. 
®
Included $182 of net insurance recoveries recorded in other operating charges for recovery of costs for customer claims related to the use of the Imprelis
® herbicide. 
herbicide.  Included a benefit of $130 in other operating charges for reduction in the accrual for customer claims related to the use of the Imprelis
Included a gain of $145, net of legal expenses, recorded in other income, net related to the company's settlement of a legal claim.
Included a $(37) pre-tax impairment charge recorded in employee separation / asset related charges, net for a cost basis investment.  See Note 4 for additional
information.
Included a $(468) restructuring charge consisting of $(463) recorded in employee separation/asset related charges, net and $(5) recorded in other income, 
net associated with the 2016 global cost savings and restructuring program.  See Note 4 for additional information.

d

d

tt

t

F-60

   
   
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

2014 included the following significant pre-tax benefits (charges) which are excluded from segment operating earnings:

Agriculture1,2,3
Electronics & Communications1
Industrial Biosciences1
Nutrition & Health1
Performance Materials1,4
Protection Solutions1
Other1

$

$

316
(84)
(20)
(15)
292
(45)
(10)
434

1.

2.

3.

4.

Included a $(407) restructuring charge associated with the 2014 restructuring program consisting of $(342) recorded in employee separation / asset related 
charges, net and $(65) recorded in other income, net.  See Note 4 for additional information. 
Included income of $210 for insurance recoveries, recorded in other operating charges associated with the company's process to fairly resolve claims related 
to the use of Imprelis® herbicide.
Included a gain of $240 recorded in other income, net associated with the sale of the copper fungicide and land management businesses, both within the
Agriculture segment.
Included a gain of $391 recorded in other income, net associated with the sale of Glass Laminating Solutions / Vinyls.  See Note 3 for additional information.

F-61

   
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

22.  QUARTERLY FINANCIAL DATA 

Unaudited

2016

Net sales

Cost of goods sold
Employee separation / asset related charges, net2
Income (loss) from continuing operations before 
income taxes

Net income

Basic earnings per share of common stock from continuing 
operations1
Diluted earnings per share of common stock from 
continuing operations1
2015

For the quarter ended

March 31,

June 30,

September 30,

December 31,

$ 7,405

$ 7,061

$ 4,917

$ 5,211

4,242
77

3,990
(90)

3,090
172

3,147
393

1,635 3,4,5
1,232

1,333 3,4
1,024

1.40

1.39

1.17

1.16

(56) 3
6

0.01

0.01

353 3
263

0.29

0.29

Net sales
Cost of goods sold
Employee separation / asset related charges, net2
Income (loss) from continuing operations before 
income taxes
Net income

$ 7,837
4,516

38

$ 7,121
4,103

2

$ 4,873
3,084

—

$ 5,299
3,409

770

1,551 6,7,8
1,035

1,234 6,9
945

227 6,7
235

(421) 7,9,10
(256)

Basic earnings per share of common stock from continuing 
operations1
Diluted earnings per share of common stock from 
continuing operations1

1.12

1.11

1.07

1.06

0.14

0.14

(0.26)

(0.26)

1. 

2. 

3. 

4. 

5. 

6. 

7. 

8. 

9. 

10. 

Earnings per share for the year may not equal the sum of quarterly earnings per share due to changes in average share calculations.
See Note 4 for additional information.
First, second, third and fourth quarter 2016 included charges of $(24), $(76), $(122), and $(164), respectively, recorded in selling, general and administrative 
expenses related to transaction costs associated with the planned merger with the Dow Chemical Company announced on December 11, 2015.  See Note 2 
for additional information.
First quarter 2016 included  a benefit of $23, in other operating charges, for reductions in the accrual for customer claims related to the use of the Imprelis®
herbicide.  The company recorded insurance recoveries of $30 in the second quarter 2016, in other operating charges, for recovery of costs for customer 
claims related to the use of the Agriculture's segment Imprelis® herbicide.
First quarter 2016 included a gain of $369 recorded in other income, net associated with the sale of the DuPont (Shenzhen) Manufacturing Limited entity, 
which held certain buildings and other assets.  See Note 3 for additional information.
First and third quarter 2015 included charges of $(12) and $(9), respectively, recorded in other operating charges associated with transaction costs related to
the separation of the Performance Chemicals segment.  Second quarter 2015 included charges of $(5) recorded in other operating charges and $(20)  recorded 
in interest expense.  See Note 3 for additional information.
First and third quarter 2015 included net insurance recoveries of $35  and $147, respectively, recorded in other operating charges in the Agriculture segment, 
for recovery of costs for customer claims related to the use of the Imprelis® herbicide.  Fourth quarter 2015 included a benefit of $130 in other operating
charges for reduction in accrual for customer claims related to the use of the Agriculture segment’s Imprelis® herbicide.
First quarter 2015 included a $(40) pre-tax charge within other income, net associated with the re-measurement of the Ukraine hyrvnia net monetary assets.  
Second and fourth quarter 2015 included gains of $112 and $33, respectively, net of legal expenses, recorded in other income, net related to the company's 
settlement of a legal claim.  This matter relates to the Protection Solutions segment.
Fourth quarter 2015 included charges of $(10) recorded in selling, general and administrative expenses related to transaction costs associated with the planned 
merger with the Dow Chemical Company announced on December 11, 2015.  See Note 2 for additional information.

h

r

F-62

 
 
 
 
E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)

23.  SUBSEQUENT EVENTS
On January 31, 2017, the company entered into a committed receivable repurchase facility of up to $1,300 (the 2017 repurchase 
facility) that expires on November 30, 2017.  Under the 2017 repurchase facility, the company may sell a portfolio of available
and eligible outstanding customer notes receivables within the Agriculture segment to participating institutions and simultaneously 
agree to repurchase at a future date.  The 2017 repurchase facility is considered a secured borrowing with the customer notes 
receivables, inclusive of those that are sold and repurchased, equal to 105 percent of the outstanding amounts borrowed utilized 
as collateral.  Borrowings under the repurchase facility will have an interest rate of LIBOR + 0.75 percent. 

F-63

Information for Investors

Corporate Headquarters

Independent Registered Public Accounting Firm

E. I. du Pont de Nemours and Company
Chestnut Run Plaza
974 Centre Road 
P.O. Box 2915
Wilmington, DE 19805
Telephone: 302 774-1000
E-mail: http://www.dupont.com (click on Contact)

Stock Exchange Listings
DuPont  common  stock  (Symbol  DD)  is  listed  on  the  New  York  Stock 
Exchange, Inc. (NYSE). Quarterly high and low market prices are shown
in Item 5 of the Form 10-K.
DuPont  preferred  stock  is  listed  on  the  New York  Stock  Exchange, Inc.
(Symbol DDPrA for $3.50 series and Symbol DDPrB for $4.50 series).

Dividends
Holders of the company's common stock are entitled to receive dividends 
when they are declared by the Board of Directors. While it is not a guarantee
of future conduct, the company has continuously paid a quarterly dividend 
since the fourth quarter 1904. Dividends on common stock and preferred 
stock  are  usually  declared  in  January,  April,  July  and  October.  When
dividends on common stock are declared, they are usually paid mid-March,
June, September and December. Preferred dividends are paid on or about 
the 25th of January, April, July and October.

PricewaterhouseCoopers LLP
Two Commerce Square, Suite 1800
2001 Market Street
Philadelphia, PA 19103

Investor Relations
Institutional  investors  and  other  representatives  of  financial  institutions
should contact:

E. I. du Pont de Nemours and Company
DuPont Investor Relations
974 Centre Road, CRP730/5360-3
Wilmington, DE 19805
or call 302 774-4994

Bondholder Relations

E. I. du Pont de Nemours and Company
DuPont Finance
974 Centre Road, CRP730/4170-5
Wilmington, DE 19805

          or call 302 999-4488
          or 302 999-4487

DuPont on the Internet
Financial results, news and other information about DuPont can be accessed 
from the company's website at http://www.dupont.com. This site includes
important  information  on  products  and  services,  financial  reports,  news 
releases,  environmental 
information  and  career  opportunities.  The 
company's periodic and current reports filed with the SEC are available on 
its website, free of charge, as soon as reasonably practicable after being filed.

Shareholder Services
Inquiries  from  shareholders  about  stock  accounts,  transfers,  certificates,
dividends  (including  direct  deposit  and  reinvestment),  name  or  address
changes  and  electronic  delivery  of  proxy  materials  may  be  directed  to
DuPont's stock transfer agent:

Product Information/Referral
From the United States and Canada:
800 441-7515 (toll-free)
From other locations: 302 774-1000
On the Internet: http://www.dupont.com (click on Contact)

Computershare Trust Company, N.A.
P.O. Box 30170
College Station, TX, 77842-3170
or call: in the United States and Canada

888 983-8766 (toll-free)
other locations-781 575-2724
for the hearing impaired-
TDD: 800 952-9245 (toll-free)

or visit Computershare's home page at
http://www.computershare.com/investor

Printed Reports Available to Shareholders
The following company reports may be obtained, without charge:

1. 2016 Annual Report to the Securities and Exchange Commission,
    filed on Form 10-K;
2. Proxy Statement for 2017 Annual Meeting of Stockholders; and
3. Quarterly reports to the Securities and Exchange Commission,
    filed on Form 10-Q
Requests should be addressed to:

  DuPont Corporate Customer Care
  CRP - 735 (second floor)
  974 Centre Road, P.O. Box 2915
  Wilmington, DE 19805

     or call:                                                                                                                  
From the United States and Canada:  800-441-7515 (toll free)
From other locations:  302-774-1000
On the Internet:  http://www.dupont.com (click on Contact)

Services for Shareholders

Online Account Access
Registered shareholders may access their accounts and obtain online answers 
to stock transfer questions by signing up for Internet access by visiting http://
www.computershare.com/investor. Shareholders have the option to request 
direct  deposit  of  stock  dividends,  and  electronic  delivery  of  account 
statements and 1099-DIV tax forms.

Dividend Reinvestment Plan
An  automatic  dividend  reinvestment  plan  is  available  to  all  registered 
shareholders.  Common  or  preferred  dividends  can  be  automatically
reinvested in DuPont common stock. Participants also may add cash for the 
purchase of additional shares. A detailed account statement is mailed after 
each investment. Your account can also be viewed over the Internet if you
have Online Account Access (see above). To enroll in the plan, please contact 
Computershare (listed above).

Online Delivery of Proxy Materials
Shareholders may request their proxy materials electronically by visiting
http://enroll.icsdelivery.com/dd.

Direct Deposit of Dividends
Registered shareholders who would like their dividends directly deposited 
in a U.S. bank account should contact Computershare (listed above).

                                                                                                          
[THIS PAGE INTENTIONALLY LEFT BLANK]

[THIS PAGE INTENTIONALLY LEFT BLANK]

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
This document includes information that does not conform to U.S. generally accepted accounting principles (GAAP) and is considered non-GAAP measures. These measures include the 
company’s earnings per share on an operating earnings basis, which excludes significant items and non-operating pension and other post employment benefit costs (operating EPS), total 
segment operating earnings, and operating costs and corporate expenses on an operating earnings basis. Management uses these measures internally for planning, forecasting and 
evaluating the performance of the company’s segments, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measurements 
are meaningful to investors as they provide insight with respect to ongoing operating results of the company and provide a more useful comparison of year-over-year results. From a liquidity 
perspective, management uses free cash flow which is defined as cash provided/used by operating activities less purchases of property, plant and equipment. Free cash flow is useful to 
investors and management to evaluate the company’s cash flow and financial performance, and is an integral financial measure used in the company’s financial planning process. These 
non-GAAP measurements supplement our GAAP disclosures and should not be viewed as an alternative to GAAP measures of performance. This data should be read in conjunction with 
previously published company reports on Forms 10-K, 10-Q and 8-K. These reports are available on the Investor Center of www.dupont.com under Filings and Reports. Reconciliations of 
non-GAAP measures to GAAP are also included below. 

RECONCILIATION OF TOTAL SEGMENT OPERATING EARNINGS 

Year ended December 31, 

          2016   

        2015

Income from continuing operations before income taxes (GAAP) 
Add: Significant items charge(1) 
Add: Non-operating pension and other post employment benefit (OPEB) costs    

      $  3,265                              $  2,591 
                                         519                                    453
                        397

              40 

Operating Earnings before income taxes (Non-GAAP) 

          3,824  

        3,441

Add: Corporate expenses                                                                                                              340                                     573 
Add: Interest expense                                                                                                                  370                                     322 
Add: Net exchange losses (gains)                                                                                                   106                                    (93)

Total Segment Operating Earnings (Non-GAAP)                                                                             $  4,640                              $  4,243

RECONCILIATION OF OPERATING EPS 

Year ended December 31, 

EPS from continuing operations (GAAP) 
Add: Significant items charge included in EPS(1) 
Add: Non-operating pension and OPEB costs included in EPS     

           2016   

         2015

                           0.48 
            0.02 

       $    2.85                               $   2.09 
                       0.39
                       0.29 

Operating EPS (Non-GAAP) 

       $    3.35  

    $    2.77 

RECONCILIATION OF OPERATING COSTS 

Year ended December 31, 

 2016 

 2015 

As Reported
(GAAP)

Less:  
Significant  
Items(1)

Less: Non- 
Operating Pension/ 
OPEB Costs

(Non- 
GAAP)

As Reported
(GAAP)

Less:  
Significant  
Items(1)

Less: Non- 
Operating Pension/ 
OPEB Costs

(Non- 
GAAP)

$     745
4,455
1,842

Other operating charges 
Selling, general and administrative expenses 
Research and development expense     

$    686
4,319
1,641

$  (53)
386
-

Total 

$ 6,646

$  333

$       -
16
6

$     22

$    739
3,917
1,635

 $    459
4,615
1,898

$  (286)
10
-

$         -
150
56

$  6,291

$  6,972

$  (276)

$     206

$  7,042

RECONCILIATION OF CORPORATE COSTS 

RECONCILIATION OF FREE CASH FLOW 

Year ended December 31, 

2016 

2015

Year ended December 31, 

     2016           2015

Corporate expenses (GAAP) 
Less: Significant items charge(1)                     351 

              $  691      $ 928 
  355

Cash Provided by Operating Activities (GAAP) 
   $  3,300       $  2,316 
Less: Purchases of Property, Plant and Equipment               1,019          1,629

Corporate expenses (Non-GAAP)     

$ 340      $ 573 

Free Cash Flow (Non-GAAP)   

   $  2,281       $   687 

(1) Further information regarding significant items can be found in our Quarterly Earnings News Release financials.

FORWARD-LOOKING STATEMENTS
This document contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, 
as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” 
“believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as 
statements about the consummation of the proposed merger of equals transaction with The Dow Chemical Company (the “DowDuPont Merger”) and the proposed transaction with FMC Corporation (“FMC”) in which, among 
other things, FMC will acquire a portion of DuPont’s crop protection business (the “Divested Ag Business”) and DuPont will acquire substantially all of FMC’s Health and Nutrition business (the “Acquired H&N Business”) and the  
anticipated benefits thereof. These and other forward-looking statements, including the failure to consummate the DowDuPont Merger or the proposed transaction or to make or take any filing or other action required to  
consummate such transactions in a timely manner or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any 
forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements 
also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking 
statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting 
products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to 
appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; 
business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; 
ability to protect and enforce the company’s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the DowDuPont 
Merger Transaction and the proposed transaction. These risks include, but are not limited to, (i) the completion of the DowDuPont Merger and the proposed transaction on anticipated terms and timing, including obtaining  
regulatory approvals, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business 
and management strategies for the management, expansion and growth of the new combined company’s or the Acquired H&N Business, and other conditions to the completion of the DowDuPont Merger and the proposed 
transaction, (ii) the possibility that the DowDuPont Merger and the proposed transaction may not close, including because the various approvals, authorizations and declarations of non-objections from certain regulatory and 
governmental authorities with respect to either the DowDuPont Merger or the proposed transaction may not be obtained, on a timely basis or otherwise, including that these regulatory or governmental authorities may not approve 
of FMC as an acceptable purchaser of the Divested Ag Business in connection with the proposed transaction, or may impose conditions on the granting of the various approvals, authorizations and declarations of non-objections, 
including requiring the respective Dow, DuPont and FMC businesses, including the Acquired H&N Business (in the case of DuPont) and the Divested Ag Business (in the case of FMC), to divest certain assets if necessary to obtain 
certain regulatory approvals or otherwise limiting the ability of the combined company to integrate parts of the Dow and DuPont businesses and/or the DuPont and Health and Nutrition businesses, (iii) the ability of DuPont to 
integrate the Acquired H&N Business successfully and to achieve anticipated synergies, (iv) potential litigation or regulatory actions relating to the DowDuPont Merger or the proposed transaction that could be instituted against 
DuPont or its directors, (v) the risk that disruptions from the DowDuPont Merger or the proposed transaction will harm DuPont’s business, including current plans and operations, (vi) the ability of DuPont to retain and hire key 
personnel, (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the DowDuPont Merger or the proposed transaction, (viii) uncertainty as to the long-term value 
of DowDuPont common stock, (ix) continued availability of capital and financing and rating agency actions, (x) legislative, regulatory and economic developments, (xi) potential business uncertainty, including changes to existing 
business relationships, during the pendency of the DowDuPont Merger or the proposed transaction that could affect DuPont’s financial performance, (xii) certain restrictions during the pendency of the DowDuPont Merger or the 
proposed transaction that may impact DuPont’s ability to pursue certain business opportunities or strategic transactions and (xiii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism 
or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well as other risks associated with the DowDuPont Merger or the proposed transaction, are or will be 
more fully discussed in (1) DuPont’s most recently filed Form 10-K, 10-Q and 8-K reports, (2) DuPont’s subsequently filed Form 10-K and 10-Q reports and (3) the joint proxy statement/prospectus included in the Registration State-
ment filed with the SEC in connection with the DowDuPont Merger. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as 
compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties, and similar risks, any of which could 
have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements, 
whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

 
 
 
 
 
  
 
 
 
  
   
 
        
    
 
 
 
 
 
 
 
 
        
 
 
       
  
 
 
 
 
 
 
  
 
 
 
 
  
   
 
 
 
 
 
 
 
 
      
 
   
  
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
  
 
DuPont 
974 Centre Road
Wilmington, DE 19805
dupont.com

Copyright © 2017 DuPont. The DuPont Oval Logo, DuPont™, and all products 
denoted with a ™ or ® are trademarks or registered trademarks of E. I. du 
Pont de Nemours and Company or its affiliates. All rights reserved.